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i 
Abstract 
 
Nitroaromatic prodrugs are biologically inert compounds that are attractive candidates 
for anti-cancer therapy by virtue of their ability to be converted to potent DNA 
alkylating agents by nitroreductase (NTR) enzymes. In gene-directed enzyme-prodrug 
therapy (GDEPT), NTR-encoding therapeutic transgenes are delivered specifically to 
tumour cells, whereupon their expression confers host cell sensitivity to subsequent 
systemic administration of a nitroaromatic prodrug. The most well studied NTR-
GDEPT system involves reduction of the aziridinyl dinitrobenzamide prodrug CB1954 
by the Escherichia coli NTR NfsB. However, low affinity of this enzyme for CB1954 
has so far limited the clinical efficacy of this GDEPT combination. The research 
described in this thesis has primarily sought to address this limitation through 
identification and optimisation of novel NTR enzymes with improved nitroaromatic 
prodrug reductase activity. 
 
Efficient assessment of NTR activity from large libraries of candidate enzymes requires 
a rapid and reliable screening system. An E. coli-based assay was developed to permit 
indirect assessment of relative rates of prodrug reduction by over-expressed NTRs via 
measurement of SOS response induction resulting from reduced prodrug-induced DNA 
damage. Using this assay in concert with other in vitro and in vivo tests, more than 50 
native bacterial NTRs of diverse sequence and origin were assessed for their ability to 
reduce a panel of clinically attractive nitroaromatic prodrugs. Significantly, a number of 
NTRs were identified, particularly in the family of enzymes homologous to the native 
E. coli NTR NfsA, which displayed substantially improved activity over NfsB with 
CB1954 and other nitroaromatic prodrugs as substrates. This work also examined the 
roles of E. coli DNA damage repair pathways in processing of adducts induced by 
various nitroaromatic prodrugs. Of particular interest, nucleotide excision repair was 
found to be important in the processing of DNA lesions caused by 4-, but not 2-nitro 
group reduction products of CB1954, which suggests that there are some parallels in the 
mechanisms of CB1954 adduct repair in E. coli and mammalian cells. Finally, a lead 
NTR candidate, YcnD from Bacillus subtilis, was selected for further activity 
improvement through site-directed mutagenesis of active site residues. Using SOS 
screening, a double-site mutant was identified with 2.5-fold improved activity over the 
wildtype enzyme in metabolism of the novel dinitrobenzamide mustard prodrug PR-
104A.  
 
In conclusion, novel NTRs with substantially improved nitroaromatic prodrug reducing 
activity over previously documented enzymes were identified and characterised. These 
results hold significance not only for the field of NTR-GDEPT, but also for other 
biotechnological applications in which NTRs are becoming increasingly significant, 
including developmental studies, antibiotic discovery and bioremediation. Furthermore, 
the in vitro assays developed in this study have potential utility in the discovery and 
evolution of other GDEPT-relevant enzymes whose prodrug metabolism is associated 
with genotoxicity.  
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Chapter 1: Introduction 
 
1.1. Chemotherapy for cancer 
 
Cancer is currently one of the leading causes of death worldwide, with the number of 
new cases and mortality rates only expected to rise over the next 50 years due to an 
expanding and ageing global population (1). Chemotherapy, the use of small molecular 
weight compounds to kill tumour cells, is currently a leading treatment option for many 
cancer types. “Traditional” chemotherapeutic drugs primarily exert their toxicity 
through the suppression of processes involved in cell division, thereby minimizing 
cancerous cell proliferation. Many classes of anti-cancer drugs have been developed and 
are in clinical use today, including DNA alkylating agents that directly damage DNA, 
nucleotide analogues (anti-metabolites) that interfere with DNA replication, 
microtubule stabilising and destabilising agents that prevent chromosomal segregation, 
and topoisomerase inhibitors, among others (2). Although they constitute the mainstay 
of current cancer chemotherapeutics, their effectiveness is severely hampered by high 
systemic toxicity (including myelosuppression, alopecia, gastrointestinal disorders and 
infertility) due to low cancer cell-type specificity, and high prevalence of drug 
resistance development (3-5). Chemotherapies that specifically target diseased cells, by 
exploiting unique molecular properties associated with cancer progression have 
therefore emerged in recent years to address many of these limitations (6). These 
chemotherapies have typically been small molecule inhibitors of, or monoclonal 
antibodies raised against certain receptor tyrosine kinases or their associated pathways, 
many of which are upregulated in cancer and found to be essential for tumour growth 
and survival (7). However, cross-reactivity of these therapies with molecular targets in 
healthy cells, and intratumoural molecular heterogeneity has been shown to be a major 
contributor to diminished therapeutic efficacy of many of these therapies (8; 9); 
nevertheless, targeted chemotherapies are becoming more clinically prevalent, with over 
70% of anti-cancer drugs approved by the US Food and Drug Administration in the last 
decade fitting this description (10).            
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1.2. Targeting tumour hypoxia 
 
To be effective, cancer chemotherapy need not solely target the cancer cells themselves. 
Growth and progression of tumours is dependent not only on internal genetic 
abnormalities and inter-cellular signalling, but also the microenvironment in which they 
reside, thus providing a novel target for chemotherapy. Factors such as tumour 
vasculature, stromal composition and tumour oxygenation have all been exploited in the 
design of chemotherapeutic drugs, with many beneficial results (11; 12).   
 A significant feature of many solid tumours is the presence of regions of 
hypoxia, characterised by greatly reduced oxygen tensions (<10 mm Hg partial 
pressure) relative to those found under normal physiological conditions (40-60 mm Hg; 
(13)). Hypoxia is a product of the inadequate and disorganized nature of the tumour 
vasculature network, which prevents sufficient oxygenation of all tumour cells. As such, 
chronic hypoxia is largely a characteristic unique to solid tumours and not found in 
healthy tissue. Hypoxia is detrimental to the efficacy of traditional anticancer therapies 
for several reasons. First, the correlation between hypoxic regions and increasing 
distance from vasculature creates difficulties in tumour penetration for many circulating 
drugs (14). Second, the decreased cellular growth rate associated with regions of 
hypoxia renders them resistant to many antiproliferative chemotherapeutics (15). Third, 
a link between hypoxia and up-regulation of certain proteins involved in multi-drug 
resistance, including p-glycoproteins has been observed (16; 17). Fourth, hypoxic cells 
are much less sensitive to the effects of radiation therapy, which requires molecular 
oxygen to aid in DNA damage induction (11). Finally, hypoxia is generally indicative of 
a poor prognosis, correlating with enhanced malignant phenotypes. This correlation is 
largely due to over-expression of hypoxia-inducible transcription factors (HIFs) in 
hypoxic cells, which mediate the expression of other genes involved in nutrient 
transport, cell survival, proliferation and metastasis (18). On the other hand, due to its 
unique association with solid tumours, hypoxia presents an attractive target for anti-
cancer drug design. To this end, some success has been observed in the specific 
targeting and inhibition of the HIF family of proteins themselves, although many of the 
small molecule inhibitors identified to date are not specific for these enzymes and are 
therefore associated with much off-target toxicity (19). 
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1.2.1. Hypoxia-activated prodrugs 
 
 More effective hypoxia-selectivity and toxicity has been demonstrated for prodrugs 
designed to specifically be activated under hypoxia. The best-characterised hypoxia-
activated prodrugs developed so far are the bioreductive prodrugs, which require 
reductive activation by endogenous cellular reductases to elicit cytotoxicity (20; 21). 
Multiple cellular oxidoreductase enzymes such as cytochrome P450s (CYP450) and 
cytochrome P450 reductase (CYP450R) are capable of one-electron reduction of these 
compounds. The first released product of enzyme-catalysed reduction is an anion radical 
that is efficiently and non-enzymatically back-oxidised to the parental compound by 
molecular oxygen, if present. Such „futile-cycling‟ results in the net production of 
rapidly degraded superoxide ions and therefore limited toxicity (see Figure 1.1). In the 
absence of molecular oxygen, this radical is stabilized and can either inflict DNA 
damage itself, or be further reduced or metabolized to intermediates capable of reacting 
readily with DNA and other macromolecules (11). Therefore, prodrug activation is 
limited to regions of extreme hypoxia, as typically found in solid tumours. Examples of 
hypoxia-activated prodrugs currently under various stages of clinical and pre-clinical 
development are illustrated in Figure 1.2.   
 
Figures 1.1A & B. Mechanism of action of hypoxia-activated prodrugs. 
A prodrug (D) is a substrate for one-electron reductases (such as CYP450R). In the presence of oxygen 
(A), the one-electron reduction product is efficiently and rapidly back-oxidised to the parent compound, 
with the net production of one super-oxide radical anion. In the absence of oxygen (B), further 
metabolism beyond the one-electron reduction product can take place, permitting accumulation of the 
desired toxic end product. Figure reproduced from Brown and Wilson (11). 
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1.2.1.1. N-oxide and quinone hypoxia-activated prodrugs 
 
One of the first hypoxia-activated prodrugs to be developed was the benzotriene di-N-
oxide tirapazamine (TPZ; see Figure 1.2), which under hypoxia experiences 
bioreduction to an oxidizing nitroxide radical capable of DNA strand cleavage, 
topoisomerase II poisoning and inhibition of DNA replication (22-24). Despite a wealth 
of promising pre-clinical data, clinical efficacy of this prodrug has largely been limited 
by off-target toxicity (25) and minimal tumour penetration of the activated prodrug (due 
to the very short half-lives of the cytotoxic metabolites; (26)). Analogues of TPZ that 
can overcome these limitations are currently being investigated (27; 28). Other well 
characterised hypoxia-activated prodrugs include the naturally-occurring quinone 
compound mitomycin C (MMC) and its synthetic analogues such as porfiromycin, EO9 
and AZQ. Similar to TPZ, the reduced (semiquinone) derivatives of quinone hypoxia-
activated prodrugs are able to kill cells by directly inducing cytotoxic DNA lesions (29). 
However, the hypoxia selectivity ratio (drug dose required for equitoxicity in normoxic 
versus hypoxic cells) of the quinone hypoxia-activated prodrugs are low (3-7 for MMC, 
compared to up to 200 for TPZ; (30)) limiting their utility as a targeted therapy (21; 31; 
32). This is largely a consequence of the efficient reduction of these compounds by two-
electron (aerobic, or oxygen-insensitive)-reductases, especially NAD(P)H:Quinone 
Oxidoreductase (NQO1, or DT-Diaphorase; (33)). These enzymes convert the parental 
prodrug directly to the final cytotoxin in a reduction step involving the simultaneous 
transfer of two electrons, therefore bypassing the initial unstable one electron radical 
reduction product. As such, they function in normoxic cells, including healthy tissue, 
and their presence is highly implicated in systemic toxicity imparted by the use of these 
compounds.  
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Figure 1.2. Hypoxia-activated prodrugs. 
 Structures of several compounds currently under investigation as hypoxia-activated prodrugs for anti-
cancer therapy.   
 
1.2.1.2. Nitroaromatic hypoxia-activated prodrugs 
 
One of the most promising families of hypoxia-activated prodrugs is the nitroaromatic 
bioreductives. Hypoxia-selectivity has long been associated with compounds containing 
bioreducible nitroaromatic groups, ever since the initial elucidation of the mode of 
action of radiosensitizing compounds such as misonidazole and other 2-nitroimidazoles 
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(2-NIs) (34). Nitroaromatic compounds are reduced sequentially at the nitro group to 
form nitroso (2 electron), hydroxylamino (4 electron) and amino (6 electron) derivatives 
(Figure 1.3); the hydroxylamino product, however, is the most common end metabolite 
observed for the reduction of the vast majority of nitroaromatics due to the very low 
redox potential required for further reduction to the amine (35). Nitro groups are 
inherently electron-withdrawing and provide stability to other functional groups. 
Conversely, nitroreduction causes a rearrangement of electron densities within the 
aromatic ring that converts the compound to a reactive and unstable electrophile. The 
change in electronic effect resulting from reduction of an aromatic nitro group to the 
hydroxylamine is among the largest known for a single catalytic step (36), making such 
a reaction highly attractive as an electronic „switch‟ for the conversion of an inert 
prodrug to a potent cytotoxin. Further cytotoxicity can be applied to nitroaromatic 
prodrugs upon addition of other functional groups, the activity of which is suppressed 
until nitroreduction occurs. This characteristic was initially explored in development of 
the 2-NI prodrug RSU 1069, which contains a dormant aziridinyl functional group on 
the N1 side chain. Upon nitroreduction, the activation of this pre-positioned aziridine 
group converts this compound into a bifunctional DNA-crosslinking agent (37). 
Interstrand crosslinks produced by bifunctional DNA alkylating agents are much more 
cytotoxic than monoadducts, due to an inherent inability of host cell DNA-repair 
machinery to process them (38). Bifunctional alkylating agents are therefore much more 
attractive as anti-cancer agents than monofunctional drugs. RSU 1069 was shown to be 
20-200-fold more toxic under hypoxia than normoxia when tested in a variety of 
mammalian cell lines (39; 40) in vitro. However, a high incidence of gastrointestinal 
distress among trialled patients, considered to be caused by the incompletely repressed 
activity of the aziridinyl functional group of the parental compound, has impaired its 
entry into clinical use (41; 42). An analogue with less toxic side effects but similar 
DNA-alkylating reactivity and hypoxia selectivity profiles, RB 6145, has also been 
unsuccessful due to induction of irreversible retinal damage in preclinical mouse models 
(43). Another 2-nitroimidazole hypoxia-activated prodrug, the ifophosphoramide-
releasing prodrug TH-302, has shown enhanced pre-clinical potential, including greater 
hypoxic cell selectivity and a higher therapeutic index relative to other 2-NIs, and is 
currently in phase I clinical trials (44).   
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Figure 1.3. Schematic overview of nitroaromatic compound reduction.  
The initial one-electron reduction step of the parental nitroaromatic, catalysed by various intracellular 
reductases, results in an unstable nitro-anion radical that can react with molecular oxygen to reform the 
parental nitro compound, with the concomitant production of superoxide. In the absence of oxygen, or via 
a two-electron reduction step (as catalysed by oxygen-insensitive nitroreductases) the nitro group can be 
irreversibly reduced to the nitroso metabolite, and further to the hydroxylamino (4-electron) and amino 
(6-electron) reduction products. 
 
1.2.1.2.1. Dinitrobenzamide mustards (DNBMs) 
 
The proven capacity of nitroaromatics to function as hypoxia-activated prodrugs 
has initiated the development of a host of next-generation lead compounds, chief among 
these being the dinitrobenzamide mustards (DNBMs; examples shown in Figure 1.4A). 
This class of compound was originally developed following investigations into the 
enhancement of toxicity and hypoxia selectivity of nitrophenyl prodrugs, through the 
addition of a nitrogen mustard functional group (45). The alkylating properties of the 
dormant mustard are restored following nitroreduction, in a mechanism akin to that of 
RSU 1069 and its aziridinyl functional group. The anti-cancer properties of nitrogen 
mustards have been acknowledged for over half a century, with some of the very first 
anti-cancer drugs belonging to this family of compounds (46). Nitrogen mustards act as 
bifunctional alkylating agents and are capable of forming long-lasting DNA interstrand 
crosslinks in cells, at high frequency (47) (see Figure 1.4C). Their effectiveness and 
cytotoxicity has ensured their inclusion as functional groups in a variety of clinically 
approved anti-cancer drugs, including chlorambucil, bendamustine and 
cyclophosphamide (Figure 1.4B). The nature of the lesions induced by these compounds 
is particularly attractive for hypoxia-activated prodrug therapy, as the non-cycling/slow 
growing nature of many hypoxic cells requires that toxic and stable DNA adducts be 
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formed in order to ensure cell death occurs either in the absence of cell division or once 
cycling restarts (48; 49).  
 
 
 
 
Figures 1.4A-C. Nitrogen mustards as anti-cancer chemotherapeutics.  
(A) Structures of two DNBM prodrugs. (B) Structures of other nitrogen mustard containing anti-cancer 
drugs. (C) Mechanism of toxicity of nitrogen mustards. Figure 1.4C adapted from Emadi et al. (50).   
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Another attractive characteristic of the DNBMs is their ability to impart highly 
efficient bystander-mediated killing in tumour models (51). The bystander effect, in the 
context of prodrug activation, involves the transfer of activated cytotoxins from the cell 
of origin to neighbouring and other nearby cells, either by passive diffusion through cell 
membranes or active transport mechanisms (52) (see Figure 1.5). This has become an 
essential component of hypoxia-activated prodrug design, as it enables drugs that are 
activated solely under strict conditions of anoxia to diffuse into nearby cells post-
reduction, including those with higher oxygen tensions. Thus, a greater volume of the 
tumour can be targeted via this method. As previously mentioned, TPZ has a poor 
bystander effect, due to the short half lives of the reduced metabolites, and therefore 
limited anti-tumour properties (26; 53). Similarly, nitroimidazole-based prodrugs are 
devoid of a measurable bystander effect (51; 54), also likely due to the short half-lives 
of the reactive metabolites (55). In contrast, the prototype DNBM prodrug SN 23862 
shows efficient bystander killing in vitro in multi-layered three-dimensional cell 
cultures, because of the stability and longer half-lives of the toxic hydroxylamino 
derivatives (51). Similar results have been observed with other DNBM prodrugs (56; 
57).  
 
 
Figures 1.5A & B. Schematic overview of the bystander effect. 
Prodrugs activated either by (A) hypoxia or (B) delivered therapeutic transgenes are able to ablate 
surrounding oxygenated and/or non-transfected cells by passive diffusion through cell membranes or 
active cell transport out of the cell of origin.    
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The 3, 5-dinitrobenzamide 2-mustard prodrug PR-104 (57) (see Figure 1.4A) is 
currently the DNBM in the most advanced stage of development, having already 
completed Phase I clinical trials as a hypoxia-activated cancer therapy (57). PR-104 
shares the characteristic traits of its family members, including high bystander-mediated 
toxicity, hypoxia selectivity and a high frequency and stability of DNA interstrand 
crosslink formation (48; 58; 59). Further, the relative positioning of the nitro groups and 
asymmetrical mustard leaving groups contribute to an overall enhanced toxicity profile 
relative to SN 23862 and other DNBMs (56; 57; 60). Like other DNBMs, PR-104 is not 
a substrate for the oxygen-insensitive reductase NQO1 (61); however aerobic 
metabolism of the drug does occur and this is mediated principally through the aldo-
keto reductase AKR1C3 (62). Although undesirable in its capacity as a uniquely 
hypoxia-activated prodrug, levels of AKR1C3 have been shown to be elevated in many 
tumour types, suggesting a selective mechanism for PR-104 in dual hypoxia and aerobic 
targeting of certain cancer types (62). Furthermore, despite the aerobic reduction, a 
phase I clinical trial has demonstrated the safety of this prodrug in patients, with few 
reported dose-limiting toxicities and a maximum tolerated dose (MTD) exceeding the 
concentration required to achieve significant anti-tumour activity in cell culture and 
xenograft models (63).         
 
1.2.2. Combining hypoxia-activated prodrugs with other cancer therapies 
 
One disadvantage of hypoxia-activated prodrugs is their dependence on functional, 
intracellular reductases to enact prodrug reduction and cytotoxin release. This 
characteristic is further confounded by the heterogeneity in reductase expression 
profiles across different cancer types (64; 65) as well as the differences in reductase 
specificity for different hypoxia-activated prodrugs (22). As previously mentioned, 
aerobic reduction by a variety of oxygen-insensitive reductases, including NQO1 and 
AKR1C3, can also affect the therapeutic outcomes of use of these drugs. Additionally, 
the hypoxia-selectivity of these drugs renders the oxygen-perfused portion of the 
tumour resistant to their cytotoxic effects, although the bystander effect of, for example, 
the DNBMs is theoretically able to compensate for this limitation. Overall, clinical 
results suggest that hypoxia-activated prodrugs are not likely to be completely curative 
as monoagent therapies. Instead, combinatorial therapy involving hypoxia-activated 
prodrugs and other treatment regimes, such as gene therapy, is potentially a much more 
effective means of successfully combating cancer.  
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1.3. Gene therapy for cancer 
 
An emerging technique for targeting treatment to cancer cells is gene therapy, which in 
its most general form involves the targeted delivery of therapeutic transgenes to specific 
target cells. In this way, host cells themselves bring about reversal of disease phenotype, 
through expression of delivered transgenes. Cancer is a particularly attractive candidate 
disorder for gene therapy due to its genetic basis and exploitable cellular characteristics 
for gene delivery. In fact, of the roughly 1,600 gene therapy clinical trials performed to 
date, more than 60% of these trials have been aimed at the treatment of cancer (66). 
Most, if not all cancers are characterized by loss-of-function mutations in tumour 
suppressor genes (e.g. p53) or gain-of-function mutations in oncogenes (e.g. bcl-2) (67). 
A major area of gene therapy research is therefore aimed at reversion of these 
aberrations to the native cellular state, either by delivering tumour suppressor genes 
themselves, or inhibition of the expression of oncogenes via anti-sense or siRNA 
delivery (68). Cancer however is generally typified by not one, but multiple genetic 
abnormalities, suggesting single gene-function restoration via gene therapy will not 
produce significant anti-tumour effects (69). Furthermore, as the action of the expressed 
transgene is limited to the host cell, the clinical success of gene therapy is largely 
dictated by the efficiency of gene delivery; even at the highest currently achievable cell 
transfection rates, the majority of tumour cells would remain unaffected with single-
gene restoration therapy. In some instances, tumour cell death can trigger T-cell and 
NK-cell-mediated immune responses that can target surrounding, non-transfected 
tumour cells, providing a certain level of bystander effect (70; 71). However, more 
substantial and prolonged bystander effects are required if significant tumour ablation is 
to be achieved. To attain this, other cancer gene therapies have been developed that aim 
to either stimulate the immune system to attack tumour cells (e.g. genes encoding 
cytokines, co-stimulatory molecules and/or tumour-specific antigens (72)), be anti-
angiogenic (e.g. by the inhibition of vascular endothelial growth factor by siRNA (73)), 
or cause cancer cell death by either direct oncolysis by replicating viral vectors (74) or 
through the activation of cytotoxic prodrugs; this latter approach is discussed in more 
detail below.  
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1.4. Gene-Directed Enzyme-Prodrug Therapy (GDEPT) 
 
Gene-directed enzyme-prodrug therapy (GDEPT), or suicide gene therapy, builds on the 
therapeutic potential of gene therapy by employing transgenes whose products are able 
to convert separately administered biologically inert prodrugs into potent cytotoxins (for 
an overview see Figure 1.6). Prodrug activation and the associated cytotoxicity are 
therefore confined to transgene expressing cells, even though the physiological 
distribution of the prodrug is widespread. Low systemic toxicity therefore allows much 
greater concentrations of chemotherapy to be administered, improving the therapeutic 
index of the treatment. The ability of activated prodrugs to transport out of the cell of 
origin, either passively or actively, and into neighbouring, non-transfected cells (the 
bystander effect, as previously described in the context of hypoxia-activated prodrugs) 
is an important, if not the most important, characteristic of GDEPT, for it provides an 
elegant solution to the unavoidable issue of low cell transfection rates (52). Studies 
using prodrugs with high bystander effects have demonstrated that significant tumour 
reduction can occur when less than 0.1% of the tumour population expresses the 
activating enzyme (75). 
Although there are some exceptions, genes in the service of GDEPT are 
typically non-human in origin, as activation by endogenous enzymes in healthy tissue is 
obviously undesirable. One potential issue therefore is the elicitation of immune 
responses against the therapeutic protein (76). However, heightened immune responses 
can also result from cancer cell death and/or reactions to viral or bacterial delivery 
vectors and are therefore not specific to GDEPT systems (77). Furthermore, elicitation 
of an immune response towards cancer cells can have significant therapeutic benefits in 
the aiding of tumour ablation, suggesting that such a response is not entirely 
detrimental. A plethora of enzyme-drug combinations have been developed for cancer 
GDEPT over the last few decades, spanning a wide range of enzymatic activities (78). 
Several of the more well-known combinations tested in GDEPT are described briefly 
below (see also Table 1.1).  
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Figure 1.6. Schematic overview of GDEPT.  
A therapeutic transgene is packaged into a targeted delivery vector (viral, bacterial, liposome) and 
delivered either locally to tumours, or systemically. Tumour cells that take up the vector then express the 
transgene, which is able to convert a systemically administered prodrug into its toxic form. In addition to 
killing the transgene expressing cell, the toxic metabolites can spread to and exert their toxic effects on 
neighbouring and nearby cells that have not been transfected (the bystander effect). Figure reproduced 
from Kerr (79). 
 
1.4.1. Herpes simplex virus thymidine kinase - ganciclovir 
 
The first GDEPT system to be designed specifically for cancer involves activation of 
the purine nucleoside analogue prodrug ganciclovir (GCV) by the herpes simplex virus 
thymidine kinase (HSVtk) enzyme (80). Phosphorylation of GCV to its triphosphate 
derivative converts the prodrug into a potent DNA polymerase inhibitor and lethal 
guanine nucleotide analogue (81). Although humans also carry thymidine kinase genes, 
these versions are roughly 1,000-fold less efficient at activating the prodrug compared 
to HSVtk (82), minimizing activation in healthy tissue. Clinical success has, however, 
been varied to date, with one phase III clinical trial reporting no clear benefit to patients 
with glioblastoma multiforme (83), while another targeting malignant glioma has 
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demonstrated a significantly increased patient survival time (84) with this therapy. 
Another phase III clinical trial has recently been completed with results due in the 
course of 2011, potentially heralding approval of the first-ever cancer GDEPT product 
for clinical use (85). 
A serious limitation to the success of the HSVtk-GCV system is the inability of 
highly-polar phosphorylated-GCV and analogues to freely diffuse through cell 
membranes. It has been shown that the observed bystander effect mediated by activated 
GCV is dependent on cell-cell contacts, primarily gap junctions, and possibly also 
through apoptotic vesicles (86). However, down-regulation or complete loss of cell-cell 
contacts often happens throughout progression of many cancer types, providing a barrier 
to efficient diffusion of this class of drug (87). Nevertheless, enhancement of this type 
of bystander effect has been demonstrated through the use of gap-junction protein up-
regulating drugs, (88), by up-regulating gap junction proteins themselves with gene 
therapy (89), or by fusing the HSVtk gene to genes involved in intercellular trafficking 
(90). 
 
1.4.2. Cytosine deaminase – 5-fluorocytosine 
 
Another prodrug used in GDEPT is 5-fluorocytosine (5-FC), which is converted into the 
toxic nucleotide analogue 5-fluorouracil (5-FU) by yeast and bacterial cytosine 
deaminases (CDs), enzymes not found in mammalian cells (91). Further metabolism of 
5-FU by native cellular enzymes creates a variety of cellular toxins, including potent 
inhibitors of thymidylate synthase (involved in thymidine catabolism) and inhibitors of 
RNA and DNA processing (92). A major advantage of the CD/5-FC system over 
HSVtk/GCV is that the bystander effect is much more pronounced and does not require 
cell-cell contacts (93). Significant tumour regression has been observed with as little as 
1% of total tumour cells expressing CD (94; 95). Conversely, it appears that one 
bottleneck to 5-FC metabolism is limited penetration of the parental prodrug into cells 
(96). Furthermore, hepatic metabolism of 5-FC is associated with moderate systemic 
toxicity (97).
Table 1.1. Several GDEPT enzyme-prodrug combinations currently in clinical development.  
Enzyme Origin Prodrug Released drug Mechanism Bystander effect References 
TK Herpes 
simplex virus 
GCV, ACV Monophosphate 
derivatives 
DNA polymerase 
inhibition, guanine 
nucleotide analogue 
Gap-junction-
dependent 
(80; 84)  
CD E. coli,  
S. Cerevisiae 
5-FC 5-FU RNA, DNA polymerase 
and thymidylate synthase 
inhibition 
Passive diffusion (91; 98) 
CYP450 Human, rat Oxazaphosphorines 
(e.g. CPA, IFO) 
Phosphoramide mustards DNA alkylation (intra, 
interstrand crosslinks) 
Passive diffusion, 
4-hydroxy 
derivatives only 
(99) 
NTR E. coli Nitroaromatic prodrugs 
(e.g. CB1954, DNBMs, 
2-NIs) 
Hydroxylamine/amine 
derivatives 
DNA alkylation (intra, 
interstrand crosslinks) 
Passive diffusion (36; 100) 
CPG2 Pseudomonas 
G16 
Glutamic acid-phenyl 
mustard conjugates  
Phenyl mustards DNA alkylation (intra, 
interstrand crosslinks) 
Passive diffusion 
of metabolites 
only 
(101; 102) 
1
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  1.4.3. Cytochrome P450 – cyclophosphamide. 
 
The oxazaphosphorine prodrugs cyclophophamide (CPA) and ifosfamide (IFO) have 
been used in general anti-cancer chemotherapeutic practices as sole agents for many 
years (103). They are metabolized by certain members of the CYP450 superfamily of 
enzymes to their 4-hydroxy forms, whereupon they rapidly degrade into phosphoramide 
mustards - potent DNA alkylating, interstrand crosslinking agents - and another toxin, 
acrolein (99). Although these compounds are effective anti-cancer compounds as sole 
agents, high levels of activating CYP450 enzymes in the liver limit their clinical 
usefulness. Therefore, GDEPT approaches, mainly using the catalytically superior rat 
CYP2B1 isoform as activating enzyme, have been in development since the mid 1990s 
(104). The activated 4-hydroxy forms of CPA and IFO freely diffuse through cell 
membranes, mediating a strong bystander effect in vitro and in vivo (104). However, the 
very short plasma half-lives of these metabolites (<6 min; (105)) and the lipid-
impenetrability of the mustard and acrolein degradation products are potential obstacles 
(99). A significant advantage of the CYP450-CPA/IFO system is the cell-cycle 
independent nature of the primary cytotoxin, the phosphoramide mustard. Directly 
DNA-damaging agents are able to kill cells whether replicating or not; as it is widely 
acknowledged that only a very small percentage of total tumour cells are dividing at any 
one time, this characteristic is a great advantage over the cell-cycle dependency of GCV 
and 5-FC.  
  
1.5. Nitroreductase GDEPT 
 
The aforementioned GDEPT systems have all proved efficacious in pre-clinical studies, 
and several have advanced into clinical trials for the treatment of a variety of cancer 
types. However, none has demonstrated all the ideal characteristics of the perfect 
GDEPT enzyme-drug combination. For example, activated GCV is devoid of a 
substantial, cell-cell contact-independent bystander effect, while both GCV and 5-FC, 
and their respective derivatives, require active cell division to exert their toxicity. 
Meanwhile, the prevalence and activity of native hepatic CYP450 enzymes limits the 
dose of the oxazaphosphorine prodrugs that can be administered in CYP-CPA/IFO gene 
therapy, with limited half lives of the activated derivatives also preventing efficient 
tumour penetration. Nitroreductase (NTR) enzymes coupled with nitroaromatic 
prodrugs are attractive combinations for GDEPT that address many of these problems, 
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and as such represent some of the most promising GDEPT systems studied to date. 
Many of the advantages of the use of nitroaromatic prodrugs in cancer therapy have 
already been described, in the context of hypoxia activation (e.g. 2-NIs, DNBMs). The 
use of GDEPT to complement the therapeutic benefits of these drugs is therefore a 
promising avenue of research.  
 
1.5.1. CB1954 and the Walker 256 Carcinoma 
 
The prototypical nitroaromatic prodrug, 5-(aziridin-1-yl)-2,4-dinitrobenzamide, or 
CB1954, was originally discovered during a series of tests on N-substituted-aziridine 
compounds for their anti-tumour effects against the rat Walker-256 carcinoma, an 
established preclinical cancer model system (106). In an unprecedented display of anti-
tumour activity, CB1954 was found to cause complete regression and cure of the 
Walker 256-carcinoma (107; 108). Such marked activity was unusual for a compound 
that, based on its structure, was predicted to act as a monofunctional DNA-alkylating 
agent by virtue of the single aziridine functional group (107). The selective ablation of 
tumour cells also pointed towards a targeted mechanism of action. Further studies 
identified its mode of action to be that of a prodrug: reduction of the 4-carbon-linked 
nitro group (4-NO2) of the compound to its hydroxylamino derivative (5-(aziridin-1-yl)-
4-hydroxylamino-2-nitrobenzamide: 4-NHOH), catalysed principally by the native 
oxygen-insensitive reductase NQO1, is required before cytotoxicity can be exerted 
(109; 110). This reductive step allows the compound to undergo two important 
electronic and structural changes that contribute significantly to its overall DNA-
reactivity. Firstly, the aforementioned redistribution of electrons within the aromatic 
ring provides the aziridine group with enhanced electrophilic properties, effectively 
„awakening‟ its repressed DNA-binding abilities. However, the difference in DNA 
alkylating reactivity of the aziridine group between the parental and 4-NHOH 
derivatives of CB1954 is modest, and does not account for the vast difference in DNA-
reactivity observed in vivo between the parental and reduced forms (110; 111). Instead, 
it has been proposed that a non-enzymatic reaction occurs between the hydroxlyamino 
group of the 4-NHOH derivative and intracellular thioesters, in particular acetyl-
coenzyme A (acetyl-CoA), to form a highly reactive N-acetoxy derivative (110) (see 
Figure 1.7). This reaction provides the compound with a secondary DNA-reactive 
centre, and explains the ability of the activated compound to form DNA interstrand 
crosslinks at high frequency (up to 70% of total DNA lesions; (112)) in cells, but not 
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naked DNA (109; 110). Furthermore, the intrinsic toxicity of CB1954-induced DNA 
lesions is enhanced even further by the inability of host cell repair mechanisms to 
process them (112; 113). In addition, CB1954 displays a marked bystander effect in 
vitro and in vivo (114-118), is not cell cycle-dependent, and kills cells via p53-
independent apoptosis (119); factors that further enhance the overall efficacy of this 
compound as an anti-cancer agent.  
Although curative against well-established rat models of cancer, CB1954 as a 
sole agent was found to be 500-5,000 times less toxic to human cancer cells, including 
cell lines expressing high levels of the native NQO1 enzyme (120). Later biochemical 
studies with purified enzymes revealed dramatic differences in catalytic abilities 
between the rat and human forms of the enzyme (kcat of 4.1 min
-1
 for the rat form, 
compared to 0.64 min
-1
 for the human), confirming the inability of human NQO1 to 
efficiently metabolize CB1954 (120). 
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Figure 1.7. Bioactivation of CB1954. 
 The first step is enzymatic nitroreduction of the parental prodrug (1) to either the 2- (2) or 4-
hydroxylamine (4) (2-NHOH/4-NHOH respectively). 2 is unstable and rapidly disproportionate, in 
aqueous solution, to the nitroso (not shown) and amine (3) derivatives (111). 4 can undergo further 
reduction to the comparatively non-toxic amine (6), or react with intracellular thioesters (such as acetyl-
CoA) to form the N-acetoxy derivative (5) (110). Over-acetylation of 5 can also form 6. Only 3 and 5 
readily react with DNA to form monoadducts, intra- and interstrand crosslinks (111; 121). 
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 1.5.2. CB1954 and Escherichia coli NfsB 
  
A major step forward in CB1954 therapy was achieved upon the identification of an 
enzyme from the bacterium Escherichia coli that was not only able to efficiently reduce 
CB1954, but could do so 90-fold faster than even the rat form of NQO1 (122), opening 
up opportunities for CB1954-mediated GDEPT. The enzyme was purified and studied, 
and found to be a 24 kDa flavoenzyme, with no discernible amino acid sequence or 
structural homology to NQO1. Instead, it has high sequence similarity to previously 
reported bacterial nitroreductases from Salmonella typhimurium and Enterobacter 
cloacae, enzymes involved in the bioreduction of nitroaromatics and quinones (123-
125) and was also identified as the same enzyme implicated in previous studies on the 
development of resistance to nitrofuran antibiotics (126; 127). Thus it was named NfsB 
(for “nitrofuran sensitivity” enzyme B).  
Unlike NQO1, reduction of CB1954 by NfsB yields equimolar amounts of both 
the 2- and 4-NO2 reduction products (however both nitro groups are unable to be 
reduced simultaneously on a single molecule). Original data suggested that the 2-NHOH 
metabolite was much less toxic than the 4-NHOH due to its inability to form DNA 
interstrand crosslinks (i.e. is a monofunctional agent) and was therefore undesirable as 
an end product (109). Recent data has however challenged this theory and suggests that 
the 2-amino (2-NH2) derivative, which is produced non-enzymatically by hydrolysis 
and disproportionation of the unstable 2-NHOH (111), is the key metabolite responsible 
for the bystander-mediated toxicity of CB1954. Furthermore, this same metabolite 
displays potency towards nucleotide-excision repair mutant cancer cell lines at a level 
comparable to, or greater than, the 4-NHOH product (121).  
E. coli NfsB has been tested preclinically in vitro and in vivo for its ability to 
confer CB1954 sensitivity to transgene expressing cancer cell lines and tumour 
xenografts. 10-2,000 fold improvements in sensitivity to the prodrug have been reported 
in vitro upon NTR over-expression, depending on the cell line, expression vector and 
CB1954 dose employed (116-118; 128-132). In NfsB over-expressing murine tumour 
xenograft models, several studies have reported an almost doubling of median survival 
times upon CB1954 administration relative to no treatment (131; 133). In addition, 
significant reduction in tumour size has been reported upon treatment with CB1954 
when only a small percentage (5-10%) of cells are expressing NfsB, which 
demonstrates the in vivo utility of bystander-mediated cell killing (115; 116; 130; 134). 
It has also been demonstrated that CB1954 is equally effective against NfsB over-
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expressing cell lines that are resistant to cisplatin and other common alkylating agents 
(131; 135).       
Clinical trials have also demonstrated the safety of systemically administered 
CB1954 (136) or nfsB expressing adenovirus (137) alone in patients with 
gastrointestinal or resectable liver cancers, respectively. The results of two phase I/II 
clinical trials of adenovirus-delivered NfsB/CB1954 therapy in patients with prostate 
cancer were released in 2009 (100; 138). Although primary aims were to investigate 
toxicity of the combined treatments, some observations were made on anti-tumour 
effects. Results were however ambiguous, with no clear advantage for the therapy in 
aiding tumour regression. Furthermore, dose escalation to improve anti-tumour effects 
has been hampered by hepatic toxicity of CB1954, with the maximum serum 
concentration achievable in patients being ~6 µM (136; 139). The basis of off-target 
toxicity of CB1954 has been examined in mouse and human liver preparations, and 
demonstrated to be the result of endogenous aerobic and anaerobic reductase activity 
independent of NQO1 (139; 140). Experimental evidence has suggested a possible 
involvement of nitric oxide synthases in this activity (141). 
 
1.5.3. CB1954 and human NQO2 
 
An alternative native human enzyme, NQO2, has more recently been identified as 
having CB1954-reducing activity (142). NQO2 has high sequence homology to NQO1 
(but not to NfsB) and is also known to be up-regulated in many cancer types. In 
addition, the catalytic efficiency of this enzyme in reducing CB1954 in vitro is 3,000 
times greater than that of NQO1, while a 100-3,000-fold difference in CB1954 dose-
dependent toxicity has been observed in human cancer cell lines upon over-expression 
of NQO2; however a stern dependence on non-biogenic co-substrates (such as 
dihydronicotinamide riboside) has ensured that activity of the endogenous enzyme 
remains dormant in vivo, with the previously reported study employing separately-
administered dihydronicotinamide riboside (NRH) as the electron donor. Investigations 
into less expensive synthetic co-factors which could act as substrates for NQO2 have 
identified several lead compounds, renewing interest in the possible use of CB1954 as a 
sole agent to control cancers in which high NQO2 levels have been reported (143). A 
phase I clinical trial involving CB1954 and the synthetic nicotinamide NQO2 co-factor 
EP0152R has recently been completed with favourable outcomes, demonstrating the 
feasibility of such an approach (144).   
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1.5.4. E. coli NfsB and alternative nitroaromatic prodrugs 
 
In order to improve potency, analogues of CB1954 and other nitroaromatic-based 
compounds have been studied as alternative prodrugs for NTR-mediated GDEPT (see 
Figure 1.8). In addition to direct variants and regioisomers of the base CB1954 structure 
(145), alternative strategies have been investigated including the attachment of 
nitrobenzylcarbamate moieties to a variety of cytotoxic agents, including mitomycin C, 
anthracyclines and aniline mustards, in order to mask their activity prior to 
nitroreduction (146). Similarly, fusions of nitrobenzene and cyclophosphamide have 
been studied as possible NTR-mediated prodrugs (147). However, despite some 
promising in vitro data, many of the above species have failed to replace CB1954 as a 
lead compound due to poor solubility, extravascular diffusion and/or NTR-selectivity 
(148-150). 
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Figure 1.8. Structures of several nitroaromatic prodrugs that act as substrates for E. coli NfsB. 
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 1.5.4.1. E. coli NfsB and DNBMs 
 
 
Studies have also demonstrated that DNBM hypoxia-activated prodrugs act as 
substrates for NfsB, securing a potential role for them in GDEPT to complement their 
hypoxia-activated cytotoxicity (151; 152). In fact, the catalytic efficiency of NfsB 
towards SN 23862 is superior to that of CB1954 (4-fold higher kcat), while in NfsB 
over-expressing UV4 cell lines the improvement in toxicity upon administration of SN 
23862 (140-fold) is over ten times that of CB1954 (12-fold) (151). Furthermore, the 
bystander effect and hypoxia selectivity of DNBMs are far in excess of those of 
CB1954 (121; 153; 154). It has been shown that the differences in cytotoxicity between 
CB1954 and certain DNBMs, in particular SN 23862, is related to the nature and 
alkylating reactivity of the reduction metabolites of the two types of compound. NfsB 
catalyzes the formation of both the 2- and 4-NHOH metabolites of CB1954, while only 
the 2-NHOH is formed from reduction of SN 23862. The 2-NHOH of SN 23862 is 
however unstable in aqueous conditions, undergoing rapid disproportionation and 
hydrolysis to form the amine (2-NH2). This amine, which can be considered the primary 
end product of SN 23862 metabolism, is roughly 2,200-fold more reactive than the 
parental compound, compared with only 17-fold for both the 4-NHOH N-acetoxy and 
2-NH2 derivatives of CB1954 (111). In contrast to CB1954, alkylating reactivity of SN 
23862 is not dependent on conjugation with intracellular thioesters, a potentially rate-
limiting step, providing a simpler and more direct mechanism of bioactivation for this 
prodrug (111). Overall, results clearly demonstrate that the 2-NH2 derivative of SN 
23862 is superior to both the 4-NHOH N-acetoxy and 2-NH2 of CB1954 in terms of 
alkylating reactivity and cytoxicity in vitro (111; 121). 
 Results with regioisomers of SN 23862, including the more potent 3, 5-dinitro 
class of benzamide mustards, are consistent with those previously mentioned, 
particularly in regards to their substrate specificity towards NfsB (152; 155). For 
example, a dibromo-analogue of PR-104, SN 27686, has been evaluated in vivo in 
mouse tumour xenograft models in conjunction with a conditionally replicating, NfsB 
over-expressing adenoviral vector. The mean survival time of animals treated with this 
regime was enhanced considerably over that of a CB1954-administered control group, 
specifically when only a fraction (10%) of cells were expressing the transgene (56). The 
emerging use of DNBMs in GDEPT alongside nitroreductase enzymes therefore 
presents a promising avenue in cancer gene therapy.    
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1.6. Alternative enzymes for cancer gene therapy 
 
Most, if not all GDEPT strategies currently being investigated for cancer treatment are 
still in preclinical development and as such require extensive optimisation before they 
can be clinically useful. Because much of the success of GDEPT is currently limited by 
modest gene-delivery and expression methods, a lot of the emphasis on improving 
GDEPT systems will rely on enhancing alternative aspects of the therapy regime. 
Prodrug modification to improve potency and tumour selectivity is an obvious 
approach, and this has already been discussed in detail for NTR GDEPT. However, a 
major limiting factor in many GDEPT strategies is often the catalytic efficiency of the 
activating enzyme for the prodrug of interest. GDEPT enzyme choices are usually made 
on a first-come first-served basis, with E. coli being a major source of prodrug-
activating enzymes (75; 122; 156; 157). However, more active enzymes can often  be 
found in other organisms. For example, the cytosine deaminase from Saccharomyces 
cerevisiae was found to have a Km 22-fold lower than that of the previously tested E. 
coli enzyme (158) towards 5-FC. More importantly, this improvement in activity was 
also seen in vitro and in vivo in transgene-expressing cancer models (159).  
 This issue is particularly relevant to NTR/CB1954 GDEPT, as plasma 
concentrations of CB1954 at the maximum tolerated dose (MTD) are more than 80 
times lower than the lowest reported Km of E. coli NfsB for this substrate (122). 
Furthermore, the Km of NfsB for  SN 23862, which displays very similar 
pharmacokinetics to CB1954 in mice (160), is 2-3 fold higher than that reported for 
CB1954 (151). Although in vitro kinetic data for members of the more potent 3, 5-
dinitro series of DNBMs are not available, our own work suggests that they are not very 
efficient substrates for NfsB and would suffer from similar low catalytic turnover in 
vivo, despite having higher MTDs in mice (56; 161) and humans (63; 136). Although 
compensated in part, relative to CB1954, through improved tissue diffusion and 
cytotoxicity, the low Km of NfsB for these substrates suggests that enzyme improvement 
would have a significant impact on in vivo efficacy. 
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1.6.1. The bacterial nitroreductases: phylogenetic and biochemical 
properties 
 
E. coli NfsB belongs to a superfamily of enzymes, the bacterial nitroreductases (NTRs), 
which are widespread amongst prokaryotes, including both bacteria and archaea (162). 
NTRs are broadly defined as any enzyme with the capability of reducing nitro groups of 
nitroaromatic compounds, either through sequential one electron steps (oxygen-
sensitive, or class II) or simultaneous two electron steps (oxygen-insensitive, or class I) 
(162; 163). In this regard, NQO1, which can reduce CB1954 aerobically, is a class I 
NTR, while CYP450R, which reduces CB1954 and many other nitroaromatic 
compounds via one electron steps, belongs to the class II NTRs. Most work with 
bacterial NTRs to date has focused on those belonging to class I, due to their ability to 
reduce nitro groups under physiological conditions (i.e. in the presence of oxygen). 
Nitroaromatic groups are found in a variety of chemical species, almost all of which 
have been produced over the last century through anthropogenic processes such as the 
manufacture of explosives, dyes, textiles and insecticides, and can therefore be regarded 
as recent additions to the chemical diversity available in the environment (162). As 
such, it is assumed that many, if not all, bacterial NTRs possess nitroreductase activity 
as a secondary, or „promiscuous‟ function to their primary activity, as there has likely 
been insufficient time to evolve specific metabolic pathways directed at such 
compounds. One interesting case has been reported, however, of an NTR from 
Haemophilus influenzae able to reduce and thereby detoxify the natural nitroaromatic 
antibiotic chloramphenicol, suggesting a possible physiological role in antimicrobial 
detoxification for this specific enzyme (164). Otherwise, physiological roles associated 
with these enzymes are largely assumed to be a function independent of nitroreductase 
activity, such as quinone reduction or NAD(P)H homeostasis in oxidative stress 
protection (165), flavin reduction for bioluminescence (166; 167), dihydropteridine 
reduction for aromatic amino acid hydroxylation (168), the production of vitamin K12 
(169), or the production of H2O2 through NAD(P)H oxidation as a defence or O2-
homeostasis mechanism (170; 171). Bacterial NTRs have been well-studied for a 
variety of reasons, including their role in development of resistance to nitroaromatic 
antimicrobials such as nitrofurazone (NFZ) and metronidazole (MTZ) (172; 173) and 
their ability to biotransform recalcitrant nitroaromatic environmental pollutants such as 
di- and trinitrotoluenes (D/TNTs), thus affording them attractive properties for 
bioremediation processes (162). Many have been purified and biochemically 
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characterised, including the elucidation of crystal structures in many cases, allowing 
detailed understanding of their molecular biology (see Table 1.2 for examples) (170; 
174-183). Most bacterial NTRs are relatively small (20-40 kDa), homodimeric flavin-
containing (typically FMN) enzymes that require NAD(P)H as co-substrates/electron 
donors to reduce other substrates. Substrate specificity is generally broad and can 
include quinones, flavins, azo-dyes, ferricyanide and chromate (VI), in addition to 
nitroaromatics (176; 184). Nevertheless, the mechanism of catalysis is usually 
conserved between all substrates and all enzymes, and proceeds via a bi-bi ping-pong 
mechanism, whereby NAD(P)H is the first substrate to enter (leading to the two-
electron reduction of the enzymatic FMN group), followed by exit of NAD(P)
+
 and 
entry of the second substrate. Electrons are then passed from reduced FMN to the 
second substrate, followed by dissociation of the reduced end metabolite. In the case of 
nitroaromatic compounds, this entire cycle is repeated once to form the hydroxylamine, 
or twice to produce the amine (see Figure 1.3). However, as previously mentioned, the 
hydroxylamine is the most common end product of the reaction, due to the lower 
reduction potential of the NHOH group relative to the parental nitro group, creating 
electrochemical difficulties in further reduction (35). 
Phylogenetically, many of the bacterial NTRs characterised to date belong to 
one of two groups, based on their amino-acid homology to either E. coli NfsA (the 
major NTR) or NfsB (the minor NTR) (176; 177). Little sequence homology is shared 
between these two groups (7% amino acid identity between E. coli NfsA and NfsB, 
across entire sequence), although biochemically (as already described) and structurally 
they are very similar and contain elements similar to many flavoenzymes (core structure 
typically consisting of a multi-stranded parallel β-sheet core flanked on each side by 
multiple α-helices; (162)). No mammalian enzyme with considerable homology to 
either of these classes has been identified to date, although several examples exist in 
protists, most likely arising through horizontal gene transfer from bacterial species (185; 
186). Outside of these two principal families, nitroreductase activity has been associated 
with several other bacterial enzyme classes, in particular the Old Yellow Enzymes 
(OYEs) (187).  
  
Table 1.2. Examples of biochemically characterised bacterial NTRs. 
NTR Organism Substrates Refs 
NfsA E. coli Quinones, chromate, ferricyanide, flavins, CB1954, TNT, NFZ, other nitroaromatics (188-190) 
Frp Vibrio harveyi Quinones, chromate, ferricyanide, flavins, NFZ, other nitroaromatics (188; 191) 
PnrA Pseudomonas putida JLR11 TNT, other nitroaromatics (192) 
SnrA Salmonella typhimurium NFZ (193) 
NfrA1 Bacillus subtilis Quinones, ferricyanide, flavins, NFZ, other nitroaromatics (167; 170) 
YcnD Bacillus subtilis Chromate, NFZ, other nitroaromatics (194)  
NitA Clostridium acetobutylicum TNT, other nitroaromatics (181) 
NfrA Staphylococcus aureus Ferricyanide, FMN, NFZ (195) 
NfsB E coli Quinones, ferricyanide, flavins, CB1954, NFZ, TNT other nitroaromatics   (122; 177; 190) 
FRaseI Vibrio fischeri Quinones, ferricyanide, flavins, NFZ, other nitroaromatics (166) 
NR/NfsI Enterobacter cloacae Quinones, flavins, NFZ, TNT, other nitroaromatics (174; 196) 
CnR Salmonella typhimurium Quinones, flavins, NFZ, other nitroaromatics (197; 198) 
RdxA Helicobacter pylori Quinones, ferricyanide, NFZ, MTZ, CB1954, other nitroaromatics (171) 
YfkO Bacillus licheniformis NFZ, CB1954, other nitroaromatics (199; 200) 
NprA Rhodobacter capsulatus NFZ, other nitroaromatics (168) 
PETNr Enterobacter cloacae TNT, other nitroaromatics (201) 
XenB Pseudomonas fluorescens TNT, other nitroaromatics (202) 
AzoR Rhodobacter sphaeroides Quinones, chromate, ferricyanide, flavins, TNT, other nitroaromatics  (203) 
DrgA Synechocystis spp. Quinones, ferricyanide, flavins, NFZ, other nitroaromatics  (204) 
NitB Clostridium acetobutylicum TNT, other nitroaromatics (181) 
Frb Bacillus subtilis Quinones, ferricyanide, flavins, NFZ, other nitroaromatics  (205) 
2
6
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1.6.2. CB1954 and alternative bacterial NTRs 
 
The widespread abundance and phylogenetic diversity of NTRs in the environment 
suggests that there are likely to be enzymes that reduce nitroaromatic prodrugs more 
efficiently than E. coli NfsB. Indeed, several research groups have focused their efforts 
on the characterisation of alternative NTRs in order to identify enzymes with enhanced 
prodrug reducing activities (see table 1.3. for examples). Many of these studies resulted 
from characterisation of NTRs in other contexts, including reduction of environmental 
contaminants and antibiotics. For example, the NTR NprA from Rhodobacter 
capsulatus was initially identified on the basis of its 2,4-dinitrophenol reducing abilities 
(182). It was later found that over-expression of this NTR in E. coli dramatically 
increased the sensitivity of the host towards CB1954 (168). Similarly, nitrobenzene 
reductase (NbzA) from Pseudomonas pseudoalcaligenes JS45, an organism able to 
survive on nitrobenzene as a sole carbon and nitrogen source, has demonstrated 
CB1954-reducing activity, with a Km for this substrate almost 80-fold lower than NfsB 
(206). The NTR RdxA from the gut pathogen Helicobacter pylori, an enzyme 
implicated in development of host resistance to MTZ, has also been purified and 
characterized and identified as having a 10-fold improved CB1954-reducing activity 
compared to NfsB (171). However, none of these reports have described in vivo or in 
vitro mammalian cell culture data comparing prodrug reducing activity directly 
alongside NfsB, rendering it difficult to gauge their utility in GDEPT. Indeed, only a 
few publications exist of NTR characterisation specifically focusing on prodrug 
reducing abilities, and therefore offer insight into comparative activities of these 
enzymes with NfsB in a more robust clinically relevant setting. Anlezark et al. (2002) 
were the first to characterise an alternative bacterial CB1954-reducing enzyme, that of 
YwrO from Bacillus amyloliquefaciens (207). Not only does YwrO have a slightly 
higher affinity than NfsB for CB1954 (Km of 617 compared with 862 µM), but it also 
exclusively generates the more cytotoxic 4-NHOH metabolite. Interestingly though, 
V79 mammalian cells incubated in the presence of this enzyme and the relevant co-
substrate were ten-fold less sensitive to CB1954 compared to those treated with E. coli 
NfsB. YwrO is also unable to catalyse reduction of the DNBM analogue SN 23862, in 
contrast to NfsB. Likewise, Theys et al. (2006) tested a panel of NfsB and YwrO 
homologues from diverse bacterial species for CB1954-induced cytotoxicity in a human 
cancer cell line and found that YwrO-like (shared significant amino acid homology with 
YwrO) enzymes were significantly outperformed by NfsB-like enzymes (208). As part 
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of this study however, they did isolate an NfsB-homologue from H. influenzae which 
had a lower ED50 value (concentration of prodrug required to inhibit cell growth to 50 
% of unchallenged control) for CB1954 than E. coli NfsB, although the difference was 
modest (4.7 compared to 6.3 µM). A separate study has characterised the NTR YfkO, 
isolated from the thermophilic bacterium Bacillus licheniformis, and found it to have 
activity with a range of nitroaromatic prodrugs, including a 5,000-fold increase in 
catalytic efficiency towards CB1954 and 5-fold increase in specific activity towards SN 
23862 compared with NfsB (199). Unfortunately, no comparative cytotoxicity tests 
were carried out in human or mammalian cell lines. Although scarce, these reports have 
unequivocally demonstrated that alternative CB1954 and nitroaromatic prodrug 
reducing enzymes exist. Furthermore, sharing significant amino acid homology to NfsB 
is not a prerequisite for CB1954-reducing activity. YwrO, for example, shares no 
sequence homology to NfsB, but does share some identity with mammalian NQO1 and 
NQO2 (207). NbzA from P. pseudoalcaligenes JS45 shares only 27% identity with 
NfsB across a 48 amino acid region, while YfkO, RdxA and NprA only share 24%, 25% 
and 30% amino acid identity, respectively, with NfsB across the entire gene sequence. 
  
Table 1.3. Kinetic parameters for all naturally-occurring CB1954-reducing 
enzymes characterised to date. 
Enzyme Km (µM) kcat (s
-1
) End products Reference 
NQO1 (human) 1,370 0.01 4-NHOH
a
 (120) 
NQO1 (rat) 840  0.07 4-NHOH (120) 
NQO1 (mouse) 1,280  0.01 4-NHOH (209) 
NfsB (E. coli) 860 6.0 2 & 4-NHOH (122) 
NQO2 (human) 260 6.01 4-NHOH (142) 
YfkO (B. licheniformis) 30 1,070 4-NHOH (199) 
YwrO (B. amyloliquefaciens) 620 8.2 4-NHOH (207) 
YdgI (B. amyloliquefaciens) 3,860 30.3 2 & 4-NHOH (208) 
YodC (B. amyloliquefaciens) 550 58 2 & 4-NHOH (208) 
NfnB (H. influenzae) 690 56.2 4-NHOH (208) 
NfnB (C. jejeuni) 217 6.1 4-NHOH (208) 
YwrO (P. gingivalis) 1,200 3.2 4-NHOH (208) 
RdxA (H. pylori) 35 10 NR
b
 (171) 
NbzA  (P. pseudoalcaligenes) 2.3 NR NR (206) 
NfsA (E. coli) 140 21 2-NHOH (189) 
a2-/4-NHOH: 2- or 4-hydroxylamine respectively. 
bNR: Not reported 
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 1.6.3. Enzyme engineering to improve activation of anti-cancer prodrugs 
 
Enzymes are flexible molecules, and as such are amenable to finite levels of mutational 
alterations without loss of considerable catalytic activity. Moreover, mutations can 
even, in some circumstances, enhance many properties of the enzyme including 
substrate specificity, catalytic efficiency and thermal and solvent stability (210). The 
purposeful targeted or random mutagenesis of enzyme sequences using standard 
laboratory genetic procedures, otherwise known as enzyme engineering or directed 
evolution, has therefore emerged as a powerful approach to hone enzyme activity 
towards desired end goals (211). 
The activity of enzymes for use in GDEPT has been improved by several 
groups. For example, Black and co-workers performed extensive studies on variants of 
HSVtk, mutated randomly at several residues in the putative active site of the enzyme, 
and identified several that confer markedly improved sensitivities towards GCV and the 
analogue aciclovir (ACV) to E. coli and mammalian cells over-expressing these 
enzymes (212-214). Furthermore, certain of these mutants were able to improve 
sensitivity of tumour cells expressing these enzymes to GCV and ACV two to five-fold 
over the wild-type enzyme, demonstrating a clear in vivo benefit (215). Similar 
successes have also been reported with bacterial and yeast CD, with mutant enzymes 
identified that can increase sensitivity of E. coli, mammalian cells and human tumour 
xenografts to the toxic effects of 5-FC compared to the wild-type enzyme (156; 216; 
217).  
 Not surprisingly, NfsB has also been the subject of a series of ongoing 
mutagenesis studies, primarily carried out by Peter Searle and co-workers, in order to 
improve its affinity and catalytic efficiency towards CB1954. An early study used site-
saturation mutagenesis (testing of all alternative amino acid possibilities at a certain 
residue) of active site residues, as determined by previously-solved crystal structures of 
the enzyme, to identify amino acids involved in CB1954 reduction (218). Out of the 
nine amino acids targeted, improved mutants were found with changes at any one of six 
sites. Most significantly, a single amino-acid mutant (F124K) was isolated that 
conferred a5-foldincrease in sensitivity of human ovarian cancer cells (over-expressing 
the relevant NTR) towards CB1954, compared with wild-type NfsB. More recently, the 
effects of pair-wise combination of some of these beneficial single mutations has been 
evaluated, with vast improvements in enzyme activity and prodrug substrate affinity 
observed with certain double mutants (219; 220). An alternative approach has been 
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explored by Jackson and colleagues (2006), using the incorporation of non-natural 
amino acids into site 124 of NfsB to improve CB1954 reducing activity (221). Of the 30 
synthetic amino acids tested, one was found that not only conferred 30-fold improved 
CB1954-reducing activity in vitro over wild-type NfsB, but also 2.3-fold improved 
activity over the best possible natural amino acid mutant of site 124. Together, these 
studies clearly demonstrate the potential of enhancing NTR activity towards CB1954 
using enzyme engineering approaches. 
  Nevertheless, the main focus of these enzyme engineering studies is still E. coli 
NfsB. The breadth of NTR-diversity available in nature suggests that alternative 
enzymes may provide better starting scaffolds for evolution experiments. A pivotal 
study in this regard was carried out by Barak et al. (222), whereby a chromate reductase 
(YieF) from E. coli was randomly mutated in order to further improve chromate 
reducing activity. One enhanced mutant, Y6, was not only found to be superior in its 
chromate reducing activity, but was also able to confer up to 10-fold improvement in 
sensitivity of HeLa cells towards CB1954, relative to wild-type YieF. Furthermore, this 
activity was also far in excess of that of E. coli NfsA, another NTR recently found to be 
superior to NfsB in CB1954-mediated cell killing (189). However, this being the sole 
report to date of evolution of an NTR other than NfsB towards improved nitroaromatic 
prodrug-reducing activity suggests that there is substantial work required in this field 
before clinically-significant results can be generated. 
 
1.7. Enzyme activity screening technologies 
 
Enzyme discovery and/or engineering studies rely on the ability to identify individual 
enzymes that are improved for a function of interest over a pre-existing scaffold from a 
pool of enzyme variants. Depending on the technique used to generate enzyme libraries, 
the number of variants that comprise this pool can exceed 10
4
 by many orders of 
magnitude meaning that precise quantitative assays such as kinetic evaluation of 
purified enzymes are far too costly and time-consuming to be employed as screening 
techniques. As such, the development of reliable and high-throughput enzyme activity 
screening methodologies has received considerable attention in these fields.     
 Strategies based on the ability of a target enzyme to complement null mutations 
in metabolic pathways and/or allow host organisms (such as bacteria or yeast) to grow 
on selective media are among the most efficient techniques applied so far. Examples of 
these selective techniques have been successfully employed in GDEPT studies for the 
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identification of enzyme variants with enhanced prodrug activating abilities, such as 
HSVtk variants improved for GCV phosphorylation (212) and E. coli CD variants for 
improved 5-FC deamination (156). Alternatively, in the absence of an appropriate 
selective function, the use of fluorescent enzyme substrates can allow very high-
throughput screening of enzyme variants through fluorescence-activated cell sorting 
(FACS). This has successfully been applied, for example, in the identification of 2‟-
deoxynucleoside kinase variants improved in the activation of nucleoside analogue 
prodrugs (223). 
 
 1.7.1. Screening for nitroaromatic prodrug reduction 
 
Unfortunately, no essential metabolic pathway or generally applicable fluorescence 
based method has yet been developed for detection of NTR-mediated nitroaromatic 
prodrug reduction, severely hindering the potential for evolution of these enzymes. One 
individual case of a nitroaromatic prodrug (6-chloro-9-nitro-5-oxo-5H-
benzo(a)phenoxazine; CNOB) that produces a fluorescent signal, in addition to 
cytotoxicity, upon reduction by NTRs has been reported (224). Although valuable for 
allowing quantitative assessment of in vitro and in vivo activation of this prodrug, 
fluorescence emission is a unique property of CNOB and not of nitroaromatic prodrugs 
in general, precluding the application of this approach for use with other NTR-prodrug 
combinations. On the other hand, the Auckland Cancer Society Research Centre 
(ACSRC) has developed a range of NTR-activated fluorophore compounds, which 
could act as prodrug surrogates for evaluation of NTR activity (Jeff Smail, personal 
communication). Assessment of the applicability of these compounds in enzyme 
screening is currently being carried out in our lab. However, in many cases fluorophore 
structure does not accurately represent that of the final application prodrug, potentially 
biasing identification of lead NTRs towards those superior in fluorophore activation, 
and not necessarily the desired prodrug activity.  
Of the few directed-evolution/protein engineering studies of NTR enzymes that 
have been carried out, the main quantitative enzyme activity screen employed has been 
based on either host organism growth inhibition (in the presence of increasing 
concentrations of prodrug) or direct spectrophotometric kinetic analysis of purified 
enzymes (218; 219; 221). Although these methods do test for the precise enzymatic 
properties desired, they are both costly, in terms of concentrations of prodrug used, and 
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laborious. Not surprisingly then, the total number of colonies screened using these 
methods have not exceeded several thousand in a single round.  
 
1.7.1.1. Use of the E. coli SOS response as a screening tool 
 
One notable case of a direct positive selection strategy for nitroaromatic prodrug-
reduction has been recorded, based on induction of the E. coli SOS response (225). The 
SOS response, present in many bacterial species, involves an up-regulation of a number 
of genes primarily involved in DNA repair and cell cycle control, in response to DNA 
damage (see Figure 1.9A) (226). It has also been shown that induction of the SOS 
response can reactivate genome-integrated lambda phages to their lytic cycle (227). 
Therefore, by using the DNA-damaging abilities of activated CB1954 to induce the 
SOS response in E. coli, Guise et al (2007) were able to identify active NTRs through 
the harvesting of released phages, and sequencing of the inserted nfsB genes, from 
CB1954-challenged lysogen cultures (225). Improved NTRs could thus be detected by 
using lower concentrations of CB1954 than was necessary to elicit a response from 
wild-type NfsB. Using this method, a library of 6.8 × 10
5
 variants was screened and a 
number of improved mutants identified, including a triple amino-acid mutant able to 
confer equitoxicity to human carcinoma cells at CB1954 concentrations 40-80-fold 
lower than the wild-type enzyme. Although clearly a powerful technique for enrichment 
of improved CB1954-activating mutants, the necessity of integration of the NTR gene 
into the lambda-phage DNA backbone and the subsequent multiple packaging, infection 
and harvesting steps precludes its use as a tool for rapidly and quantitatively assessing 
multiple NTRs simultaneously. Nevertheless, the utility of the E. coli SOS response as a 
quantifiable measure of DNA-damaging prodrug activation has been firmly illustrated 
by this example, especially in light of the absence of any exploitable nitroreductase-
associated metabolic pathway able to be used as the basis of a selection strategy.  
 The E. coli SOS response has been exploited elsewhere in biotechnological 
research, in particular for the assessment of cytotoxicity of environmental pollutants. 
The most widely used technique in this field employs E. coli strains containing a 
reporter gene (lacZ, gfp, lux) under transcriptional control of an SOS response linked 
promoter (228-232). In this case, reporter gene activity is directly proportional to the 
extent of SOS response induction (see Figure 1.9B). Reporter gene products provide 
signals, typically colorimetric, fluorescent or luminescent, that are readily detectable 
from intact cells or whole cell lysates, permitting rapid evaluation of their presence and 
  
33 
quantity using simple substrates and common laboratory equipment and procedures. 
Therefore both the ability and the magnitude of SOS induction by a test drug can be 
measured using this system, allowing relative assessment of genotoxic potencies of 
multiple test compounds. In addition to environmental toxins, studies have shown that 
activated nitroaromatic prodrugs including CB1954, RSU-1069 and nitrofurazone (233-
235) also induce strong, dose-dependent SOS responses using the SOS response 
reporter gene assay. The ability to relatively quantify SOS response induction between 
multiple strains/drugs and the ease with which the assay is performed suggests 
advantages for this system over the lambda phage induction method in assessment of 
prodrug reducing abilities of multiple NTRs. Furthermore, directly assessing 
transcription from SOS-linked promoters is considered to be a more sensitive measure 
of SOS response induction compared to lambda phage activation, due to the 10-fold 
higher rate of RecA-mediated LexA (SOS response inhibitor) cleavage relative to λcI 
(lambda phage lytic cycle repressor) cleavage (228). 
 
 
Figures 1.9A & B. Schematic overview of the E. coli SOS response. 
 (A) In wildtype E. coli, DNA damage induces the formation of sections of single-stranded DNA, which 
is recognized and bound by RecA protein. RecA “activated” in this fashion then causes a conformational 
change to occur in the LexA protein, an SOS-gene repressor, permitting de-repression of SOS-linked 
genes. (B) In SOS reporter strains of E. coli, reporter genes such as lacZ or gfp are transcriptionally or 
translationally fused downstream of an SOS-gene promoter. DNA damage occurring in this strain can 
therefore be relatively quantified by way of measurement of reporter-gene activity. Figure adapted from 
Sutton et al. (236). 
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1.8. Research objectives 
 
The overriding goals of this project were three-fold:  
 
1) To develop a screening system, based on the E. coli SOS response reporter gene 
assay, able to rapidly and accurately measure relative levels of nitroaromatic 
prodrug (principally CB1954) reduction by candidate NTRs. These aims were 
investigated in Chapters 3 and 4. 
2) To apply this screen to a range of phylogenetically diverse bacterial NTRs in 
order to identify lead candidate enzymes with the ability to reduce a variety of 
nitroaromatic prodrugs. These aims were investigated in Chapters 3, 4 and 5.   
3) To further optimise a lead NTR (selected from results gained in goal 2 above) 
towards an enhanced catalytic rate of reduction of a specific nitroaromatic 
prodrug (in this case the DNBM PR-104A) via enzyme engineering techniques. 
This aim was investigated in Chapter 6. 
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Chapter 2: Materials and Methods 
 
2.1. Chemicals, enzymes, reagents, media 
 
Chemicals, reagents and growth media were analytical grade and obtained from Sigma-
Aldrich (St. Louis. MO, USA) or Thermo Fisher Scientific (Waltham, MA, USA) 
unless otherwise stated. PR-104A, RB 6145, SN 27686, SN 29176 and SN 30444 
parental prodrugs and synthetic CB1954 reduction metabolites were generous gifts from 
the Auckland Cancer Society Research Centre (ACSRC; Auckland, NZ). IPTG 
(isopropyl β-D-thiogalactoside), BioMix™ Red and Accuzyme™ Mix were supplied by 
Bioline (London, UK). Restriction enzymes were supplied by New England Biolabs 
(NEB; Ipswich, MA, USA). T4 DNA ligase was supplied by Fermentas (Thermo Fisher 
Scientific) or Bioline. Phusion™ high-fidelity DNA polymerase was supplied by 
Finnzymes (Espoo, Finland).    
 
2.2. Oligonucleotide primers 
 
All primers used in this study were synthesized by Invitrogen (Carlsbad, CA, USA) or 
Integrated DNA Technologies (IDT; Coralville, IA, USA) and supplied lyophilized. For 
long-term storage, primers were resuspended in 1 × TE pH 8.0 (10 mM Tris-Cl pH 8.0, 
0.1 mM EDTA) to 100 µM and stored at -20 °C. For working stocks, aliquots were 
diluted in autoclaved, 0.22 µm filter-sterilized distilled and deionised (ddH2O) water to 
10 µM final concentration. Primers are listed in Table 2.1. 
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Table 2.1. Oligonucleotide primers used in this study.  
Underlined sequences indicate restriction sites. Bold type indicates homology regions 
used in recombination.  
Primer name Sequence (5’→3’) 
NTR specific primers 
NfsA_Ec_Fw GGCATATGACGCCAACCATTGAAC 
NfsA_Ec_Rv GGGTCGACTTAGCGCGTCGCCCAACCCTG 
NfsA_St_Fw GGGGCATATGAGTCCGACCATTGAA 
NfsA_St_Rv GGGGTCGACTTAGCGCGTCGCCCAGCC 
NfsA_Ck_Fw GGGGCATATGACTCCAACCATTGATTT 
NfsA_Ck_Rv GGGGGTCGACTTAGCGCGTCGCCCAA 
NfsA_Kp_Fw GGGGCATATGACGCCGACCATTGAG 
NfsA_Kp_Rv GGGGTCGACTCAGCGCGTTGCCCACC 
NfsA_Es_Fw CCCCCATATGACGCCAACGATTGAGCTGC 
NfsA_Es_Rv GGGGCTCGAGTTAGCGTGTCGCCCAGCCCTG 
NfsA_Vf_Fw CCCCATATGAACCCTGTTATCGATAC 
NfsA_Vf_Rv CCCGTCGACTCACTTAATAGCTAGGC 
NfsA_Vv_Fw GGGGCATATGAACGCTGTTATTGAC 
NfsA_Vv_Rv GGGGTCGACTTACTTTGTCGCCAAGCC 
Frp_Vh_Fw GGGCATATGAACAATACGATTGAAA 
Frp_Vh_Rv GGGGTCGACTTAGCGTTTTGCTAGCC 
NfrA_Bs_Fw GGGGCATATGAATAACACAATCGAAACC 
NfrA_Bs_Rv GGGGGTCGACTTAGTTTTTATTAAAGCCCT 
NfsA_Li_Fw GGGGCATATGAATCAGGCGATAGATGCCATTTT 
NfsA_Li_Rv GGGGGTCGACTTATTTTTGATTTAAATGTTGC 
EcD_Pp_Fw CCCCCATATGAGCCTTCAAGACGAAG 
EcD_Pp_Rv CTAGGTCGACTCAGCGCAGGCCGAAAC 
YcnD_Bs_Fw CCCCCATATGAATGAAGTGATTAAATC 
YcnD_Bs_Rv CCCCGTCGACTTATTTTTCAACTTTAAATC 
NfsB_Ec_Fw GGGCATATGGATATCATTTCTG 
NfsB_Ec_Rv GGGGAATTCTTACACTTCGGTTAAG 
NfsB_Ck_Fw CCCCCATATGGATATCGTTTCTGTCGC 
NfsB_Ck_Rv CCCGTCGACTCAGACTTCCGTCAGGGTG 
NfsB_St_Fw GGGGCATATGGATATCGTTTCTGTC 
NfsB_St_Rv GGGGGTCGACTTAGACTTCCGTCAGTG 
NfsB_Kp_Fw GGGGCATATGGATATCGTATCGGTC 
NfsB_Kp_Rv GGGGCTCGAGTTAAATCTCGGTAATGGT 
NfsB_Vv_Fw GGGGCATATGACTATTGTTCAAGCT 
NfsB_Vv_Rv GGGGTCGACTTAGATTTCGGTAAAAACAG 
2432_Pp_Fw GGGGCATATGGATACCGTATCGCTG 
2432_Pp_Rv GGGGCTCGAGTCAGAGGAAGGTGAACACTT 
NfsB_Es_Fw CCCCCATATGAACCTTAATGAGATCATTCGC 
NfsB_Es_Rv CCCGTCGACTCAGAGCTGCGTGATCAC 
FraseI_Vf_Fw GGGGCATATGACGCATCCAATTATTCA 
FraseI_Vf_Rv GGGGGTCGACCTAAAGAATGGTAATTAC 
NfsB_Vh_Fw CCCCCATATGTCTCATCAAATCATTACAGAC 
NfsB_Vh_Rv CCCCTCGAGTTAAAGAGTAGTAATTACGTC 
YfkO_Bs_Fw GGGGCATATGGCAGATCTAAAGACACA 
YfkO_Bs_Rv CTAGGTCGACTTAAACCCACTTCACAACAT 
YdgI_Bs_Fw GGGGCATATGATCAAAACAAACGATTTTATGG 
YdgI_Bs_Rv GGGGGTCGACTTATTTCCATTCTGCAATTG 
5190_Pa_Fw GGGGCATATGCATATCGAAGACGCC 
5190_Pa_Rv GGGGGTCGACTCAGAAGCGGTCGCGAATGA 
AzoR_Ec_Fw GGGGCATATGAGCAAGGTATTAGTTCTT 
AzoR_Ec_Rv GGGGGTCGACTTATGCAGAAACAATGCTGT 
AzoR_St_Fw CCCGCATATGAGCAAGGTATTAGTTCTT 
AzoR_St_Rv CCCGTCGACTTAAGCGGCCACGAC 
AzoR_Vv_Fw CCCGCATATGTCTCGTTTACTAGTATT 
AzoR_Vv_Rv CCCGGTCGACTTAAGCTGTTAGCGCTGCAAG 
4538_Pp_Fw GGGGCATATGTCCCGCGTACTGATCATC 
4538_Pp_Rv GGGGCTCGAGTCAGGCCACCGCTGCCAGCTT 
NemA_Ec_Fw_NdeIa CCCATATGTCATCTGAAAAACTG 
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NemA_Ec_Fw_BamHIa CTAGGGATCCATGTCATCTGAAAAACTG  
NemA_Ec_Rv CTAGGTCGACTTACAACGTCGGGTAATC 
NemA_St_Fw CCCGGATCCATGTCATCAGCAAAACTG 
NemA_St_Rv CCCGGTCGACTTACAGAGTAGGGTAGTC 
NemA_Kp_Fw CCCCATATGTCGGAAGCAA 
NemA_Kp_Rv CCCCTCGAGTTACAGAGTCGGGTAA 
NemA_Vv_Fw CCCCATATGAGCAAACTGTTTGAA 
NemA_Vv_Rv CCCGTCGACTCACACATGCAAAGCGGT 
YwrO_Bs_Fw AAATTTGGATCCATGAAAATATTGGTTTTGGC 
YwrO_Bs_Rv CCCGTCGACTTAAACAAAAGGCTGCTG 
YwrO_Li_Fw CCCCCATATGAAAACATTAGTTATTAT 
YwrO_Li_Rv CCCGTCGACCTAATTTAACGTTTTAATA 
YwrO_Vf_Fw AAATTTGGATCCATGACAAGCCCGGCT 
YwrO_Vf_Rv CCCGTCGACTTATTCCTTAATAAATTTATC 
YieF_Ec_Fw GGGGCATATGTCTGAAAAATTGCAGGTG 
YieF_Ec_Rv GGGGGTCGACTTAGATCTTAACTCGCTG 
1204_Pa_Fw GGGGCATATGAGCGACGACATCAAG 
1204_Pa_Rv GGGGGTCGACTCAACCGCGCAGGCGGCGCA 
MdaB_Ec_Fw GGGCATATGAGCAACATCCTG 
MdaB_Ec_Rv GGGGTCGACTTAACCAAAAATTTC 
MdaB_Ps_Fw GGGGCATATGAAAAAAGTATTGTTCCTCAAC 
MdaB_Ps_Rv CTAGCTCGAGTTACTGCGCACCAAACACTT 
WrbA_Ec_Fw GGGCATATGGCTAAAGTTCTGGTG 
WrbA_Ec_Rv GGGGTCGACTTAGCCGTTAAGTTT 
WrbA_Ps_Fw GGGGCATATGAGCAAACCTTACATTCTGG 
WrbA_Ps_Rv CTAGGTCGACTCAGCTGCGTGTTGTGTC 
YdjA_Ec_Fw CTAGCATATGGATGCACTCGAACTATTG 
YdjA_Ec_Rv CTAGGTCGACTCAGAAATAAGTTACAAACGG 
YdjA_Kp_Fw CCCCCATATGGATGCTCTCGATCTACTGC 
YdjA_Kp_Rv CCCCGTCGACTCAGAATCGCGTCACAAACG 
3720_Pp_Fw GGGGCATATGCTTGTGAATGTACTG 
3720_Pp_Rv GGGGGTCGACTCACGTCAGCGGGTACAACG 
4975_Pa_Fw GGGGCATATGAACGTACTGATCGTC 
4975_Pa_Rv GGGGGTCGACTCAGCGCGCCAGCGGCTGGA 
YcdI_Ec_Fw CTAGCATATGAACGAAGCCGTTAGCC 
YcdI_Ec_Rv CTAGGTCGACTTACAACAGCCCGCAGG 
YcdI_Kp_Fw GGGGCATATGAACGACGCGATAAACCA 
YcdI_Kp_Rv CTAGCTCGAGTTATGCCAGGCAGGCT 
  
NTR KO primers 
NfsA_KO_Fw GGGCAGAAAGAGAAAAAGATAATGACGCCAACCATTGAATGT
GTAGGCTGGAGCTGCTTC 
NfsA_KO_Rv GGGTACATCGACGTGGCGGTTTTAGCGCGTCGCCCAACCCAT
ATGAATATCCTCCTTAG 
NfsB_KO_Fw GGGCCCGGCAAGAGAGAATTACACTTCGGTTAAGGTGATTGT
GTAGGCTGGAGCTGCTTC 
NfsB_KO_Rv GGGTCACATGGAGTCTTTATGGATATCATTTCTGTCGCCCATA
TGAATATCCTCCTTAG 
AzoR_KO_Fw TTATGCAGAAACAATGCTGTCGATGGCTGCTTTTGCTGTGTAG
GCTGGAGCTGCTTG 
AzoR_KO_ext_Fw CAAACATCTATAAGGAAACACCATGAGCAAGGTATTAGTTC 
AzoR_KO_Rv ATGAGCAAGGTATTAGTTCTTAAATCCAGCATCCTGCATATGA
ATATCCTCCTTAG 
AzoR_KO_ext_Rv CCACATCAAGACCGTGTCCGGTTATGCAGAAACAATGCTG 
NemA_KO_Fw ATGTCATCTGAAAAACTGTATTCCCCACTGAAAGTGTGTGTAG
GCTGGAGCTGCTTC 
NemA_KO_ext_Fw ATCACCAGACGACCGGGAGCCTTTATGTCATCTGAAAAACGT 
NemA_KO_Rv TTACAACGTCGGGTAATCGGTATAGCCTTCCGCGCCCATATGA
ATATCCTCCTTAG 
NemA_KOext_Rv CTTTACGCCGCTCGCAATGTTGGATTACAACGTCGGGTAAT 
  
Other KO primers 
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TolC_KO_Fw ATCGGCCTGAGCCTTTCTGGGTTCAGTTCGTTGAGCTGTGTAG
GCTGGAGCTGCTTC 
TolC_KO_ext_Fw ATGAAGAAATTGCTCCCCATTCTTATCGGCCTGAGCCTT 
TolC_KO_Rv GTTACTGGTGGTAGTGCGTGCGGATGTTTGCTGAACCATATG
AATATCCTCCTTAG 
TolC_KO_ext_Rv TCAGTTACGGAAAGGGTTATGACCGTTACTGGTGGTAGT 
Ada_KO_Fw GCGAAAAAAATTAAAGCGCAAGATTGTTGGTTTTTGCGTGTGT
GTAGGCTGGAGCTGCTTC 
Ada_KO_ext_Fw TCCTTAACCAGGGAGCTGATTATGAAAAAAGCC 
Ada_Fw2 CCTGGATGTCACCACAG 
Ada_KO_Rv GGCTCTTGCCACGGTTCAGCATCGGCAAACAGATCCAACACA
TATGAATATCCTCCTTAG 
Ada_KO_ext_Rv CTCTTGCCACGGTTCAGCATCGGCAAACAGATCCA 
Ada_Rv2 CTTGCCACGGTTCAGCATC 
Ogt_KO_Fw GGTCCGGGTATTTACCCACGTTTGTCTTAAGAGAGAACGGTG
TGTAGGCTGGAGCTGCTTC 
Ogt_KO_ext_Fw GTTTGTCTTAAGAGAGAACGGATGCTGAGATTAC 
Ogt_Fw2 CTTGTCGGTCTGCCGATAGGTC 
Ogt_KO_Rv CATAAAAGTGTGAACAAGCTGGCACAAATTGTTTAATGTCATA
TGAATATCCTCCTTAG 
Ogt_KO_ext_Rv TGGCACAAATTGTTTAATGTTTACAGCAAAAG 
Ogt_Rv2 CATAAAAGTGTGAACAAGCTGG 
MutS_KO_Fw ATCACACCCCATTTAATATCAGGGAACCGGACATAACCCCTGT
GTAGGCTGGAGCTGCTTC 
MutS_KO_ext_Fw GATTACAACGAAAATAAAAACCATCACACCCCA 
MutS_Fw2 GGTATCATGTGCGCCTTATG 
MutS_KO_Rv GTTAATATTCCCGATAGCAAAAGACTATCGGGAATTGTTACAT
ATGAATATCCTCCTTAG 
MutS_KO_ext_Rv TATTTTATTCGTCAGTTGTCGTTAATATTCCCG 
MutS_Rv2 CGTCAGTTGTCGTTAATATTCCCG 
UvrB_KO_Fw TCCTTCAGGTAGCGACTCATGAGTAAACCGTTCAAATGTGTAG
GCTGGAGCTGCTTC 
UvrB_Fw2 GCTTTGGGGATAACCCGGTAAGGC 
UvrB_KO_Rv GTCTTCTTCGCTATCCTGTTACGATGCCGCGATAAACATATGA
ATATCCTCCTTAG 
UvrB_Rv2 CTGGAAAAGGCGTTACAGGCTTTA 
  
Primers for construction of pUCX and pUCXKT 
pUCF1Fw CTAGACCGGTGCTCTTCCGCTTCCT 
pUCF1Rv GGGGACTAGTGTGCACTCTCAGTACAAT 
NewpUCF2Rv CTAGACCGGTTCACTGCCCGCTTTCCA 
BlaPromFw GGGGACTAGTCGGATACATATTTGAATG 
pETRBSRv GGGGCATATGATATCTCCTTCTTAAAGTTAAACAAAATTATTTCT
AGAGGGGAATTGTTATCCGCTC 
pUCXWTFw CCCCCATATGGGATCCTCTAGAGTCGAC 
KantruncSalIFw3 CCCCGTCGACTAATAGAGCTCGATGGATTGCACGCAGGTTC 
KantruncHindIIIRv CCCCAAGCTTTCAGAAGAACTCGTCAAGAAGG  
pUCXSacIRv CCCCGAGCTCAATCATACTCTTCCTTTTTCAATCCGCCAAAACAG
CCAAGC 
  
Primers for NTR site-directed mutagenesis 
YcnD_NdeIdisruptFw AGCTGACGTCTTACATTCAGGCTTACGATGAGAAAATGTCTG 
YcnD_NdeIdisruptRv CTGAATGTAAGACGTCAGCTCATC 
YcnD_SDM15Fw TAACAGACCACCGCTCGATTNNKAGCTATACAGATGAACC 
YcnD_SDM15Rv AATCGAGCGGTGGTCTGTTAATG 
YcnD_SDM41Fw TACAATCTGCCCCAACTTCTNNKAACGGGCAGCAAGTGAC 
YcnD_SDM41Rv AGAAGTTGGGGCAGATTGTACCGC 
YcnD_SDM65Fw AGAAAATCTCCGAGCTGTCANNKGGACAGCCTTGGATTG 
YcnD_SDM67Fw AGAAAATCTCCGAGCTGTCAGGCGGANNKCCTTGGATTGACCAG
GC 
YcnD_SDM69Fw AGAAAATCTCCGAGCTGTCAGGCGGACAGCCTNNKATTGACCAG
GCTCCTG 
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YcnD_SDM65_67_69Rv TGACAGCTCGGAGATTTTCTTTTTGCG 
YcnD_SDM105Fw TGGAAATCACAAATGGCTTANNKTCTGTTCTTGTCGGCG 
YcnD_SDM105Rv TAAGCCATTTGTGATTTCCATTTTG 
YcnD_SDM139Fw CGGTTCCGATCGGTGCGGTTNNKGGAAACCCTCAAGAGC 
YcnD_SDM140Fw CGGTTCCGATCGGTGCGGTTCGCNNKAACCCTCAAGAGCTGATC 
YcnD_SDM139_140Rv AACCGCACCGATCGGAACCG 
YcnD_SDM227Fw GGTCACAGGGCATCGCATCCNNKTATGAGCGCCTGTAC 
YcnD_SDM227Rv GGATGCGATGCCCTGTGACC 
YcnD_SDM233Fw CCTATTATGAGCGCCTGTACNNKCCACACATCCGTGAAATG 
YcnD_SDM233Rv GTACAGGCGCTCATAATAGGATGC 
YcnD_65upstreamFw AGTCCAGGATAAAGAGCGC 
YcnD_139upstreamFw TGAATCACTCGGACTTGGC 
YcnD_227upstreamFw AGAAACTGGTCACAGGGC 
YcnD_233upstreamFw TATGAGCGCCTGTAC 
YcnD_233upstreamRv GTACAGGCGCTCATA 
 
Miscellaneous primers 
pMMBFw GGCTCGTATAATGTGTGG 
pMMBRv GACCGCTTCTGCGTTCTGAT 
T7prom TAATACGACTCACTATAGGG 
T7term GCTAGTTATTGCTCAGCGG 
M13Fw GTAAAACGACGGCCAG 
M13Rv CAGGAAACAGCTATGAC 
T7FwpMMBFw TAATACGACTCACTATAGGGGGCTCGTATAATGTGTGG 
T7FwpUCXpromBamHIFw TAATACGACTCACTATAGGGGGATCCTCACTGCATAATTCGTGTC
G 
V5Rv ACCGAGGAGAGGGTTAGGGAT 
AKR1C3 Fw CCCCATATGGATTCCAAACACCAGTG 
AKR1C3 Rv CCCGTCGACTAATATTCATCTGAATA 
aPrimer NemA_Ec_Fw_BamHI was used for cloning the nemA gene from E. coli into pET28a(+), while 
primer NemA_Ec_Fw_NdeI was used for cloning into pUCX.  
 
 
2.3. Bacterial strains and plasmids 
 
All bacterial strains used in this study are listed in Tables 2.2 and 2.3. Plasmids are 
listed in Table 2.4. 
 
Table 2.2. Bacterial strains used in this study. 
Strain Relevant characteristics Source 
DH5α F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
- mK
+), λ– 
Invitrogen 
DH5α λ(pir) F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG 
Φ80dlacZΔM15 Δ(lacZYA-argF)U169, hsdR17(rK
- mK
+), λ(pir) 
Invitrogen 
BL21(DE3) F– ompT gal dcm lon hsdSB(rB
- mB
-) λ(DE3 [lacI lacUV5-T7 gene 
1 ind1 sam7 nin5]) 
Novagen 
ADA510 F lac-6(del) λΦ(sulA::lacZ) (231) 
SOS-R1 ADA510 ΔnfsA ΔnfsB This study 
SOS-R1 Δadaogt SOS-R1 Δada Δogt This study 
SOS-R1 ΔmutS SOS-R1 ΔmutS This study 
SOS-R1 ΔuvrB SOS-R1 ΔuvrB This study 
SOS-R1B SOS-R1 ΔazoR ΔnemA This study 
SOS-R2 SOS-R1B ΔtolC This study 
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Table 2.3. Bacterial strains used as sources of NTRs in this study 
Bacterial genus, species and strain
a
 Source 
Escherichia coli W3110 Lab stock 
Salmonella enterica (typhimurium) Ty2 ESR culture collectionb 
Klebsiella pneumoniae ATCC 13883 ESR culture collection 
Vibrio vulnificus ATCC 27562 ESR culture collection 
Vibrio harveyi ATCC 33843 ESR culture collection 
Vibrio fischeri ATCC7744b ESR culture collection 
Pseudomonas aeruginosa PAO1 Lab stock 
Pseudomonas putida KT2440 Lab stock 
Pseudomonas syringae 1448a Lab stock 
Bacillus subtilis subsp. Subtilis NZ isolate ESR culture collection 
Enterobacter (Chronobacter) sakazaki ATCC 29544 ESR culture collection 
Citrobacter koseri ATCC 27156 ESR culture collection 
Listeria innocua Clip11262 ESR culture collection 
aAll strains were propagated in LB media, with the exception of V. vulnificus and V. harveyi (marine 
broth).  
bInstitute of Environmental Science and Research, Porirua, NZ.  
cOnly genomic DNA was available for V. fischeri.   
 
Table 2.4. Plasmids used in this study. 
Plasmid Relevant characteristics Source 
pUC19 AmpR. Cloning plasmid, pMB1 origin of replication. 
Source of DNA for pUCX 
Invitrogen 
pMMB67EH(nfsA) AmpR E. coli-Pseudomonas expression vector. tac 
promoter, lac operator, E. coli nfsA gene insert. 
Source of DNA for pUCX 
(184) 
pUCX AmpR. E. coli expression vector. tac promoter, lac 
operator, pET28a(+) RBS. 
This study 
pUCXKT AmpR. pUCX with truncated kanR gene downstream 
of MCS. 
This study 
pUCXKG:ntr AmpR, KanR. pUCXKT with ntr gene insert and 
functional kanR gene. 
This study 
pET28a(+) KanR. Expression vector for 6His-tagged enzyme 
purification. T7 promoter.  
Novagen 
pDONR221 KanR. Entry vector for Gateway recombination 
cloning. 
Invitrogen 
pF527-V5 AmpR. Destination vector for Gateway 
recombination cloning. Mammalian expression 
vector. Elongation-factor-1α promoter (constitutive) 
ACSRC 
pKD4 AmpR, KanR. Pir-origin of replication. kanR gene-
template for KO-PCR.  
(237) 
pKD46 AmpR. Heat sensitive origin of replication. 
Recombinase expression vector. ara operon 
promoter.  
(237) 
pCP20 AmpR. Heat sensitive origin of replication.  (237) 
 
 
2.4. Bioinformatics 
 
Protein homology searches were carried out in the National Centre for Biotechnology 
Information (NCBI) protein database using the alignment search algorithm protein-
protein BLAST (blastp; http://blast.ncbi.nlm.nih.gov/; (238)). 
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2.5. Bacterial growth and maintenance 
 
 2.5.1. Growth media 
 
Unless otherwise stated, all media listed below were made up to the required volume 
with ddH2O and sterilized by autoclaving for 30 min at 121 °C prior to use. Media were 
stored at either room temperature (no supplements), or 4 °C (supplemented with 
antibiotics or other heat-sensitive chemicals).   
 
 2.5.1.1. Lysogeny Broth (LB)
a
 
 
Component Final concentration 
Tryptone 10 g L
-1
 
Yeast extract 5 g L
-1
 
NaCl 10 g L
-1
 
aLB was supplied from the manufacturer as a premixed powder. 
   
 2.5.1.2. SOB, SOC
a
 
 
Tryptone 20 g L
-1
 
Yeast extract 5 g L
-1
 
NaCl 10 mM 
KCl 2.5 mM 
MgCl2
b
 10 mM 
MgSO4
b
 10 mM 
aTo make SOC, glucose was added to 20 mM final concentration to SOB, post-autoclave. 
bMgCl2 and MgSO4 were added post-autoclave. 
 
 2.5.1.3. ZYP5052 (autoinduction medium) 
 
ZY Base
a
 919 mL L
-1
 
20 × NPS
a
 50 mL L
-1
 
50 × 5052
a
 20 mL L
-1
 
100 × metal salts
a
 10 mL L
-1
 
MgSO4 1 mM 
aAll solutions were made up separately and autoclaved prior to mixing.  
 
 2.5.1.3.1. ZY Base 
 
Tryptone 10.9 g L
-1
 
Yeast extract 5.4 g L
-1
 
 
 2.5.1.3.2. 20 × NPS 
 
NH4SO2 0.5 M 
KH2PO4 1 M 
Na2HPO4 1 M 
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 2.5.1.3.3. 50 × 5052 
 
Glycerol 250 g L
-1
 
Glucose 25 g L
-1
 
Lactose 100 g L
-1
 
 
 
 2.5.1.3.4. 100 × metal salts 
 
CaCl2.2H2O 0.1 g L
-1
 
CoCl2.2H2O 0.04 g L
-1
 
CuSO4.5H2O 0.02 g L
-1
 
EDTA 1 g L
-1
 
FeSO4.7H2O 0.5 g L
-1
 
MgCl2.6H2O 10 g L
-1
 
MnCl2.2H2O 0.1 g L
-1
 
NaMoO4.2H2O 0.02 g L
-1
 
ZnSO4.7H2O 0.2 g L
-1
 
 
 2.5.1.4. M63 minimal medium 
 
5 × M63
a
 200 mL L
-1
 
MgSO4
b
 2 mM 
Carbon source (glucose, lactose)
b
 4 g L
-1
 
Cas-amino acids
a
 2 g L
-1
 
Thiamine-HCl
b
 10 mg L
-1
 
aSolutions were made up and autoclaved separately. 
bSolutions were made up separately and sterilized by passage through a 0.22 µm filter. 
 
 2.5.1.4.1. 5 × M63
a 
 
KH2PO4 68 g L
-1
 
FeSO4.7H2O 2.5 mg L
-1
 
(NH4)2SO4 10 g L
-1
 
aSolution was adjusted to pH 7.0 with KOH prior to autoclaving. 
 
 2.5.1.5. Marine Broth 
 
Marine broth was supplied by the manufacture (Sigma-Aldrich) as a ready mixed 
powder. Liquid Marine broth was prepared according to the manufacturer‟s instructions. 
 
 2.5.1.6. Solid media 
 
To make solid media, molecular biology-grade agar was added to liquid media to 1.5 % 
(w/v) final concentration, prior to autoclaving. If supplements were to be added, the 
agar was allowed to cool to <50 °C, post-autoclave, before addition. Subsequently, 
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medium was aliquoted (15-20 mL each) into sterile 90 mm × 15 mm Petri dishes in a 
laminar fume hood and left to solidify. Plates were stored at 4 °C. 
 
 2.5.2. Antibiotics and other media supplements 
 
All antibiotics and media supplements used in this study were made up to the indicated 
stock concentration in the recommended solvent (see Table 2.5), filter-sterilized using a 
0.22 µm filter and stored indefinitely at -20 °C.  
 
Table 2.5. Properties of media supplements used in this work 
Supplement Stock 
concentration 
Solvent 
Ampicillin 100 mg mL
-1
 ddH2O 
Kanamycin 50 mg mL
-1
 ddH2O 
Rifampicin
a
 50 mg mL
-1
 DMSO 
IPTG 100 mg mL
-1
 ddH2O 
aRifampicin was stored wrapped in aluminium foil due to inactivation by light. 
 
 2.5.3. Bacterial growth and storage 
 
For routine growth in liquid media, E. coli strains were propagated in LB medium, with 
relevant supplements, at 37 °C and shaking at 200 revolutions per minute (rpm), unless 
otherwise stated. Bacteria grown on solid media were stored at 4 °C for no longer than 
one month. For longer term storage, bacteria in liquid media were supplemented with 
glycerol to 40 % (w/v) final concentration, and kept at -80 °C.   
 
2.6. Cloning methods, routine molecular biology 
 
 2.6.1. Preparation of genomic DNA (gDNA) 
 
Bacterial gDNA was extracted from 3 mL overnight culture using the DNeasy™ Blood 
and Tissue kit (Qiagen, GmbH, Germany), following the manufacturer‟s instructions. 
Genomic DNA preparations were stored at -20 °C. 
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2.6.2. PCR protocols 
 
For construction of vectors and amplification of NTR genes for cloning, either 
Phusion™ high-fidelity polymerase or Accuzyme™ Mix were used. For all other PCRs, 
including colony screening, diagnostic and gene-knockout PCR creation, BioMix™ Red 
was used. PCR reactions were set up as outlined in Table 2.6 and thermal cycling 
parameters were employed as outlined in Table 2.7.  
 
Table 2.6. Composition of PCR reactions 
Biomix™ Red, Accuzyme™ Mix Volume per 20 µL reaction 
Biomix™ Red/Accuzyme™ Mix 10 µL 
Primer 1 1 µL 
Primer 2 1 µL 
Template DNA
a
 0.2-1 µL 
ddH2O To 20 µL final volume 
  
Phusion™ Volume per 20 µL reaction 
5 × Phusion™ HF buffer 4 µL 
10 mM dNTP mix 0.4 µL 
Phusion™ high-fidelity polymerase 0.2 µL 
Primer 1 1 µL 
Primer 2 1 µL 
Template DNA 0.2-1 µL 
ddH2O To 20 µL final volume 
aFor colony PCR screens, a small amount of E. coli colony, picked directly from an agar plate with a 
sterile toothpick or pipette tip, was used as template DNA 
 
Table 2.7. Thermal cycling parameters of PCR reactions, in chronological order. 
Temperature (°C) Time Cycles
a
 
Phusion™   
98 1 min  
98 15 sec 
30-35 
72 30 sec per kb 
72 5 min  
16 Hold  
   Biomix™ Red, Accuzyme™ Mix  
94 5 min  
94 20 sec 
15 
56 30 sec 
72 BioMix™ Red: 1 min per kb 
Accuzyme™ mix: 2 min per kb 
   94 20 sec 
15-20  
52 30 sec 
72 BioMix™ Red: 1 min per kb 
Accuzyme™ mix: 2 min per kb 
72 5 min  
16 Hold  
aWhere no number is indicated, cycle was only performed once. 
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 2.6.3. PCR product purification 
 
Purification of PCR products was carried out using the commercially available DNA 
Clean and Concentrator™ kit (Zymo Research; Irvine, CA, USA), according to the 
manufacturer‟s instructions. Products were eluted using sterile-filtered (0.22 µm) 
ddH2O and stored at -20 °C. 
 
 2.6.4. Agarose gel electrophoresis 
 
To analyse the size and purity of PCR products, plasmid digests and other DNA 
samples, small aliquots were run on ethidium bromide-containing 1 % agarose gels (1 % 
w/v agarose in 1 × TAE buffer, 1 µg mL
-1
 ethidium bromide), submerged in 1 × TAE 
buffer in a suitable electrophoresis tank at 120-140 V for 20-40 min. DNA markers of 
known size were run alongside samples for band comparison. DNA bands were viewed 
under ultra-violet (UV) light.     
 
2.6.5. Restriction digests 
 
Restriction digests were set up as outlined in Table 2.8. Restriction digests were 
incubated at 37 °C for 1-6 h, prior to heat inactivation at the recommended (by the 
manufacturer) temperature and time for the enzyme(s) being used. Digested DNA was 
then either purified (using the PCR purification protocol outlined in section 2.6.3) and 
stored at 4 °C, or analysed directly via agarose gel electrophoresis (see section 2.6.4). 
Purified digested DNA was used for downstream applications either immediately, or 
within 1-2 days. 
 
Table 2.8. Composition of restriction digests. 
Component Volume per 20 µL reaction 
10 × Restriction buffer
a
 2 µL 
20 × Bovine Serum Albumin (BSA) 1 µL 
Restriction enzyme 1 0.5-1 µL 
Restriction enzyme 2
b
 0.5-1 µL 
DNA As desired 
ddH2O To 20 µL final volume 
aFor single enzyme digests, the optimal restriction buffer for the enzyme was used. For double digests, the 
buffer in which both enzymes had the highest activity was used. Restriction enzyme – buffer 
compatibility data was obtained from the NEB website (http://www.neb.com/nebecomm/default.asp). 
bSecond enzyme only added if required. 
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2.6.6. Ligation 
 
DNA ligation reactions were set up as outlined in Table 2.9. Reactions were left at room 
temperature for at least 4 h (typically overnight), prior to heat inactivation at 65 °C for 
10 min. Products were then used directly to transform E. coli (see below), or stored 
indefinitely at -20 °C. 
 
Table 2.9. Composition of ligation reactions. 
Component Volume/quantity per 10 µL reaction 
10 × DNA ligase buffer 1 µL 
T4 DNA ligase 0.2 µL 
Digested vector DNA 40-60 ng
a
 
Digested insert DNA 10-50 ng
a
 
ddH2O To 10 µL final volume 
aTotal amount of DNA in a ligation reaction never exceeded 100 ng total. Molar ratios of 1:1 to 1:3 vector 
DNA:insert DNA were used.  
 
2.6.7. Transformation/Electroporation 
 
2.6.7.1. Generation of chemically competent cells 
 
3 mL LB + 10 mM MgCl2 cultures of E. coli strains to be made competent were 
inoculated from a single colony (on an agar plate) or a glycerol stock and grown 
overnight at 37 °C, 200 rpm. The following day, the overnight culture was diluted 50-
fold into a fresh 10-50 mL LB + 10 mM MgCl2 culture and grown at 37 °C, 200 rpm for 
several hours, until the OD600 reached ~0.4-0.6. At this point the cells were transferred 
to ice for 10-15 min. Cells were then centrifuged at 4,000 rpm for 10 min at 4 °C, the 
supernatant discarded and the cell pellet resuspended in 1 volume ice-cold TFB I (see 
Table 2.10 for recipe). Resuspended cells remained on ice for 2 h, prior to another round 
of centrifugation at 4,000 rpm, 10 min at 4 °C. The supernatant was discarded and the 
cell pellet resuspended in 0.1 volumes of ice-cold TFB II (see Table 2.10 for recipe). 
Cells were aliquoted (100-200 µL) into sterile 1.5 mL microfuge tubes and snap frozen 
using a metal tube rack pre-chilled to -80 °C. Competent cell aliquots were stored at -80 
°C indefinitely.      
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Table 2.10. Recipes for transformation buffers.  
Component Final concentration 
TFB I
a
  
Potassium acetate 30 mM 
MnCl2 50 mM 
CaCl2 10 mM 
Glycerol 15 % (w/v) 
  
TFB II
a
  
MOPS, pH 7.0. 10 mM 
CaCl2 75 mM 
KCl 10 mM 
Glycerol 15 % (w/v) 
aTFB I and TFB II transformation buffers were sterile-filtered (0.22 µm) prior to use. Long term storage 
was at 4 °C. 
 
2.6.7.2. Transformation 
 
Chemically competent cell aliquots were removed from the -80 °C storage and thawed 
on ice for 5-10 min. 50-100 µL competent cells were used per transformation. Plasmid 
DNA to be transformed was added (never more than 0.1 the volume of competent cells 
being used) to the cells and the mixture kept on ice for 15-20 min. Cells were then heat-
shocked at 42 °C for 90 sec, typically in a water bath or heating block, and then returned 
to ice for 1-2 min. 9 volumes of LB or SOC was then added to each tube, followed by 
incubation at 37 °C for 45 min to 1 h. Cells were then spread directly onto LB agar 
plates containing the necessary antibiotics and supplements and incubated at 37 °C for 
at least 16 h, or until colonies became visible.  
 
2.6.8. Miniprep 
 
Preparation of plasmid DNA was carried out using either the commercially available 
Zyppy™ Plasmid Miniprep kit (Zymo Research; Irvine, CA, USA), according to the 
manufacturer‟s instructions, or by using the following protocol:  
 
3 mL of an overnight culture (LB) of E. coli carrying the plasmid of interest was 
transferred into 2 1.5 mL microfuge tubes and centrifuged at 13,000 rpm for 1 min at 
room temperature. The supernatants from both tubes were discarded and the remaining 
cell pellets resuspended in 250 µL buffer P1 (per 3 mL of original culture; see Table 
2.11 for recipes of all buffers used in this protocol) and transferred into a single 
microfuge tube. Cells were lysed by addition of 250 µL buffer P2 and the tube gently 
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inverted 10-15 times or until turbidity had dissipated (no longer than 3 min). The lysis 
reaction was terminated by addition of 350 µL buffer N3 and the tube gently inverted 
10-15 times or until precipitation was uniform. The tube was then centrifuged at 13,000 
rpm for 5 min at room temperature, following which the supernatant was carefully 
transferred to a clean miniprep column (either ZYMO or QIAGEN) inserted into a 2 mL 
collection tube. The column was then centrifuged for 30 sec at 13,000 rpm and the flow 
through discarded. 200 µL buffer PB was then added to the column, and centrifuged for 
15 sec at 13,000 rpm. 400 µL buffer PE was next added to the column and centrifuged 
for 1 min at 13,000 rpm. The column was then carefully removed from the collection 
tube (being sure not to let the column come into contact with any ethanol or liquid 
remaining in the collection tube) and inserted into sterile a 1.5 mL microfuge tube. 30-
50 µL of either sterile ddH2O or 1 × TE buffer was applied directly to the column 
matrix and left to stand at room temperature for at least one minute. The tube was then 
centrifuged for 1 min at 13,000 rpm to elute the plasmid.   
 
All eluted plasmid samples were stored indefinitely at -20 °C. 
 
Table 2.11. Recipes of buffers used in miniprep protocol described in section 2.6.8. 
Component Concentration 
Buffer P1  
Tric-HCl pH 8.0 50 mM 
EDTA pH 8.0 10 mM 
RNase A 50 µg mL
-1
 
  
Buffer P2  
NaOH 200 mM 
SDS 1 % 
  
Buffer N3  
Guanidine hydrochloride 4.4 M 
Potassium acetate 0.65 M 
Acetic acid 3.1 M 
  
Buffer PB  
Guanidine hydrochloride  5 M 
Tris-HCl pH 6.6 10 mM 
Ethanol 30 % 
  
Buffer PE  
Tris-HCl pH 7.5 10 mM 
Ethanol 80 % 
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2.6.9. DNA quantification 
 
Measurement of DNA concentration and purity of purified PCR and plasmid samples 
was performed using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific), 
according to the manufacturer‟s instructions. 
 
2.6.10. DNA Sequencing 
 
All vectors constructed throughout this study were sequence confirmed using 
commercial DNA sequencing services. All DNA sequencing was carried out either at 
the Allan Wilson Centre (Palmerston North, NZ) or by Macrogen Inc. (Seoul, South 
Korea).  
 
2.7. Gene knockout in E. coli 
 
In frame gene-deletion in E. coli was carried out using a modified version of the 
protocol of Datsenko and Wanner (237), described below. 
 
 2.7.1. Gene knockout PCR amplification 
 
Firstly, plasmid pKD4 was used as a template to PCR-amplify a kanamycin resistance 
(kan
R
) gene flanked either side by FLP-recombinase recognition sites. Primers for 
amplification contained 15-20 bp of sequence at the 3‟ end for priming and 
amplification from pKD4, while the remaining 30-40 bp at the 5‟ end of the primers 
were homologous to either end of the genomic region targeted for deletion (see Table 
2.1 for primer sequences). The complete process is illustrated in figure 2.1. In order to 
improve knock-out efficiency in certain cases, the genomic homologous regions at each 
end of the PCR-amplified kan
R
 cassette were lengthened via a second PCR, using the 
first PCR product as template and knock-out extension primers (see Table 2.1) for 
amplification. The final PCR product was purified and concentrated to at least 100 ng 
µL
-1
 in sterile-filtered ddH2O.  
 
  
50 
 
Figure 2.1. Overview of E. coli gene knockout procedure.  
Figure adapted from Datsenko and Wanner (237). See text (section 2.7) for details. 
 
 2.7.2. Preparation of electrocompetent cells 
 
The E. coli strain to be genetically altered was first transformed with the heat-sensitive 
plasmid pKD46. Transformation plates were grown at 30 °C, instead of 37 °C. 3 mL LB 
+ amp (100 µg mL
-1
) was inoculated with a single colony and grown overnight at 30 °C, 
200 rpm. The following day, 50 mL LB + amp (100 µg mL
-1
) was inoculated with 1 mL 
overnight culture and incubated at 30 °C, 200 rpm for several hours, until the OD600 
reached 0.1. At this point, expression of recombinase genes from pKD46 was induced 
by the addition of L-arabinose to 0.1 M final concentration. The culture was then left to 
incubate at 30 °C, 200 rpm until the OD600 reached 0.4-0.6. Cells were then transferred 
to ice to chill for 10-15 min, followed by centrifugation at 4,000 rpm, 10 min, 4 °C. The 
supernatant was discarded and the cell pellet gently resuspended in 50 mL ice-cold 10 
% (w/v) glycerol. The cells were then centrifuged, as previously, the supernatant 
discarded and the cells resuspended in 25 mL fresh ice-cold 10 % glycerol. 
Centrifugation and resuspension was repeated once more, then after a final 
centrifugation step, the cell pellet was resuspended in 250 µL 10 % glycerol. At this 
point, the concentration of E. coli was determined by measuring the OD600 of a 1:1,000 
FRT FRT 
Kanamycin resistance gene 
Gene A Gene B Gene C 
H
1 
H
2 
P
1 
P
2 
H
1 
H
2 
FRT FRT 
Kanamycin resistance gene 
Gene A Gene C 
Gene A Gene C 
FRT “scar” 
1. PCR amplification of FRT-flanked kanamycin resistance gene 
from pKD4 plasmid 
2. Electroporation into red-recombinase expressing host strain 
3. Selection of positive recombinants on kanamycin-containing media 
4. Deletion of kanamycin resistance gene with plasmid (pCP20) encoded 
FLP recombinase 
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dilution of the cell prep. Assuming that an OD600 value of 1.0 is equivalent to an E. coli 
density of 2.5 × 10
8
 cells mL
-1
 (239), the cell prep was adjusted to 2-3 x 10
10
 cells per 
mL, either by the addition of extra 10 % glycerol, or by re-centrifuging and 
resuspending in a lower volume. The electrocompetent cells were then split into 40 µL 
aliquots and either used immediately, or stored at -80 °C for future use.  
  
 2.7.3. Electroporation 
 
Up to 4 µL (0.1 volumes) of knock-out PCR product from step 2.7.1. was added to 40 
µL electrocompetent cells and incubated on ice for 1-2 min. Cells were then added to a 
sterile, pre-chilled 2 mm gap electroporation cuvette and electroporated (2.5 kV, 25 µF, 
100 Ω) using a Gene Pulser Xcell™ electroporation system (Bio-Rad) Time constants 
typically ranged from 5.0-5.2 msec. Immediately after electroporation, 1 mL SOC + 10 
mM L-arabinose was added to the cuvette, mixed thoroughly but gently, and transferred 
to a 1.5 mL microfuge tube. Electroporated cells were left to recover for 3 h at 37 °C, 
200 rpm, before being spread onto LB + kan (40 µg mL
-1
) agar plates. These were left 
to incubate at 37 °C overnight.             
 
 2.7.4. Curing of kanamycin resistance cassette 
 
Colonies were PCR screened for successful recombination of the kan
R
 gene into the 
region of interest using knock-out diagnostic primers (see Table 2.1), which primed 
from regions upstream of the PCR integration sites. Bands of ~1,600 bp indicated a 
successful recombination. These colonies were then grown in LB + kan (50 µg mL
-1
) at 
42 °C, followed by dilution onto LB + kan (50 µg mL
-1
) agar plates to obtain single 
colonies. These colonies were then tested for loss of the pKD46 plasmid by replica 
streaking onto LB + amp (100 µg mL
-1
) and LB + kan (50 µg mL
-1
) agar plates. 
Colonies that were sensitive to ampicillin but still resistant to kanamycin were selected 
for further processing. These colonies were grown overnight in liquid media, made 
chemically competent (supplementing all growth media with kanamycin to 50 µg mL
-1
) 
and transformed with the heat-sensitive plasmid pCP20. Transformation plates were 
incubated at 30 °C, 200 rpm until colonies appeared. Successful transformants were 
grown in LB + amp (100 µg mL
-1
) overnight at 30 °C, 200 rpm, re-innoculated into 
fresh LB + amp (100 µg mL
-1
) the following day and incubated for another full day and 
night at 30 °C, 200 rpm. Afterwards, a fresh culture of LB (without antibiotics) was 
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inoculated with the overnight culture and grown to an OD600 of ~0.1 at 30 °C, 200 rpm. 
The culture was then transferred to 42 °C, 200 rpm and left to grow until stationary 
phase was reached (OD600 > 0.8). Aliquots were then diluted 1:50,000 and spread onto 
LB (without antibiotics) agar plates and incubated overnight at 42 °C. The following 
day, individual colonies from this plate were replica-streaked onto LB (without 
antibiotics), LB + kan (50 µg mL
-1
) and LB + amp (100 µg mL
-1
) agar plates and 
incubated at 37 °C until bacterial growth was evident. Colonies that failed to grow on 
both LB + kan and LB + amp agar plates were PCR tested for kan
R
 cassette curing using 
gene specific or knock-out primers. Colonies that produced PCR banding patterns 
indicative of loss of the kan
R 
gene (i.e. retained the scar region only; Figure 2.1) were 
grown in LB medium (without antibiotic) overnight at 37 °C, 200 rpm and stored as a 
glycerol stock at -80 °C). 
 
2.8. SDS-PAGE 
 
Preparation and running of SDS-PAGE was carried out essentially as described by 
Laemmli et al. (240). 12-15 % polyacrylamide gels (1 mm thickness) were cast and run 
on a Bio-Rad Protean II™ apparatus, according to the manufacturer‟s instructions. 
Briefly, ~5 mL of pre-set 12-15 % separating gel (see Table 2.12 for all SDS-PAGE 
recipes) was applied to the gel cast and covered with ~1 mL 100 % isopropanol (drum 
grade). The gel was left to set for roughly 30 min, followed by discarding of the 
isopropanol. Roughly 1.5 mL of pre-set 4 % stacking gel was then poured over the top 
of the separating gel, a multi-well comb inserted and left to solidify for roughly 1 h. At 
this point the gel could be stored (wrapped in glad-wrap) for 1-2 days.  
Samples to be run on SDS-PAGE were added in a 2:1 ratio to 3 × SDS-load 
buffer. Samples (typically 30 µL total) were heated at 95 °C for 5 min prior to 
electrophoresis. Gels were run in 1 × SDS-Run buffer, at constant voltage (200 V) for 
45 min to 1 h. Protein bands in gels were stained by gentle shaking in Coomassie blue 
stain solution for 30 min to 1 h. Destaining was carried out by washing the gel of all 
Coomassie blue stain in running tap water, followed gentle shaking in destain solution 
for as long as necessary to achieve the desired contrast.  
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Table 2.12. Recipes of gels and buffers used in SDS-PAGE. 
Component Concentration 
15 % separating gel Per 50 mL 
40 % acrylamide solution 18.23 mL 
2 % Bis-acrylamide solution 10.05 mL 
1.5 M Tris-Cl pH 8.8 12.5 mL 
10 % SDS 0.5 mL 
ddH2O 8.72 mL 
  
4 % stacking gel Per 50mL 
40 % acrylamide solution 4.8 mL 
2 % Bis-acrylamide solution 2.6 mL 
0.5 M Tris-Cl pH 6.8 12.5 mL 
10 % SDS 0.5 mL 
ddH2O 29.5 mL 
  
3 × SDS-load buffer Final concentration 
Tris-Cl, pH 6.8 150 mM 
SDS 6 % (w/v) 
Bromophenol blue 0.3 % (w/v) 
Glycerol 30 % (w/v) 
β-mercaptoethanol 300 mM 
  
1 × SDS-run buffer
a
 Per 1 L 
Glycine 14.4 g 
Tris 3.03 g 
SDS 1 g 
  
Coomassie blue stain Per 1 L 
Coomassie Brilliant Blue 2.5 g 
100 % Ethanol 450 mL 
100 % Acetic Acid 100 mL 
ddH2O 450 mL 
  
Destain Per 1 L 
100 % Methanol 400 mL 
Acetic acid 100 mL 
ddH2O 500 mL 
aSDS-run buffer was prepared as a 10 × solution, with ddH2O used to dilute to 1 × when necessary. 
 
2.9. Enzyme purification 
 
 2.9.1. Enzyme expression in LB media 
 
A single colony or small inoculum of E. coli BL21(DE3) harbouring pET28a(+):ntr 
(where ntr denotes any NTR cloned into the MCS of pET28a(+)) was used to inoculate 
3 mL LB + kan (50 µg mL
-1
). This was incubated overnight at 37 °C, 200 rpm. The 
following day, 50-200 mL LB + kan (50 µg mL
-1
) was inoculated with a 1:100-fold 
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dilution of the overnight culture. This was incubated at 37 °C, 200 rpm until the OD600 
of the culture reached 0.4-0.6. At this point, enzyme expression was induced by the 
addition of IPTG to 0.5 mM final concentration. The culture was returned to the 
incubator (37 °C, 200 rpm) for a further 3-5 h, prior to chilling on ice for 15 min. The 
cell pellet was then collected by centrifugation at 4,000 rpm, 4 °C for 15 min. After 
discarding the supernatant, the cell pellet was either processed immediately, or stored at 
-80 °C until required.  
 
 2.9.2. Enzyme expression in ZYP-5052 media 
 
A single colony or small inoculum of E. coli BL21(DE3) harbouring pET28a(+):ntr was 
used to inoculate 50 mL ZYP-5052 + kan (100 µg mL). This culture was left to incubate 
at 37 °C, 200 rpm for at least 16 h, before chilling on ice for 15 min. The cell pellet was 
then collected by centrifugation at 4,000 rpm, 4 °C for 25 min. After discarding the 
supernatant, the cell pellet was either processed immediately, or stored at -80 C until 
required.  
 
 2.9.3. Cell lysis 
 
Lysis of cells to extract protein was achieved by one of three different methods, none of 
which appeared to have any detrimental downstream effect on enzyme activity 
(personal observations) and were therefore used interchangeably throughout this thesis, 
depending on availability of reagents/apparatus.  
 
 2.9.3.1. BugBuster™ 
 
The first method employed BugBuster™ protein-extraction reagent (Novagen; Merck, 
Darmstadt, Germany) and was carried out according to the manufacturer‟s protocol. 
Briefly, the cell pellet resulting from either of steps 2.9.1 or 2.9.2 above was 
resuspended in BugBuster™ reagent, to a final volume equating to either 2.5 mL 
reagent per 50 mL initial culture for LB/IPTG expressed proteins, or 10 mL reagent per 
50 mL initial culture for ZYP-5052-expressed proteins. The resuspended cell pellet was 
gently mixed on a rotating platform at room temperature for 20 min, followed by 
chilling on ice for 10-15 min.   
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 2.9.3.2. French press 
 
The second method involved lysis of cells by passage through a French press. Cell 
pellets were resuspended in 10-20 mL 1 × His•Bind™ Binding buffer (see below) and 
pressure at 40,000 psi applied three times to achieve uniform lysis. Lysed cells were 
then kept on ice until further processing 
 
 2.9.3.3. Sonication 
 
The third method employed ultra-sonication. Cell pellets were resuspended in 10-20 mL 
1 × His•Bind™ Binding buffer and sonicated, on ice, at 70 % maximum output, with 50 
% duty cycle for five 30 s bursts, alternated with 1 min cooling-down periods.  
 The soluble fraction of the cell lysate resulting from any of the lysis methods 
listed above was then separated from the insoluble fraction by centrifugation at 17,000 
g, 4 °C for 10 min. All components were kept chilled (on ice) at all times. 
 
 2.9.4. Enzyme purification and storage 
 
Recombinant his6-tagged NTRs were purified by nickel-affinity chromatography, 
employing the His•Bind Kit (Novagen) and following the manufacturer‟s instructions. 
The final settled-bed resin volume per column was between 500 µL and 1 mL. Upon 
elution, flow through was collected in a 1.5 mL microfuge tube, until the eluate started 
to become noticeably yellow. At this point, 1.5 mL of the flow-through was collected in 
a new sterile, pre-chilled 1.5 mL microfuge tube. 15 µL of 100 mM FMN (or FAD for 
MdaB (E.c)) was then added to the eluted protein and the tube kept on ice or at 4 °C for 
at least one hour, or overnight when necessary. Buffer-exchange into 40 mM Tris-Cl pH 
7.0 was then conducted using a 5 mL HiTrap™ Desalting column (GE Healthcare, 
Chalfont St. Giles, UK) according to the manufacturer‟s instructions. Only 1 mL of 
column flow-through was collected upon elution, to minimize contamination with 
excess free FMN. Samples were then mixed 1:1 with 80 % glycerol and stored at -20 °C 
indefinitely. The presence of glycerol was found to have no detrimental effect on 
enzyme activity (results not shown). 
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 2.9.5. Removal of His6 tags from purified enzymes 
 
When required, the Novagen Thrombin Kit was used to cleave His6 tags from purified 
recombinant enzymes, according to the manufacturer‟s instructions. 
 
 2.9.6. Determination of enzyme concentration 
 
Concentrations of purified protein samples were measured using the Dc™ protein assay 
kit (Bio-Rad), following the manufacturer‟s instructions. Bovine serum albumin (BSA), 
reconstituted in 20 mM Tris-Cl pH 7.0 and 40 % glycerol, was used to establish a 
standard curve with concentrations ranging from 0.25 to 1.5 mg mL
-1
.  
 
2.10. Determination of substrate extinction coefficients 
 
100 µM substrate (PR-104A, SN 27686, SN 29176 or SN 30444) in 10 mM Tris-Cl pH 
7.0, 4 % DMSO was scanned for total absorbance between 325 and 500 nm wavelength, 
with a 1 cm path length, using a Helios γ UV-Vis spectrophotometer (Thermo-Fisher). 
The same concentration of substrate was then incubated with 300 µM NADPH and ~1 
µg purified recombinant NfsA (E.c). This reaction was left to run for 15-20 min, or until 
NADPH oxidation had terminated (assessed by decrease in absorbance at 340 nm; note 
that NfsA (E.c) has innate NADPH-oxidase activity, eliminating any excess reduced co-
substrate from the reaction mix). This reaction was then scanned for absorbance 
between 325 and 500 nm and any changes relative to the absorbance plot of parental 
substrate noted, especially at wavelengths ≥400 nm, due to no interference by reduced 
or oxidised NAD(P)H co-substrate at these wavelengths. The wavelength at which this 
difference was maximal was chosen for determination of the extinction coefficient (ε). 
This was calculated by measuring the difference in absorbance between the parental and 
reduced forms of the substrate and adjusting for concentration, so that the final constant 
was expressed in M
-1
 cm
-1
. 
  
2.11. In vitro kinetics of purified enzymes  
 
Steady-state enzyme kinetics of purified NTRs were assessed spectrophotometrically at 
either 420 nm for CB1954 (based on equal absorption of both 2- and 4-hydroxylamine 
reduction products of CB1954 at this wavelength; ε = 1,200 M-1 cm-1; (241)) or 400 nm 
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for PR-104A (ε = 6,000 M-1 cm-1; see Figure 5.12), SN 27686 (ε = 7,000 M-1 cm-1), SN 
29176 (ε = 4,000 M-1 cm-1), SN 30444 (ε = 7,000 M-1 cm-1) and NFZ (12,960 M-1 cm-1; 
(176)) using a Helios γ UV-Vis spectrophotometer. Reactions were performed in 60 µL 
in UVettes™ (Eppendorf, Hamburg, Germany), containing 10 mM Tris–Cl (pH 7.0), 4 
% DMSO, 0.25 mM NAD(P)H and varying substrate concentrations (the range used 
was dependent on substrate and enzyme being tested, but was always within 10-2000 
µM). Reactions were commenced by addition of 6 µL of an appropriate purified enzyme 
dilution and changes in absorbance were measured for the initial 15–30 s. For 
calculation of apparent Km and kcat values, substrate concentrations were varied from 
~0.2 × to 5 × Km (although CB1954 and PR-104A solubility and absorbance limits 
precluded analysis of the full range of concentrations for enzymes with high Km values; 
maximum CB1954 concentration tested was 5 mM, maximum PR-104A concentration 
tested was 800 µM). Non-linear regression analyses and Michaelis-Menten curve fitting 
were performed using SigmaPlot™ 10.0 (Systat Software, Richmond, CA, USA).  
 
2.12. pUCX construction 
 
The inducible, high-copy number, E. coli expression vector pUCX was used for 
expression of native NTRs (without His6-tags or other sequence additions associated 
with pET28a(+) in E. coli SOS reporter strains (SOS-R1 and all derivatives thereof) for 
use in the SOS-chromotest and other in vivo E. coli assays of NTR activity. pUCX was 
originally constructed so that the completed vector would already contain a test-NTR (in 
this case azoR from E. coli) in the MCS. This was to facilitate expression testing of the 
final vector, prior to making an empty version for subsequent cloning of NTRs. Two 
templates were required for creation of pUCX:azoR. The first, pMM67EH:azoR, had 
previously been made in the lab by cloning the E. coli azoR gene (PCR-amplified using 
azoR_Ec_Fw and Rv primers) between the NdeI and SalI sites of digested 
pMMB(nfsA) (184). From this, a 2,669 bp fragment (encompassing the lacIq gene, 
promoter region, MCS and T0T1 transcriptional terminator sequence) was PCR-
amplified, using primers BlaPromFw and NewpUCF2Rv. The second template was 
pUC19 (Invitrogen), from which a 2,198 bp fragment (encompassing the amp
R
 gene and 
origin of replication) was PCR-amplified using primers pUCF1Fw and pUCF1Rv. Both 
of these PCR products were purified, digested with AgeI and SpeI and ligated together 
to form pUC19X:azoR. To remove the His6-tag sequence from the expression region, a 
4.7 kb segment was PCR-amplified from pUC19X:azoR using primers azoR_Ec_Fw 
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and pETRBSRv. This PCR product was then digested with NdeI and self-ligated to 
form pUCX:azoR. The empty (no inserted NTR) vector was created by PCR-amplifying 
a 4.2 kb segment of pUCX:azoR using primers pUCXWTFw and pETRBSRv. This was 
then digested with NdeI and self ligated to form pUCX:empty. 
All other NTRs were cloned directly into the MCS of pUCX after PCR amplification of 
the gene using the relevant NTR specific primers listed in Table 2.1.     
 
 
 
 
 
 
Figure 2.2. Map and MCS sequence of pUCX:empty. 
 
See 
inset 
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2.13. SOS assay 
 
 2.13.1. Chapter 3 and 4 protocol 
  
Individual microtitre plate wells containing 200 µL LB + amp (100 µg mL
-1
) + 0.4 % 
(w/v) glucose were inoculated with SOS-R1 (and derivatives) pUCX:ntr strains and 
incubated overnight at 30 °C, 200 rpm. 10 µL of the overnight cultures were used to 
inoculate 190 µL of fresh assay media (LB + amp 100 µg mL
-1
, 0.05 mM IPTG, 0.2 % 
glucose) in a sterile microtitre plate and incubated at 30 °C, 200 rpm for 3 h (pre-
challenge growth). Cultures were then split into 100 µL duplicates into a clean 
microtitre plate and supplemented with either 100 µL challenge media (assay media + 
prodrug, 2 % DMSO) or 100 µL control media (assay media + 2 % DMSO). OD600 
readings were recorded using either a VERSAmax™ microplate reader (Molecular 
Devices, Sunnyvale CA, USA) or an EnSpire™ 2300 Multilabel Reader (PerkinElmer, 
Waltham, MA, USA) and the plate returned to the incubator (challenge; 30 °C, 200 
rpm). Following the appropriate length of time (typically 3 h), plates were removed, 
OD600 readings recorded and 10 µL cells removed for β–galactosidase analysis (except 
for section 4.2.1, where cell volumes were varied from 2.5 to 20 µL and compensated 
for by altering the amount of 40 mM sodium phosphate buffer pH 7.0 added to an 
accumulative total of 100 µL). If multiple time points were to be analysed, plates were 
returned to the incubator for further growth. The 10 µL aliquots were added to 90 µL of 
40 mM sodium phosphate buffer pH 7.0 and 50 µL ZOB buffer (4 parts Z buffer, 1 part 
T-Base, see Table 2.13 for recipes; (242)) in a sterile microtitre plate, which was 
incubated at 37 °C without shaking for 20-40 min until sufficient colour development 
from the o-nitrophenyl-β-D-galactopyranoside (ONPG) substrate was observed. 
Reactions were terminated by addition of 50 µL of 1 M Na2CO3 to each well. 
Absorbance readings at 420 nm and 550 nm were recorded and Miller units were 
calculated by the Miller equation (243). Miller unit calculation was altered from the 
original equation for all β-galactosidase activity measurements from Chapter 4 onwards, 
as described in section 4.2.1. 
 
 2.13.2. Chapter 5 and 6 modifications 
 
Through general observations and increasing experience at running SOS assays, 
alterations to the SOS methodology that led to improved signal output and reliability 
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were noted and incorporated into the protocol. These were as follows: 15 µL overnight 
cultures were inoculated into 195 µL fresh assay media at commencement of assay. Pre-
challenge incubation time was increased to 3.5 h. 95 µL of pre-challenge culture was 
added to 95 µL challenge media at the commencement of challenge (both challenged 
and unchallenged cultures being transferred to new plates). The time allowed for colour 
development upon addition of ONPG and ZOB was kept constant at 25 min. When 
working with SOS-R2 carrying pUCKG:ntr, IPTG concentration was increased to 0.25 
mM.  
 
Table 2.13. Recipes of buffers required for measurement of β-galactosidase activity 
in SOS assays. 
Component Concentration 
1 M Sodium phosphate buffer pH 7.0  
Na2HPO4 0.577 M 
NaH2PO4 0.423 M 
  
Z-Buffer  
NaH2PO4 0.074 M 
Na2HPO4 0.126 M 
MgSO4 2 mM 
MnSO4 0.4 mM 
CTAB 399 mg L
-1
 
Sodium deoxycholate 199.5 mg L
-1
 
β-mercaptoethanola 0.174 M 
  
T-Base  
K2HPO4 0.08 M 
KH2PO4 0.044 M 
(NH4)2SO4 15.1 mM 
Tri-sodium citrate 1 g L
-1
 
ONPG
b
 8 mg mL
-1
 
aβ-mercaptoethanol was added to Z-buffer directly prior to use. Z-buffer without β-mercaptoethanol was 
stored long term at 4 °C. 
bAfter ONPG was added, T-Base was stored in aliquots at -80 °C. T-Base without ONPG was made up 
and stored long term at 4 °C. 
 
 
2.14. IC50 measurements 
 
 2.14.1. LB liquid media version (Chapter 3) 
 
Cultures of SOS-R1 pUCX:ntr were set up and challenged as described for the SOS 
assay (see section 2.13.1). CB1954 concentrations used ranged from 0-2,000 µM. IC50 
values were calculated by finding the concentration of CB1954 that inhibited growth of 
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NTR over-expressing strains to 50 % of unchallenged controls, after 3 h challenge with 
the prodrug. Cell growth was monitored by spectrophotometry (absorbance of cell 
culture at 600 nm wavelength). IC50 values were calculated using non-linear regression 
analysis in SigmaPlot, fitting the data to a 4-parameter logistics curve. 
 
 2.14.2. M63 minimal media version (Chapters 5 and 6) 
 
Cultures of SOS-R2:pUCX or pUCXKG:ntr were grown overnight as described for the 
SOS assay (see section 2.13.2). The following day 100 µL of overnight culture was used 
to inoculate 2 mL M63IA (1 × M63 + amp + 50 µM IPTG) and incubated at 30 °C, 200 
rpm for 3.5 h. This culture was then split into 100 µL aliquots and added to 100 µL 
aliquots of MD63AI + CB1954/PR-104A at varying concentrations (0-1,600 µM for 
CB1954, 0-800 µM for PR-104A, DMSO final concentration of 1 %) in a sterile 96 well 
plate. Alternatively, cultures were aliquoted (40 µL each) into wells of a 384 well plate, 
each containing 40 µL M63AI plus prodrug. Each concentration of prodrug was assayed 
in duplicate for each NTR over-expression strain. Culture turbidity was monitored at 
600 nm every hour for at least three and up to six hours post-challenge. IC50 values were 
calculated as previously described (see section 2.14.1).  
  
2.15. Mutagenicity testing 
 
Overnight and day cultures of SOS-R1 and SOS-R1 ΔuvrB pUCX:ntr were set up as 
described in section 2.13.1 (using at least 6 wells for each strain to be tested). Following 
3.5 h pre-challenge growth of the assay cultures, OD600 readings were taken and 800 µL 
of each strain transferred to sterile 1.5 mL microfuge tubes on ice. Cells were chilled for 
10 min, centrifuged at 13,000 rpm for 1 min and the supernatant discarded. Cell pellets 
were then resuspended in 1 × M63 (without glucose or casamino acids) to an OD600 of 
0.3, and 200 µL aliquots, in duplicate for each strain, transferred to sterile 1.5 mL 
microfuge tubes. CB1954 was added to one tube (“challenged”) of each duplicate to the 
desired concentration with a final DMSO concentration of 1 % v/v. DMSO was added 
to 1 % v/v concentration to the other tube (“unchallenged”). Cultures were then 
incubated at 30 °C, 200 rpm for an additional 3 h, prior to centrifugation at 13,000 rpm 
for 1 min and discarding of supernatant. Cell pellets were resuspended in 1 volume of 
0.22 µm-filtered 1 × PBS (8 g L
-1
 NaCl, 0.2 g L
-1
 KCl, 1.44 g L
-1
 Na2HPO4, 0.24 g L
-1
 
KH2PO4) and 100 µL used to inoculate 3 mL of LB + amp (100 µg mL
-1
) media, which 
  
62 
was left to incubate overnight at 37 °C, 200 rpm. The following day, 100 µL of 
overnight recovered cultures were spread onto LB agar plates containing amp and rif 
(both 100 µg mL
-1
). Aliquots from the remaining cultures were then diluted 1 in 10
6
 and 
1 in 10
7
 in sterile 1 × PBS and 100 µL spread onto LB + amp (100 µg mL
-1
) agar plates. 
All agar plates were incubated at 37 °C overnight or until colonies were visible. 
Frequency of rifampicin resistance (expressed as Rif
R
 mutants per 10
8
 cells) for each 
strain was then calculated by normalising the total number of Rif
R 
colony forming units 
(CFUs) to the total number of viable cells per mL of initial culture (as calculated from 
CFUs on ampicillin only-containing agar plates). 
 
2.16. HPLC 
 
 2.16.1. Identification of CB1954 nitroreduction products 
 
Reactions of 100 µL containing 10 mM Tris-Cl pH 7.0, 200 µM CB1954, 1 mM 
NAD(P)H and initiated by addition of 0.5-2 µM purified enzyme were incubated for 10-
30 min at room temperature before being stopped by addition of 1 volume ice-cold 100 
% methanol. Samples were immediately transferred to -80°C for at least 1 h to 
precipitate proteins, followed by centrifugation at 12,000 g for 10 min at 4 °C. The 
supernatant was then diluted 1:20 in 45 mM formate buffer pH 6.5 containing 2.5 % 
methanol and 100 µL of each sample was analysed by reverse phase-HPLC employing 
an Agilent 1100 system with an Alltima™ C8 5µ 150 x 2.1 mm column. The mobile 
phase used 45 mM formate buffer (pH 6.5) as aqueous and 80 % acetonitrile as organic. 
Assay conditions consisted of 4 min at 5 % organic, a linear increase to 50 % organic 
from 4-19mins, and a further gradient increase to 70 % organic for 2 min. Flow rate was 
constant at 0.3 mL min
-1
. The eluate was monitored at 262 nm. Elution profiles from 
NTR-CB1954 reactions were compared against pure standards of each potential 
metabolite: CB1954, its 2- and 4-hydroxylamines (2-/4-NHOH), and 2- and 4-amines 
(2-/4-NH2). 
 
 2.16.2. Identification of PR-104A nitroreduction products 
 
Reactions with PR-104A as substrate were set up and carried out identically to those 
outlined for CB1954, in section 2.16.1. Following centrifugation, samples were diluted 
1:20 in 45 mM formate buffer pH 4.5, 20 % methanol. Column type used and volume of 
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sample employed were the same as for CB1954. The mobile phase used 45 mM formate 
buffer (pH 4.5) as aqueous and 80% MeCN as organic. Assay conditions consisted of 4 
min at 20 % organic, a linear increase to 100 % organic over the following 21 min, 
followed by an extra 1 min at 100 % organic. Flow rate was constant at 0.3 mL min
-1
. 
Eluates were monitored continuously at 254 nm. Reaction products were identified 
through comparison of chromatograms to those obtained from pure, chemically 
synthesized metabolites: PR-104A and the para nitro group reduction products PR-
104H (hydroxylamino derivative) and PR-104M (amino derivative). 
 Further identification and confirmation of reaction products was achieved 
through mass spectrometry, carried out as described elsewhere (57; 244). Electrospray 
ionisation and quadrupole detection methods were employed, set at positive ionisation 
mode.  
 
2.17. HCT-116 general methods 
 
All methods outlined in this section were carried out by Dr. Sophie Syddall at the 
ACSRC. 
 
Generation of mammalian expression vectors and testing of candidate NTRs in the 
human colon carcinoma cell line HCT-116 was performed by Dr. Sophie Syddall at the 
ACSRC. Each NTR gene was PCR-amplified using oligonucleotide primers that 
incorporated a mammalian kozak consensus sequence and a Shine-Dalgarno prokaryote 
consensus sequence up stream of the 5‟ end of the gene, a TAG stop codon in place of 
the native gene stop codon, and Invitrogen Gateway™ BP recombination sites both 
upstream of the 5‟ end and downstream of the 3‟ end of the gene sequence (consensus 
sequence for forward primer: GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGA                                                                                                       
AGGAGATAGAACCATGGGC-3‟, followed by 15-20 bp homology to the 5‟ end of 
the desired gene, without including the initial ATG codon; consensus sequence for 
reverse primer: 5‟-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTA-3‟, followed 
by 15-20 bp homology to the reverse complement of the 3‟ end of the desired gene, 
without including the native stop codon). PCR products were recombined into the 
pDONR221™ vector (Invitrogen) and sequence verified using M13 sequencing 
primers. NTR genes were then recombined into the F527-V5 vector (62). Plasmids were 
transfected into HCT-116 colon cancer cells using Fugene-6 (Roche, Basel, 
Switzerland), according to the manufacturer‟s instructions. Transiently transfected cells 
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were assayed 1 h later, or to select stably transfected pools cells were left untreated for 3 
days after which fresh αMEM media containing 5% FCS and 1 µM puromycin was 
added. Puromycin concentrations were increased daily until a maximum of 3 µM was 
achieved. Media was changed daily until cell death was no longer evident and growth of 
transfected cells was achieved.  
For IC50 cytotoxicity analysis of stably transfected pools, cells (500 per well) were 
seeded into 96-well plates and left to attach for 4 h. After the attachment period cells 
were exposed to a range of CB1954 concentrations for 18 h, washed 3 times, then left to 
grow for 5 days. Plates were stained with sulforhodamine B as previously described 
(245) and absorbance measured on an ELx 808 Absorbance Microplate Reader (Bio-tek 
Instruments, Winooski, VT, USA). IC50 values were defined as the drug concentration 
required to reduce absorbance to 50% of that of unchallenged controls on the same 
plate. Each cell line was independently tested 2 –10 times.  
NTR expression was assessed using expression of a V5 tag by infection of 5x10
5
 
cells (stably transfected cell lines, or simultaneously during transient transfections) with 
50 MOI Tag-On-Demand™ Suppressor Supernatant (Invitrogen). Cells were incubated 
for 27 h post-infection then lysed in situ in 50 mM Tris-Cl pH 8.0 containing 150 mM 
NaCl, 1 mM EDTA, 1% (v/v) Nonidet P40 (Roche), 0.5% sodium deoxycholate and 1% 
protease inhibitor cocktail (Sigma-Aldrich). Samples were incubated on ice for 20 min 
with periodic agitation, collected by centrifugation and protein was quantified using the 
BCA assay (Pierce, Thermo-Fisher) with BSA as reference. Soluble proteins were 
fractionated by denaturing PAGE, transferred onto nitrocellulose (Bio-Rad) and blocked 
in PBS containing 5% non-fat dry milk powder and 0.05% Tween-20. Blots were 
incubated for 2 h with HRP-conjugated primary anti-V5 antibody (Invitrogen) diluted to 
1:5,000 in PBS-Tween-20, or 1 h with mouse anti-β-actin diluted to 1:10,000 
(Chemicon) followed by incubation for 1 h with a HRP-conjugated secondary antibody 
diluted 1:10,000 (Zymed). HRP signal was detected by enhanced chemiluminescence 
(Pierce). Images were acquired on an ImageReader LAS-3000 (Fujifilm). 
 
2.18. Site-directed mutagenesis 
 
 2.18.1. pUCXKT construction 
 
Plasmid pUCXKT is a derivative of pUCX that confers kanamycin resistance to host 
cells only when a gene amplified using the pUCXSacIRv primer has been correctly 
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inserted into the MCS. As such, the frequency of false positive transformants that arise 
either through incomplete digestion of parental plasmid, re-circularized plasmid through 
ligation of degraded, blunt ended DNA ends, or insertion of rogue DNA sequences, is 
significantly reduced when using kanamycin in the selective media.   
 pUCXKT was constructed as follows: A 794 bp fragment, containing (in order, 
5‟ to 3‟) 2 stop codons (TAA, TAG), a SacI site and a truncated version of a 
kanamycin-resistance gene (missing the first 12 nucleotides), was PCR amplified from 
plasmid pKD4 using primers KantruncSalIFw3 and KantruncHindIII Rv. This was 
purified, digested with SalI and HindIII and ligated into similarly digested 
pUCX:empty, resulting in plasmid pUCXKT (Amp
R
, Kan
S
; see Figure 2.3A) 
 
2.18.2. pUCXKG construction  
 
Genes to be inserted into pUCXKT were PCR amplified from previously constructed 
pUCX:ntr vectors using gene-specific Fw and pUCXSacIRv primers. pUCXSacIRv 
primer contains (in order, 5‟-3‟) a SacI site, the first two codons of the kanamycin 
resistance gene and a 17-base pair linker region identical to the sequence separating the 
ampicillin and kanamycin resistance genes of plasmid pCR2.1 (Invitrogen). The primer 
also contains 18 base pairs of homology with pUCX, downstream of the MCS 
(terminating within the HindIII site). This latter property allows pUCXSacIRv to 
amplify any gene already inserted into pUCX. This scheme is illustrated in Figure 2.3B. 
Genes amplified in this manner were purified, digested with NdeI and SacI and ligated 
into similarly digested pUCXKT. Ligations were heat-inactivated and transformed into 
E. coli SOS-R2 as previously described. During the transformation process, 50 µM 
IPTG was added to the recovery media to permit expression of the re-constituted kan
R
 
gene. Positive clones were selected for on LB agar containing amp (100 µg mL
-1
), kan 
(50 µg mL
-1
) and IPTG (50 µM). Successful constructs were termed pUCXKG:ntr, 
where ntr denotes the relevant inserted NTR gene.          
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NTR gene 
NdeI SalI 
HindIII 
pMMBFw 
pUCXSacIRv 
NTR gene  
NdeI SalI 
HindIII 
SacI 
Upstream section 
of pUCX 
pUCX:ntr template 
PCR product 
GCTTGGCTGTTTTGGCGGATTGAAAAAGGAAGAGTATGATTGAGCTCGGG
G 
SacI RBS 2 
linker region 
pUCX priming region 
First 4 amino 
acids of kanR 
gene 
pUCXSacIRv 
(shown 3’-5’ for clarity) 
See 
inset 
A 
B 
  
67 
 
 
Figures 2.3A-C. pUCXKT and pUCXKG: vector maps, sequences and cloning procedure. 
 (A) Map and sequence of MCS of pUCXKT. (B) Diagram of PCR protocol used to create product for 
cloning into pUCXKT, to form pUCXKG:ntr. The sequence provided by the primer pUCXSacIRv is 
shown. (C) Map and sequence of MCS of pUCXKG:ntr (the product of ligation between NdeI-SacI 
digested pUCXKT and PCR product from (B).    
 
 
 
 
 
 
 
See 
inset 
C 
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2.19. Site directed mutagenesis 
 
 2.19.1. Overlap PCR 
 
To perform saturation mutagenesis at a specific codon of YcnD (B.s), an overlap PCR 
protocol was used (see Figure 2.4). A site-directed mutagenesis (SDM) forward primer 
containing (5‟ to 3‟) 20 nucleotides homologous to the 20 base pairs directly upstream 
of the codon to be mutated, the nucleotide sequence NNK in place of the codon to be 
mutated (where N denotes any of the four possible nucleotides and K denotes either 
guanine or thymine) and finally 15-20 nucleotides homologous to the region directly 
downstream of the codon to be mutated was used in conjunction with primer pMMBRv 
to amplify the relevant segment from the appropriate pUCX:ntr construct. 
Simultaneously, a separate PCR was set up using a SDM Rv primer, consisting of 20 
nucleotides directly complementary to the initial 5‟ 20 nucleotides of the SDM Fw 
primer, in conjunction with primer T7FwpMMBFw, to amplify the relevant segment 
from the appropriate pUCX:ntr construct. High-fidelity polymerase (Accuzyme™ or 
Phusion™) was employed for both of these PCR steps. The total amount of template 
plasmid used did not exceed 0.01 ng µL
-1
 final concentration to minimise carry over of 
parental plasmid into the final PCR reaction. PCR products were purified, digested for 3 
h with DpnI, heat-inactivated at 80 °C for 20 min and re-purified. Both PCR products 
were then added (~10 ng each) to triplicate primer-less PCR reactions (10 µL total, 
BioMix™ Red). Control reactions containing each of the PCR fragments alone were 
also set up. These PCRs were applied to thermal cycling as previously described, except 
the annealing temperature was reduced to 50 °C. After 15 cycles, the reactions were 
held at 72 °C while primers (T7Fw and pUCXSacIRv) were added (to 0.5 µM final 
concentration, each primer) along with extra BioMix™ Red (to a final volume of 12.5 
µL for each reaction) to each tube. Amplification was then continued for an additional 
15 cycles, with an annealing temperature of 56 °C. PCR products were analysed for 
correct length by agarose gel electrophoresis, purified and finally cloned into pUCXKT 
using the procedure described previously (see section 2.18.2).  
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Figure 2.4. Schematic outline of overlap PCR protocol used for single codon mutagenesis. 
 See text in section 2.19.1 for details. 
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2.19.2. Mutant enzyme library creation 
 
88-92 colonies of SOS-R2: pUCXKG:ycnD (B.s), mutated at a specific site as described 
in section 2.19.1, were picked directly from transformation agar plates and inoculated 
into separate wells of a 96-well plate containing 120 µL LB + amp (100 µg mL
-1
) and 
glucose (0.2 % w v). At least 2 wells were reserved for SOS-R2 pUCXKG expressing 
the wildtype NTR, and one well for SOS-R2 pUCXKG:empty. One well was also 
reserved as a blank (no inoculation). Plates were then grown overnight at 30 °C, 200 
rpm, before being diluted 1:1 with 80 % (w v) glycerol, mixed thoroughly and stored 
indefinitely at -80 °C.   
 
2.20. Statistical analysis 
 
All pairwise comparisons of means were performed using the unpaired Student‟s t-test 
(online at http://www.graphpad.com/quickcalcs/ttest1.cfm). Regression analysis was 
performed using in-built statistical software in SigmaPlot. 
 
2.21. Enzyme active site modelling 
 
The protein 3D structure viewing program DeepView (SwissPDB) was used for all 
comparisons of NTR active sites and active site modelling (located at http://spdbv.vital-
it.ch/; (246)) 
  
71 
Chapter 3: Screening putative nitroreductases of E. coli for 
CB1954-reducing activity: validation of the SOS assay as a 
prodrug reduction screen 
 
3.1. Introduction 
  
This chapter describes the preliminary testing and optimisation of the SOS assay as a 
potential screen for the assessment of CB1954 reduction by bacterial NTRs. In the first 
part of this chapter, the ability of the SOS assay to function in microplate format and to 
detect CB1954 reduction in a dose–dependent manner, was experimentally confirmed 
using over-expression of the prototypical NTR NfsB from E. coli, in the E. coli SOS 
reporter strain ADA510 (sfiA:lacZ). Secondly, the SOS assay was employed to assess 
the breadth of CB1954-reductase activity in E. coli by applying it to a small panel of 
phylogenetically diverse native E. coli enzymes with putative NTR activity, based on 
amino acid/structural homology to previously identified CB1954 or other nitroaromatic 
compound-reductases. Finally, the results obtained from the SOS assay were validated 
by comparison with those gained through a series of other in vivo and in vitro tests, 
including cytotoxicity in a human cancer cell line. Overall, the results from this study 
demonstrate the utility of the SOS response as a sensitive and efficient screen for 
detection and relative quantification of CB1954 activation by NTRs. Furthermore, 
CB1954-reductase activity was identified with two enzymes previously un-characterised 
in this regard, proving the existence of multiple enzyme families capable of 
nitroaromatic prodrug metabolism. 
The majority of results presented in this chapter have been published 
independently in the peer-reviewed Journal Biochemical Pharmacology, as Prosser et al. 
(247). 
 
3.2. Initial testing and optimisation of SOS assay 
  
 3.2.1. Choice and optimisation of reporter strain 
 
A multitude of E. coli SOS reporter strains have been constructed over the last few 
decades, encompassing a variety of reporter genes (e.g. lacZ, gfp, the lux operon) and 
SOS promoters (e.g. recA, umuDC, sfiA, cda, uvrA) (229; 248-250). Some have been 
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plasmid based, while others contain the SOS promoter-reporter gene fusion as a single 
genome-integrated copy (228; 229; 251; 252). The strain chosen for this study 
(ADA510; (231)) belongs to the latter group, and consists of the reporter gene lacZ, 
encoding β-galactosidase, transcriptionally coupled to the sfiA gene promoter. ADA510 
was chosen for several reasons. Firstly, β-galactosidase is one of the best-characterised 
reporter gene products available, having been used in a variety of studies over several 
decades (243). As such, its genetic and biochemical properties are well-understood and 
numerous colorimetric substrates are available for enzyme detection. The substrate 
employed throughout this body of work was o-nitrophenyl-β-D-galactopyranoside 
(ONPG), a colourless, water-soluble substrate that is converted into a yellow 
nitrophenol derivative upon cleavage by β-galactosidase. ONPG is cheap, easy to use 
and a highly sensitive substrate for β-galactosidase (243). The sfiA promoter employed 
is widely considered to have one of the most tightly regulated expression profiles of all 
SOS-linked genes (253). The SfiA protein itself is involved in inhibition of cell 
division, and as such, basal levels (in the absence of SOS induction) are minimal (253). 
Additionally, cytosolic SfiA levels can increase up to 125-fold upon SOS induction, the 
highest of all SOS genes studied to date, providing a high dynamic range for reporter 
gene expression from this promoter (254). Lastly, a genome-integrated reporter gene 
fusion strain was chosen over a plasmid-based system to prevent high background 
reporter activity or reporter gene stability problems arising (230; 255), as well as to 
facilitate transformation and maintenance of NTR over-expression vectors, precluding 
plasmid-incompatibility issues.  
 ADA510 is a lac null mutant, preventing interference from high background 
rates of native β-galactosidase activity. In order to further optimise this strain for 
prodrug reduction screening, the native major and minor NTR genes (nfsA and nfsB) 
were deleted from the ADA510 chromosome, thereby minimizing background reduction 
of nitroaromatic prodrugs in this strain. Our justification of targeting NfsA was through 
preliminary data (not shown) that implied a substantial role of this enzyme in CB1954 
metabolism. The work of Vass et al. (189) was not available at the time of this study. 
The resultant strain was termed SOS-R1 (SOS Reporter strain 1). 
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Figure 3.1. Schematic outline of the SOS assay.  
An SOS reporter strain containing a genome-integrated reporter gene (in this case lacZ encoding β-
galactosidase) fused downstream of an SOS-responsive promoter (pSOS) is transformed with an NTR 
expression vector. Transformants are grown, induced for NTR expression and challenged with a 
nitroaromatic prodrug (e.g. CB1954). The prodrug is reduced by active NTRs leading to formation of 
DNA adducts. DNA damage activates the SOS response leading to expression of SOS-linked genes, 
including lacZ. Following prodrug challenge, cells are lysed and incubated with a reporter substrate (e.g. 
ONPG) to allow measurement of reporter gene activity (e.g. via spectrophotometry). 
 
3.2.2. NTR over-expression and SOS assay optimisation 
 
In order to over-express candidate NTRs in SOS-R1, an inducible expression plasmid 
(pUCX) was constructed by cloning the IPTG-inducible tac promoter region and 
ribosome binding site from pMMB67EH into the high-copy number cloning plasmid 
pUC19 (See section 2.12 for details on plasmid construction and Figure 2.2 for vector 
map). The native E. coli nfsB gene was cloned into the MCS of pUCX, transformed into 
SOS-R1 and the resultant strain tested under a variety of conditions, alongside an empty 
plasmid (pUC19)-containing control, for its ability to elicit β-galactosidase activity 
upon incubation with CB1954. A schematic diagram of the SOS assay is illustrated in 
Figure 3.1. Variable parameters that were tested included IPTG concentration, CB1954 
concentration and total CB1954 challenge time (length of incubation of prodrug with 
SOS-R1 prior to β-galactosidase detection). Figure 3.2 depicts the positive correlation 
between β-galactosidase (and therefore SOS) activity and the various parameters tested 
for NfsB-over-expressing SOS-R1. Minimal SOS activity was recorded with the empty 
plasmid control over the entire range of conditions tested (Figure 3.2C), except for a 
modest (~2-fold) increase in activity at the highest CB1954 concentrations (0.5 and 
1mM) and the longest challenge time (5 h) employed. Thus, NTR-mediated reduction of 
CB1954 is readily detectable over background levels using the SOS assay. Based on the 
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results gained from NfsB over-expressing SOS-R1, optimal conditions were chosen for 
subsequent SOS assays. For IPTG concentration, no significant increase in β-
galactosidase activity was observed between 50 and 200 µM (Figure 3.2A) and 
therefore the former was selected for future experiments. Also, because IPTG is a 
known inhibitor of β-galactosidase activity (256), it was deemed beneficial for the SOS 
assay to work with this lower concentration. SOS activity correlated positively with 
CB1954 concentrations up to 200 µM, after which a steep decrease in SOS activity was 
observed (Figure 3.2B). This was most likely due to decreased cell viability (as 
measured by culture turbidity) at these high concentrations, as illustrated in Figure 
3.2D. Optimal CB1954 concentrations were therefore judged as being ≥10 µM and 
≤100 µM, a range over which SOS activity was significantly higher than background 
and correlated positively with CB1954 concentration. For challenge time, a large 
increase in SOS activity was seen at each time point from 0 to 2 h, after which increases 
in activity were more modest (Figure 3.2B). A challenge time of 3 h was selected for 
subsequent work, as it allowed sufficient time for SOS response pathways to be 
activated and was short enough to allow ease of assay processing over a single working 
day.  
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Figures 3.2A-E. Optimisation of SOS assay parameters.  
(A) SOS response of SOS-R1 over-expressing E. coli nfsB (pUCX:nfsB) or no enzyme (empty vector) 
after 3 h challenge with 100 µM CB1954 at varying IPTG concentrations. SOS response fold induction 
refers to the ratio of raw β-galactosidase activity (in Miller units, (243)) of challenged cultures to 
unchallenged isogenic strains. (B & C) SOS response of (B) SOS-R1:pUCX:nfsB and (C) SOS-R1:empty 
vector after challenge with multiple concentrations of CB1954 at multiple time points. (D & E) Relative 
cell survival (as measured by changes in culture turbidity at 600 nm and expressed as a percentage of 
unchallenged isogenic control cultures) of (D) SOS-R1 pUCX:nfsB or (E) SOS-R1 empty vector over 
multiple concentrations of CB1954 and at multiple time points. 50 µM IPTG was employed in all assays 
used to generate figures B-E. Each data set is the average of 1-3 independent assays, ± 1 standard 
deviation. 
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3.3. Candidate NTR selection 
 
In order to further assess the applicability and accuracy of the SOS assay as a measure 
of CB1954-reductase activity, additional candidate enzymes were tested. This also 
afforded the opportunity of exploring potential NTR activity in previously 
uncharacterised enzymes. The enzymes selected for this section were all native to E. 
coli, so as to minimize problems arising from heterologous gene expression. They also 
all adhered to at least one of the following criteria, chosen so as to maximise the 
possibility of locating novel nitroaromatic prodrug-reducing enzymes:  
1. Proven (published) CB1954-reductase activity. Literature searches revealed 
that only three native E. coli enzymes had been directly associated with the 
ability to reduce CB1954. These included the major and minor NTRs (NfsA 
and NfsB) and the chromate reductase YieF (122; 222). We noted that 
although NfsA had previously been recorded as an enzyme with the capacity 
to reduce CB1954, this activity had never formally been characterised (222). 
2. Amino acid sequence homology (≥25 %) to proven CB1954-reductase 
enzymes. BLAST searches within the NCBI database using the protein 
sequences of E. coli NfsA, NfsB,YieF, mammalian NQO1, B. 
amyloliquefaciens YwrO or P. pseudoalcaligenes NbzA (the report on YfkO 
from B. licheniformis had not been published at the time of these 
experiments) as query sequences were conducted to find possible native E. 
coli homologues. Three genes were located. KefF, annotated as a 
flavoprotein subunit of the KefC potassium efflux system (257) has 40% 
amino acid identity to B. amyloliquefaciens YwrO across 162 residues. 
Similarly, the hypothetical protein YcaK is 44% homologous to Human 
NQO1 across 127 residues. Lastly, the “minimal nitroreductase” YdjA, of 
which a crystal structure has been determined despite a lack of experimental 
evidence for nitroreductase activity (258), was chosen due to both its 
annotation as an NTR and 53% amino acid similarity across a 65 amino acid 
region with P. pseudoalcaligenes NbzA.    
3. Proven nitroreductase activity. This encompassed any enzyme (or a close 
homologue thereof) with the ability to reduce nitroaromatic compounds 
other than CB1954. Two enzymes fitted this description: NemA (a member 
of the OYE family with proven TNT reductase activity (190)) and the 
azoreductase AzoR (proven quinone and azo dye reductase activity (259; 
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260)), which is a close homologue of an enzyme possessing nitroreductase 
activity from Rhodobacter shpaeroides (203). Additionally, the enzyme 
YcdI, believed to play a role in pyrimidine metabolism, is annotated in the 
NCBI database as a nitroreductase, although no experimental data exists to 
confirm this (261). It shares 22% identity and 37% similarity with NfsB, 
across the entire protein sequence.   
4. Enzymes published as having structural similarity to known CB1954-
reductases. Two previously characterised NAD(P)H:quinone 
oxidoreductases, MdaB and WrbA, belonged to this group. Both have had 
their crystal structure solved and similarities observed with that of human 
NQO1 (262; 263). Furthermore, MdaB is considered orthologous with an 
NTR from H. pylori (264).   
 
3.4. Screening candidate NTRs for CB1954-reductase activity 
 
 3.4.1. SOS assay 
 
The genes of the 10 additional candidate NTRs listed above were PCR amplified and 
cloned into the MCS of pUCX (restriction sites as indicated in primer sequences listed 
in Table 2.1) for activity screening. Based on SDS-PAGE analysis, expression of 9 of 
the 11 genes from pUCX in SOS-R1 was equivalent under the conditions used in the 
SOS assay (see Figure 3.3). The remaining two, YcdI and KefF, were visibly reduced in 
expression relative to the other NTR candidates (30-60% of other proteins based on 
densitometric calculations).    
The panel of NTRs was assessed for CB1954 reductase activity via the SOS 
assay (see Figure 3.4). No substantial SOS response was induced in the absence of 
prodrug for any of the 11 over-expressed enzymes or empty plasmid control. However, 
clear and dose-dependant increases in β-galactosidase activity were observed with 
NfsA, NfsB, AzoR and NemA over-expression strains upon challenge with CB1954, 
over the range of prodrug concentrations tested. In case low level CB1954-reductase 
activity from other enzymes was missed due to prodrug concentrations being too low, 
SOS response induction was also tested at higher CB1954 concentrations. No increase 
in β-galactosidase activity relative to the empty plasmid control was observed for any of 
the remaining enzymes at concentrations of CB1954 up to and including the highest (1 
mM) tested (results not shown). 
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Figure 3.3. Relative expression levels of candidate NTRs in SOS-R1. 
SDS-PAGE indicating relative levels of expression of each candidate NTR from pUCX in SOS-R1. 
Samples for SDS-PAGE analysis were whole cell lysates taken directly from a completed SOS assay (50 
µM IPTG) and normalised for cell density (OD600) before electrophoresis. 
 
    
 
Figure 3.4. CB1954-induced SOS response induction of NTR over-expressing SOS-R1 strains  
SOS-R1 strains over-expressing candidate NTRs were grown in liquid media and challenged with the 
indicated concentrations of CB1954 for 3 h prior to assessment of SOS response induction. Data are the 
average ± 1 SEM of 4 independent assays.  
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The development of colour during the β-galactosidase activity assessment stage 
of the assay is due to the enzymatic hydrolysis of ONPG into galactose and the 
chromogenic compound o-nitrophenolate (2-nitrophenol). Because this latter species is 
itself a nitroaromatic compound, we reasoned that the ability of candidate NTRs to use 
2-nitrophenol as a substrate might interfere with β-galactosidase activity measurements. 
Using purified His6-tagged enzymes (see section 3.4.3) and spectrophotometry, each 
candidate NTR was individually tested for its ability to reduce 2-nitrophenol in the 
presence of NAD(P)H co-substrates (measured as decrease in absorbance at 340 nm due 
to oxidation of NAD(P)H; (265)). No increase in NAD(P)H oxidation above 
background levels was observed for any enzyme using this method (results not shown), 
confirming that 2-nitrophenol is not a substrate for any of the candidate NTRs used in 
this study. 
 
 3.4.2. Bacterial IC50s 
 
To validate the results obtained in the SOS assay, the candidate NTRs were 
subsequently assessed for CB1954-reductase activity using a variety of other in vivo and 
in vitro tests. The first was based on the ability of reduced CB1954 to arrest bacterial 
growth through its cytotoxicity, as already demonstrated in this study (Figure 3.2D) and 
elsewhere in the literature (218; 219). This assay was carried out by subjecting NTR 
over-expressing SOS-R1 strains to increasing concentrations of CB1954 and monitoring 
growth rate (via optical density at 600 nm) relative to unchallenged isogenic cultures 
over a 3 h challenge period. These results were then used to calculate IC50 values 
(defined as the concentration of prodrug required to inhibit bacterial growth to 50 % of 
that of an unchallenged isogenic strain) of CB1954 for each candidate NTR over-
expression strain. Survival curves and IC50 values for each over-expressed NTR are 
displayed in Figure 3.5. In agreement with SOS assay results, NfsA, NfsB and NemA 
over-expression strains showed greatly reduced IC50 values (higher sensitivity) relative 
to the empty plasmid control. Furthermore, the relative ranking of the NTRs was also 
the same (NfsA>NfsB>NemA). However, this assay was not able to distinguish any 
clear difference between AzoR (low level activity based on the SOS assay results) and 
the rest of the seemingly inactive NTRs, although there was a modest difference relative 
to the empty vector control. 
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Figure 3.5. CB1954-mediated growth inhibition of NTR over-expressing E. coli SOS-R1 strains.  
Turbidity (OD600) of NTR over-expressing cell cultures was recorded directly before and after 3 h 
incubation with varying concentrations of CB1954. Cell survival is expressed as the percentage of total 
growth (change in OD600) of challenged cells relative to the unchallenged control for each strain, over the 
3 h challenge. IC50 values indicate the concentration of CB1954 at which bacterial growth is inhibited to 
50% of that of unchallenged isogenic strains. Data are the average ± 1 SEM of 4 independent assays. 
 
 3.4.3. In vitro kinetics of purified NTR candidates with CB1954 
 
Reductive metabolism of CB1954 by candidate NTRs was further investigated through 
in vitro purified enzyme kinetics. Each candidate NTR gene was cloned into the 
expression vector pET28a(+), over-expressed in E. coli BL21 and recombinant enzymes 
purified to homogeneity as hexahistidine (His6) tagged derivatives. All NTRs except 
YcdI and KefF were able to be purified using the methods described in section 2.9. 
Variations in the parameters used for protein expression, including reduced growth 
temperature and addition of betaine and sorbitol (266) were also tested; however no 
soluble protein under any condition was able to be extracted for either of these two 
enzymes. Based on inactivity of these two enzymes from the previous studies (SOS and 
IC50 analysis), their purification was not pursued any further. SDS-PAGE was used to 
determine purity (>90% by densitometric analysis; results not shown) and correct size 
for each enzyme (Figure 3.6). Although most enzyme preparations displayed banding 
patterns indicative of a second protein species at higher molecular weight, size 
comparisons suggested that these were dimeric forms of the respective enzyme and 
therefore were not considered to be contaminants. 
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Figure 3.6. SDS-PAGE of purified, His6-tagged candidate NTRs 
NTRs were cloned into pET28a(+) vectors and over-expressed in E. coli BL21, followed by purification 
of recombinant enzymes via nickel-affinity chromatography. Each lane was loaded with 10 µL of enzyme 
sample at 0.1mg mL-1.   
 
Measurement of the rate of CB1954-reduction by individual purified enzymes 
was carried out using a spectrophotometric method devised by Race et al. (241). As 
previously demonstrated, CB1954 can be reduced at either the 2- or 4-NO2, but not 
both, resulting in either the 2- or 4-NHOH as an end metabolite, which each display 
distinct absorption spectra (241). Nitro group preference can differ between enzymes 
resulting in reduction of only the 4-NO2 (109; 199; 207), only the 2-NO2 (189) or 
mixtures of both in various ratios (122; 208). Race and colleagues showed that both the 
4-NHOH and 2-NHOH absorb equally at 420 nm wavelength, with an extinction 
coefficient of 1,200 M
-1
 cm
-1
, allowing comparative assessment of enzymatic reduction 
of CB1954 without prior knowledge of the reduction pathway taken. 
 Buffered reactions containing CB1954, co-substrate (NAD(P)H) and purified 
enzyme were set up and monitored for CB1954 reduction by measuring the rate of 
change in absorbance of the reaction mixture at 420 nm wavelength. Detectable activity 
was only obtained from NfsA, NfsB, AzoR and NemA. Both NADH and NADPH were 
tested as possible co-substrates in the reaction. Consistent with previous results, NfsA 
and NemA both had a strong preference for NADPH (176; 267), while NfsB showed 
roughly equal activity with both (177). In contrast to previous reports, AzoR displayed 
higher activity with NADPH as co-substrate (259; 260). Affinity (Km) and catalytic (kcat) 
constants for each of the four active enzymes with CB1954 were then extrapolated from 
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reaction rate data obtained over a range of CB1954 concentrations (see Table 3.1). All 
four of these enzymes have previously been determined to catalyze substrate reduction 
via a bi-bi ping pong mechanism of action (described in section 1.6.1), an implication of 
which is that kinetic parameters for the substrate being tested (in this case CB1954) can 
vary for a specific enzyme depending on the concentration of the second substrate 
(NAD(P)H) used in the reaction (268). Co-substrate concentrations were kept constant 
throughout all these experiments (250 µM) and as such kcat and Km values are apparent 
(not global) indicators of substrate affinity and catalysis. However, the ratio of kcat:Km 
for such reactions remains constant across different co-substrate concentrations (268) 
and therefore it is this value, the specificity constant (kcat/Km), that provides a true 
measure of relative enzyme activity towards CB1954 in the context of this study. Based 
on these principles, NfsA was ~10-fold more active with CB1954 than NfsB, which was 
in turn approximately twice as active as NemA and 60-fold more active than AzoR, 
when using their preferred co-substrates (Table 3.1).  
 To further investigate the presence or absence of any discernible nitroreductase 
activity from the remaining six enzymes, reductive metabolism of the archetypal 
nitroaromatic compound nitrofurazone (NFZ) was assessed (by monitoring the change 
in absorbance at 400 nm, ε = 12,960 M-1 cm-1; (176)) Surprisingly, all candidate NTRs, 
except YdjA, were capable of in vitro reduction of NFZ at the concentration tested (50 
µM), albeit with widely varying rates (Table 3.1). This activity therefore confirmed 
these enzymes as bona fide NTRs. These observations also confirmed that the enzyme 
preparations employed were active and that the lack of CB1954-reducing activity 
associated with these enzymes was unlikely due to poor quality of the purified sample.  
 The effect of the His6 tag on enzyme performance was also assessed. His6 tags 
were cleaved from enzyme preparations by thrombin treatment and the resultant native 
enzymes assessed for CB1954-reductase activity as previously described. No 
discernible difference in activity was detected between His6 tag-containing and His6 
tag-deficient enzymes (data not shown). 
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Table 3.1: Steady-state kinetic parameters of purified His6-tagged candidate NTRs 
with CB1954. 
Enzyme Co-subs.
a 
kcat (s
-1
) Km (µM) kcat/Km 
(M
-1 
s
-1
) 
NFZ activity 
(µmol min
-1
 mg
-1
)
b
 
NfsA NADPH 16.1 ± 0.48 219 ± 18 73,500 ± 6,400 10.5 
NADH 2.88 ± 0.15 45.8 ± 7.0 62,800 ± 10,000 3.5 
NfsB NADPH 25.9 ± 2.6 3,570 ± 660 7,250 ± 1,500 5.7 
NADH 61.5 ± 11 11,000 ± 2,600 5,600 ± 1,700 6.8 
AzoR NADPH 0.153 ± 0.008 1,420 ± 160 108 ± 13 1.1 × 10
-1
 
NADH 0.148  ± 0.02 6,600 ± 1,000 22.4 ± 5 8.7 × 10
-2
 
NemA NADPH 0.216 ± 0.003 55.7 ± 2.2 3,880 ± 160 3.2 × 10
-2
 
NADH 0.048 ± 0.002 54.7 ± 5.1 878 ± 90 5.8 × 10
-2
 
MdaB NADH ND
c
 ND - 6.0 × 10
-3
 
NADPH ND ND - 2.3 × 10
-2
 
WrbA NADH ND ND - 2.7 × 10
-3
 
NADPH ND ND - 1.8 × 10
-2
 
YcaK NADH ND ND - 1.6 × 10
-2
 
NADPH ND ND - 1.4 × 10
-2
 
YieF NADH ND ND - 2.9 × 10
-2
 
NADPH ND ND - 6.3 × 10
-2
 
YdjA NADH ND ND - ND 
NADPH ND ND - ND 
aInitial co-substrate concentration in all protein assays was 0.25 mM 
bCatalytic rates were measured at 50 µM initial concentration of NFZ 
cND: not detected 
 
 3.4.4. In vivo cytotoxicity in HCT-116 human colon carcinoma cell line 
 
All results presented in this section were generated by Dr. Sophie Syddall, 
ACSRC.  
 
To evaluate the ability of the candidate NTRs to confer CB1954-sensitivity to a human 
cell line model, genes encoding the eleven enzymes were individually recombined into 
the Gateway™ compatible expression plasmid F527-V5 and transfected into the 
cultured human colon carcinoma cell line HCT-116. Following transient transfection, 
protein translation was detected by concurrent cell infection with TAG stop suppressor 
adenovirus (Tag-On-Demand™, Invitrogen), permitting read through of all eleven 
  
85 
TAG-terminated NTRs to give rise to an immunoreactive V5-epitope at the C-terminus. 
All transfected cell lines gave a detectable V5 band of the expected size in western 
blots, confirming that it was possible to express each enzyme in HCT-116 cells (Figure 
3.7A). However, the amplitude of expression varied between the different candidates 
with the most highly expressed enzyme KefF being measured by densitometry at an 8.1-
fold greater level than NfsB; and the lowest, NfsA, at only 0.24-fold the level of NfsB 
(Table 3.2).  
The range of expression levels was even greater with stable expression in pooled 
cell line populations generated under puromycin selection (Figure 3.7B, Table 3.2). 
YcdI and YcaK could no longer be detected in V5 western blots, and while NfsA was 
now detected at 0.3-fold the level of NfsB, KefF was found at 15.7-fold higher levels 
than NfsB. Nonetheless, transient and stable expression levels correlated (r
2
 = 0.65; P = 
0.02; paired t-test). The relative protein expression levels did not appear related to the 
presence of codons with poor human bias, as artificially synthesized versions of nfsA 
and nfsB that were codon optimized for maximal human cell expression did not yield a 
detectably stronger signal on V5 western blots (results not shown). Thus, the variation 
in expression levels of the 11 NTR candidates appeared to be due to intrinsic variations 
in mRNA or protein stability in HCT-116 cells. 
In contrast to results in bacterial assays and at a purified protein level, cytotoxicity 
testing identified nfsB expressing cells as having the greatest sensitivity to CB1954, 
about twice as sensitive as those expressing nfsA and approximately 20-fold more 
sensitive than those expressing nemA (in terms of IC50 normalized against the relative 
expression levels of each NTR; Table 3.2). Although each of the remaining E. coli NTR 
candidates appeared to slightly enhance sensitivity to CB1954 relative to untransfected 
HCT-116 cells (p<0.05; One-way ANOVA), none of these (including AzoR) were 
within three orders of magnitude of NfsB.  
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Figure 3.7. Expression of E. coli NTRs in the human colon carcinoma cell line HCT-116. 
(A) HCT-116 cells were transiently transfected with F527-V5 vectors containing each of the E. coli 
NTRs. Cells were concurrently infected with Tag-On-Demand™ Suppressor Supernatant, lysed, and 
immunoblotted for induced C-terminal V5 tag. Relative densitometry measurements for each NTR band 
(and a 40 kDa V5 tag control) are presented in Table 3.2. (B). HCT-116 cells engineered for stable 
expression of each of the E. coli NTRs were infected, lysed, immunoblotted and quantified as in (A). (C) 
Representative β-actin loading control (in this instance derived from the transiently transfected 
immunoblot in (A)).   
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Table 3.2. Relative sensitivity of the HCT-116 cell lines to CB1954 per unit NTR 
protein expressed. 
NTR 
candidate 
Expression 
Transient
a 
Expression 
Stable
b 
IC50 (µM)
c 
Relative 
Sensitivity
d 
NfsB 1.00 1.00 0.18 ± 0.03 100 
NfsA 0.24 0.30 1.4 ± 0.2 43 
NemA 1.98 9.40 0.397 ± 0.003 4.8 
KefF 8.11 15.70 19 ± 4 0.060 
YdjA 2.76 2.40 192 ± 48 0.039 
AzoR 4.20 7.20 107 ± 55 0.023 
MdaB 2.16 10.90 83 ± 43 0.020 
YieF 5.12 11.40 178 ± 64 0.009 
WrbA 3.26 9.50 237 ± 75 0.008 
YcdI 1.45 ND
e
 356 ± 93 NA
f
 
YcaK 1.34 ND 526 ± 74 NA 
aRelative expression level of each NTR protein in the transiently transfected HCT-116 cell line (derived 
from densitometry of the immunoblot presented in Figure 3.7, with each NTR normalized against the 
corresponding actin control and presented relative to NfsB) 
bRelative expression level of each NTR protein in the stably transfected HCT-116 cell line (normalized 
against actin and presented relative to NfsB) 
cMean ± 1 SEM (IC50 for untransfected HCT-116 line was 469 ± 54 µM) 
dIC50 values multiplied by the relative expression level of each NTR in the stable cell line and presented as 
a percentage relative to NfsB 
eND: not detected 
fNA: not applicable 
 
3.4.5. Identification of reduced CB1954 metabolites generated by the 
different E. coli NTRs 
 
The 2- and 4- NHOH derivatives of CB1954 have been shown to elicit cytotoxicity by 
distinct mechanisms (110; 111). To investigate whether differences in the CB1954 
metabolite ratios generated by each candidate NTR may have contributed to disparities 
between measurements of purified enzyme kinetics, SOS assays, and bacterial and 
mammalian cell IC50s, the relative levels of 2-NHOH and 4-NHOH produced by each of 
NfsA, NfsB, NemA and AzoR were measured by reverse-phase HPLC (Figure 3.8). 
Consistent with previous studies, NfsB was found to generate equimolar levels of 2-
NHOH and 4-NHOH. In contrast, NfsA was shown to reduce primarily the 2-nitro 
group to give 2-NHOH with a minimal HPLC peak corresponding to 4-NHOH, whereas 
AzoR and NemA both produced almost exclusively 4-NHOH, with only a very small 
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peak corresponding to 2-NHOH for AzoR. As previously observed for NfsB, reduction 
to the terminal (6e
-
) amino-product at either the 2- or the 4- position was not observed 
with any of the enzymes, irrespective of the duration of incubation or concentration of 
NAD(P)H employed. 
        
 
Figures 3.8A-F. HPLC analysis of products of NTR-catalysed reduction of CB1954. 
Buffered reactions consisting of CB1954 (200 µM), co-substrate (NAD(P)H; 1 mM) and purified 
candidate NTR (0.5-2 µM) were incubated at room temperature for 10-30 minutes prior to 
chromatographic separation of reaction products (as outlined in section 2.16). Eluates were continuously 
monitored at 262 nm. Authentic CB1954 metabolite standards were generous gifts from Prof. William 
Denny and Graham Atwell (ACSRC). CB1954 standards (Figure 3.8F) are (1) CB1954, (2) 2-NHOH, (3) 
2-NH2, (4) 4-NHOH and (5) 4-NH2.  
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3.5. Discussion 
 
This study investigated the ability of eleven native E. coli enzymes to reduce the 
nitroaromatic anti-cancer prodrug CB1954, via a panel of in vivo and in vitro assays, 
including a novel colorimetric screening method based on the E. coli SOS response. Of 
the candidate NTRs tested, four were found to produce detectable levels of CB1954 
reduction products, two of which (AzoR and NemA) had not previously been studied in 
the context of nitroaromatic prodrug activation. Also, at the time of performing this 
study NfsA had only been characterised in minor detail regarding its CB1954 reductase 
activity (222), with the publication of Vass et al. (189) appearing subsequently. A 
major facet of this study was to assess the ability of a novel screening method, the SOS 
assay, to accurately determine relative CB1954-reductase activity among candidate 
enzymes. The SOS assay is an attractive technique for NTR-mediated prodrug 
activation screening, as it affords the possibility of moderate to high-throughput analysis 
of candidate enzyme activity and does not require high prodrug concentrations; both of 
which are key elements of any enzyme discovery study and have not been thoroughly 
developed for the NTR-CB1954 system. This study demonstrated that not only was the 
SOS assay able to detect NTR-mediated CB1954 reduction at very low substrate 
concentrations (<10 µM depending on the enzyme, see Figure 3.4), but could also 
provide a semi-quantitative assessment of the relative CB1954-reducing abilities of 
multiple NTRs simultaneously. This latter point sets the SOS assay apart from the SOS-
mediated lambda-phage based assay previously developed for evaluation of CB1954 
reduction (225): although the latter system provides a highly efficient means of 
selecting NTRs improved for CB1954 reductase activity from a pool of enzyme 
variants, it appears to lack the capability of rapidly analysing relative levels of 
individual candidate enzymes simultaneously. Using the SOS assay, it was shown that 
NfsA was the most active CB1954-reducing enzyme tested, followed closely by NfsB 
and more distantly by NemA and AzoR. Results from E. coli IC50s and purified enzyme 
kinetics were all in good agreement (in particular regarding the relative rankings of the 
four active NTRs) with those obtained in the SOS assay, proving the validity and 
accuracy of this technique as a suitable CB1954-reduction screening tool.  
 The final application of NTR-CB1954 GDEPT is for use in human tumours and 
therefore it is imperative that results gained through E. coli and in vitro testing are 
reliably indicative of the clinical scenario. Testing of the eleven candidate NTRs in the 
human colon carcinoma cell line HCT-116 yielded a CB1954-sensitivity pattern in 
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general agreement with the E. coli results, with only NfsA, NfsB and NemA providing 
CB1954-sensitivities more than 3 orders of magnitude lower than the non-transfected 
control; however one significant discrepancy was the superiority of NfsB over-
expression relative to NfsA over-expression in conferring CB1954 sensitivity, with 
NfsB generating an expression level normalized IC50 in HCT-116 ~2-fold lower (p 
<0.05; t-test) than NfsA (see Table 3.2). It is noteworthy that in another study focusing 
on NfsA, a clear advantage of this enzyme was observed over NfsB in imparting 
CB1954 sensitivity towards the ovarian cancer cell lines SKOV-3. The basis of the 
variation among these different organisms and cell lines therefore requires significant 
discussion.           
 Firstly, western-blot analysis of NTR over-expression in HCT-116 indicated that 
expression levels varied widely between NTRs (Figure 3.7). In particular, over-
expressed NfsA levels were the lowest out of all NTRs tested, being less than one third 
that of NfsB. Normalised CB1954 sensitivities were calculated by dividing raw IC50 
values by relative protein expression levels (established by scanning densitometry of 
blots); however there is no data to definitively confirm that a direct linear relationship 
exists between NTR expression levels and sensitivity to CB1954, in particular at either 
very high or very low enzyme levels. Indeed, Chen et al. (1995) demonstrated a lack of 
correlation between HSV-TK expression levels in 9L glioma cells and sensitivity to 
GCV (269). Other studies on enhanced enzymes for prodrug activation either do not 
report or do not at all test enzyme expression levels in mammalian cell lines (216; 270), 
including that of NfsA in SKOV-3 (189), impeding further investigation into this 
phenomenon. Therefore, NfsA levels in HCT-116 may have not been high enough to 
elicit a significantly toxic response, with the low levels of reduced metabolites possibly 
out-competed by cellular detoxification machinery.     
 Another possible source of variation is the difference in susceptibility between 
cell types to the various end products of CB1954 metabolism. Although much of the 
emphasis on CB1954-reduction studies has been towards the 4-NHOH metabolite, 
widely considered to be the primary toxin of CB1954 metabolism (111; 121), studies 
have shown that products of reduction of the 2-NO2, in particular the 2-NH2, can be 
equally, if not more toxic than the 4-NHOH in certain cell lines (121). Results described 
here, in agreement with other studies, demonstrate that NfsA only reduces the 2- NO2 
(189), while NfsB produces equimolar ratios of both the 2- and 4-NHOH metabolites 
(122). HCT-116 could therefore be inherently more resistant to the DNA adducts 
formed by 2- NO2 reduction products, compared to both E. coli and SKOV-3, 
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diminishing any cytotoxic effect conferred by NfsA-catalysed reduction of CB1954 in 
this cell line. It has previously been shown that cell sensitivity to the 4-NHOH of 
CB1954 is more pronounced in nucleotide excision repair (NER) deficient genetic 
backgrounds (111; 121). Although E. coli, HCT-116 and SKOV-3 are NER-proficient, 
both HCT-116 and SKOV-3 (but not E. coli) are deficient in mismatch-repair (MMR), a 
pathway that is known to affect resistance of cells to certain DNA-alkylating 
compounds (271). More importantly, in contrast to HCT-116, SKOV-3 lacks a 
functional p53 gene (272; 273), the product of which is involved in DNA repair and cell 
cycle control (274). Together, these factors suggest that heterogeneity in DNA repair 
pathway proficiencies could affect the relative sensitivities of cell types to the different 
CB1954 reduction products, and in particular provide an explanation to the differences 
observed in sensitivities towards CB1954 between various NfsA over-expressing cell 
lines.  
 It should also be noted that the intercellular diffusion properties of the two 
principal hydroxylamine metabolites are disparate (121) and consequently their 
cytotoxic effects are likely to be non-uniform in low cell density cultures. The 2-NH2 
product is the major contributor to the bystander effect of CB1954 (121), and the 
efficiency of bystander killing is dependent upon cell density (153). In this study, 500 
cells (HCT-116) were plated per well, whereas Vass et al. employed a density of 2 × 10
4
 
cells per well for cytotoxicity assays of transfected cell lines (189). Thus, the 
contribution of the bystander effect (and hence the contribution of NfsA) to cell killing 
may have been greater in the experiments of Vass et al.   
 Alternatively, differences in co-substrate availability between the cell types 
could have an impact on the relative abilities of each NTR to impart CB1954 sensitivity. 
This study, among others, has demonstrated a strong preference of NfsA for NADPH, 
while NfsB is equally capable of utilizing both NADH and NADPH as co-substrates 
(177). A few studies have shown that NADPH is typically at lower levels 
intracellularly, in both bacteria and human cells, compared to NADH (275; 276), while 
relative levels of each co-factor can vary significantly between disease and non-disease 
states (275; 277). NADPH levels could therefore be a limiting factor in HCT-116, 
relative to E. coli and SKOV-3, possibly explaining the lower NfsA-mediated CB1954-
sensitivity observed in the former. Consistent with this explanation, NemA and AzoR 
(which also exhibit a NADPH co-substrate preference) were also less active in HCT-
116 relative to NfsB than might have been predicted from the E. coli IC50 and SOS 
assay or in vitro purified protein kinetics. Lower levels of NADPH in E. coli could also 
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explain the modest difference in SOS response induction relative to kinetic activity, 
compared with NfsB (1.2 and 1.5-fold increase in SOS activity for NfsA, over NfsB, at 
50 µM and 100 µM CB1954 respectively, compared to a ~10-fold increase in kcat/Km for 
NfsA over NfsB, with CB1954).  
 Another salient message from the points discussed above is that there is an 
inherent heterogeneity in cellular metabolism and redox status of different human cell 
lines, especially those with malignant phenotypes; and hence results obtained in one cell 
line may only be generally predictive of those that would be obtained in a different cell 
line, or for a tumour in vivo. Consequently, the use of E. coli as a model organism to 
study enzyme-catalyzed prodrug activation may prove an equally reliable – and far 
more efficient – alternative to creating and testing panels of transfected tumour cell 
lines. In particular, the SOS assay provides a simple and elegant means of overcoming 
undesirable characteristics of other traditional negative-selection strategies, such as 
growth inhibition and cell survival assays. CB1954 concentrations required to elicit a 
response in the SOS assay were significantly lower than in the corresponding IC50 
experiments and, unlike purified protein kinetics, the SOS assay is also able to 
distinguish between toxic and non-toxic end products of metabolism. While reduction of 
either the ortho or para nitro groups of CB1954 yields toxic species, this is not the case 
for the DNBM prodrugs; for example, the DNBM PR-104 undergoes internal 
cyclisation to a non-toxic derivative upon reduction of the ortho nitro group (57). 
Although application of the SOS assay is inherently limited to agents that either directly 
damage DNA or indirectly interfere with DNA replication and maintenance, there are a 
number of prodrugs under various stages of development that meet this criterion (for 
example 5-FU, which has been shown to induce the E. coli SOS response (278).  
As well as the most active NTRs NfsA and NfsB, this study also identified two 
enzymes previously uncharacterized in their ability to reduce CB1954: AzoR and 
NemA. NemA is of particular interest, as at a purified level it has kinetic properties 
towards CB1954 of a similar magnitude to NfsB (kcat/Km of 3,870 M
-1
s
-1
 for NemA, 
7,250 M
-1
s
-1
, for NfsB, NADPH as co-factor), while unlike NfsB it only forms the 4-
NHOH reduction product, suggesting possible utility against cancer types with 
increased sensitivity towards this metabolite. Furthermore, NemA presents a completely 
novel enzyme structural scaffold for CB1954 reduction, having no sequence or 
structural homology to any previously characterised CB1954-reductase. In contrast, 
AzoR shares roughly 45% amino acid sequence similarity to NQO1 across 152 residues 
and demonstrates close structural homology to this enzyme (279), especially within the 
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enzyme active site, perhaps explaining the similar CB1954 reduction kinetics between 
these two enzymes (kcat/Km of 22 and 7.8 M
-1
s
-1
 respectively with NADH as co-
substrate; Table 3.1, (120)). However, both MdaB and WrbA are also known to share 
structural (though little sequence) homology to NQO1 (262; 263), yet in this study no 
CB1954-reductase activity was obtained from these two enzymes. It is possible that 
minor structural variations in the active sites of the enzymes could interfere with 
CB1954 binding. Alternatively, this lack of activity may be related to the low one-
electron reduction potential (E0) of CB1954 (E0 =-385 mV; (280)), relative to NFZ (E0 
= -257 mV; (281)), the latter of which acted as a substrate for all three enzymes (see 
Table 3.1). Therefore, the 2 electron mid-point potentials of MdaB and WrbA (as well 
as the other NFZ-active/CB1954-inactive enzymes characterised in this study), but not 
AzoR and other CB1954-reductases, may not be low enough to reduce CB1954, yet 
sufficiently low to retain NFZ reductase activity. Such a mechanism has previously 
been described as the driving force behind the inability of most oxygen-insensitive 
NTRs to reduce nitroaromatic compounds beyond hydroxylamino derivatives (35). This 
hypothesis is also supported by the ability of all three enzymes to reduce menadione (E0 
= -203 mV, (282)) (259; 283; 284), while only AzoR has been documented to catalyse 
the reduction of the much more electronegative azo-dye methyl red (E0 = -395 mV, 
(285)) (259). In contrast, both NfsA and NfsB are unable to aerobically reduce azo-
dyes, despite high activity with CB1954 and other compounds with similar reduction 
potentials (176; 177; 286). Together, these considerations demonstrate the importance 
of both active site conformation and enzyme reduction potential in substrate specificity 
and catalytic activity, providing strong support for the impetus behind screening of 
multiple, divergent enzyme families for prodrug reduction.  
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Chapter 4: Contribution of various DNA repair pathways to 
CB1954-adduct processing, and their effects on the SOS assay 
 
4.1. Introduction 
 
The previous chapter introduced the E. coli-based SOS assay as a means of detecting 
and comparing rates of CB1954 reduction by over-expressed NTRs. For the SOS assay 
to be accurate and reliable in this context, SOS response induction must be proportional 
to both the total amount (as determined by rate of enzymatic reduction) and type 
(toxicity) of DNA adducts induced by the activated prodrug. However, the SOS 
response is not the only DNA repair pathway in E. coli that responds to DNA damage. 
For example, base-excision repair (BER), mismatch repair (MMR) and the adaptive 
(Ada) response are all SOS-independent DNA repair mechanisms that act on a variety 
of DNA lesions and base pair mismatches to maintain genome stability and integrity 
(287-289). Although adduct type and structure largely determine the DNA repair 
pathway that is activated for processing of a certain lesion, considerable overlap in 
substrate specificities can occur, often leading to complex interactions between DNA 
repair machineries for a specific adduct type (290-292). As such, levels of SOS 
response induction may not always correlate with the extent and magnitude of DNA 
damage within a cell, especially when multiple adduct types are involved. This may be 
particularly relevant to CB1954 due to the different DNA lesions induced by the two 
principal reduction products (110; 121). In this chapter the mechanisms of repair in E. 
coli of the different CB1954-induced DNA adducts were investigated, to determine 
whether alternative DNA repair pathways affect SOS assay accuracy.  
 Additionally, as mentioned in Chapter 3, differences in DNA repair pathways 
between E. coli and mammalian cells may affect how each organism responds to the 
different reduction products of CB1954. As the utility of the SOS assay relies on an 
accurate representation of conditions within human cells, potential differences in DNA 
repair mechanisms should be investigated.   
 The primary aim of this chapter was to test the possible involvement of 
alternative, SOS-independent DNA repair pathways on processing of different CB1954-
induced DNA adducts in E. coli and how mutations in these repair mechanisms might 
affect SOS induction for each reduction product. This was achieved by comparison of 
relative SOS induction levels, in response to the different CB1954 metabolites, in SOS-
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R1 reporter strains deficient in the relevant repair genes (achieved through targetd gene 
knock out). The rationale was that the SOS response might increase in the absence of a 
repair pathway involved in processing of a specific lesion. Such a compensatory 
mechanism has previously been demonstrated, for example with oxidative DNA 
damage in strains deficient in oxidative stress response genes (293; 294), or for strains 
deficient in either O
6
-methylguanine methyl transferase activity or mismatch repair in 
response to the anti-cancer alkylating agent chlorambucil (295). 
 Initially, the main pathway targeted to this end was the „adaptive‟ response to 
DNA alkylation damage, a response primarily orchestrated by the O
6
-methylguanine 
methyl transferase enzyme Ada. The primary lesion recognized and repaired by the Ada 
protein and adaptive response is O
6
-methylguanine, a toxic DNA adduct that occurs at 
relatively high frequency and is induced by both endogenous and exogenous alkylating 
agents (296). However, Ada substrate specificity is also known to include much bulkier 
butyl, benzyl and pyridyloxobutyl adducts (297; 298). Furthermore, ada-deficient 
mutant strains are much more sensitive to the toxic effects of aromatic amines (297), 
while the nitroaromatic antibiotic nitrofurazone and the nitrogen mustard-containing 
alkylating agent chlorambucil have also both been demonstrated to induce the Ada 
response (295; 299). It is also noteworthy that the O
6
 position of guanine has been 
postulated as a primary target of the N-acetoxy 4-NHOH derivative of CB1954 (110; 
300). More importantly however, induction of the Ada response has been demonstrated 
to negatively affect subsequent induction of the SOS response by UV-irradiation (301). 
Together these observations indicate a potential involvement of the Ada response in 
both repair of CB1954-induced adducts and regulation of the SOS response. 
The role of the MMR pathway was also investigated, as previous studies have 
found that the analogous system in mammalian cells is involved in the recognition and 
repair of a number of DNA adducts, including those induced by alkylating agents such 
as cisplatin, N-methyl-N'-nitro-N-nitrosoguanidine and temozolomide (271; 291; 302). 
Furthermore, HCT-116 cells are deficient in this pathway (271) while the E. coli 
reporter strain used in this study is proficient, suggesting a possible source of 
discrepancy between the two organisms in response to and tolerance of CB1954 induced 
adducts.  
Finally, two SOS-dependent E. coli repair mechanisms were investigated, to 
further understand repair of CB1954 induced adducts in this organism. The first, 
nucleotide excision repair (NER), was targeted due to the fundamental role that the 
equivalent mammalian pathway plays in repair of 4-NHOH CB1954 adducts, but not 2-
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NO2 reduction product-induced adducts (111; 121). Secondly, through assessment of 
mutagenic potential of the various prodrug metabolites, a possible role of damage-
inducible error-prone polymerases was investigated. Error-prone polymerases (such as 
PolB and UmuDC in E. coli) are employed in both mammalian and bacterial cells to 
bypass a variety of DNA lesions in a process known as translesion synthesis (TLS) 
(303). As this process is often mutagenic due to the low replication fidelity of these 
enzymes, their involvement in repair of certain DNA adducts can be monitored through 
mutagenesis screens. Investigating the involvement of error prone polymerases in E. 
coli in the repair of CB1954 induced adducts could provide valuable insight into the 
respective roles of the analogous enzymes in mammalian cells.  
  
Select results from sections 4.2.2, 4.2.4 and 4.2.5 have been published independently in 
the peer-reviewed Journal of Biotechnology, as Prosser et al. (304). 
 
4.2. Results 
 
 4.2.1. Development of an improved Miller Unit calculation 
 
Prior to commencement of DNA repair mutant testing, a method for improving data 
calculation in the SOS assay was investigated, in order to improve assay reliability and 
accuracy. 
 The original calculation for determining β-galactosidase activity in a sample 
when ONPG is used as the reporter substrate (i.e. the Miller equation) is as follows: 
 
Miller units = (OD420 – [1.75 × OD550])/(OD600 × t × v) 
 
Where t is the time allowed for ONPG metabolism (from addition of assay buffer to 
reaction termination with sodium carbonate) and v is the volume of cells (in mL) used 
for the final ONPG incubation step (243). In order to modify the original Miller assay 
protocol for use in microplate format, it was necessary to reduce all reagent volumes, 
including the volume of cells added. The culture volume used throughout all SOS 
assays in this work was 10 µL, a volume that was transferred from the original culture 
plate into the assay plate using a multi-channel pipette. I hypothesised that pipetting 
error at this crucial step would be a major source of variation in the final Miller unit 
calculation and therefore affect the quality of the overall results. 
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With no available substitute to manual pipetting at this step, an alternative 
method of calculating Miller units was investigated in order to compensate for possible 
pipetting error. The OD550 measurement provides an estimation of the amount of cell 
debris present in the well and, in the original Miller equation, is used to compensate for 
the effect that this cellular matter has on absorbance at 420 nm; (243). However, if the 
assumption is made that the degree of cell lysis is equivalent in each well of the assay, 
OD550 could instead be used to provide an indication of the total amount of cells 
originally transferred into the assay well, or in other words, be directly proportional to 
the product of OD600 (cell concentration) and cell volume transferred (v). OD550 could 
then replace OD600 × v in the Miller equation, providing ultimately more accuracy to 
SOS measurements. 
The first step in testing this hypothesis was to demonstrate the existence of a direct and 
linear relationship between OD550 and OD600 × v. SOS assays were carried out as 
previously described except that the volume of cells transferred to the final assay plate 
was varied from 2.5 to 20 µL. Results, shown in Figure 4.1, demonstrated that there is a 
strong linear correlation between OD550 and OD600 × v, over the range of volumes 
tested. Next, the effect of substituting OD550 for OD600 × v in the Miller equation on 
overall SOS response fold induction measurements was tested by comparing the 
variation in SOS response fold inductions generated from multiple replicates of 
identically treated (100 µM CB1954), isogenic NfsB over-expressing SOS-R1 reporter 
strains, as calculated by either the original or the adjusted Miller equations. As 
illustrated in Figure 4.2, altering the Miller equation had no significant effect on overall 
SOS response fold induction calculations (mean SOS response fold inductions of 5.62 
and 5.29 for calculations based on the original and adjusted Miller equation, 
respectively; p>0.05; t-test). Furthermore, the amount of variation (as indicated by 
standard deviation) observed across the data when using the altered Miller equation was 
almost 4-fold lower than when using the original equation (standard deviation:mean 
ratio of 0.08 compared to 0.28 for adjusted and original Miller equation calculations, 
respectively).  
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Figure 4.1. Correlation between OD550 and OD600 × v of samples used in SOS assays.  
Different volumes (2.5-20 µL) of NfsA over-expressing SOS-R1 cultures challenged with CB1954 were 
transferred to fresh 96 well plates for SOS activity assessment. OD600 readings of the assay cultures 
multiplied by the volume of cells transferred (x axis) were plotted against the respective OD550 readings 
of the SOS plate (y-axis). Results are the average ± 1 SEM of duplicate assays, each performed with 12 
replicates for each cell volume used.  
 
 
Figures 4.2A & B. Variation in SOS response fold inductions from replicate cultures using different 
Miller equations. 
20 individual replicates of NfsB over-expressing SOS-R1 were challenged for 3 h with 100 µM CB1954 
and then assessed for SOS activity as previously described. Miller units were calculated by either (A) the 
original Miller equation, or (B) the adjusted equation developed in this study.   
 
In conclusion, due to the higher degree of accuracy and reliability associated 
with the adjusted Miller equation compared to the original, this method was used 
throughout this work for calculation of β-galactosidase activity in SOS response 
analysis. The adjusted equation is as follows: 
 
 Miller units = (OD420 – [1.75 × OD550])/(t × OD550) 
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4.2.2. Identification of novel NTRs for reduction of either the 2- or 4-NO2 of 
CB1954 
 
In this chapter, generation of the different CB1954 reduction products was achieved 
through over-expression of the relevant NTRs in each test strain. Five NTRs were 
chosen, three of which had been characterised in Chapter 3: E. coli NfsA (2-NHOH 
producer), NfsB (2- and 4-NHOH, equimolar) and NemA (4-NHOH). Seeking to add an 
additional 2-NO2 and a 4-NO2 reducing enzyme to the panel, an NfsA homologue from 
K. pneumoniae (83 % amino acid identity) and a B. subtilis homologue of B. 
licheniformis YfkO (67 % identity) were selected for further investigation. These 
enzymes were chosen based on strain availability in the lab and with the assumption that 
metabolite production by each enzyme would be similar to their previously 
characterised homologues, i.e. 2-NHOH for K. pneumoniae NfsA and 4-NHOH for B. 
subtilis YfkO (as determined by Emptage et al. (2008); (199)). Kinetic characterisation 
of His6-tagged purified enzymes established that they each efficiently reduced CB1954 
(see Table 4.1) and HPLC analysis of reaction products confirmed that NfsA (K.p) 
reduced solely the 2-NO2 while YfkO (B.s) reduced solely the 4-NO2 of CB1954 
(Figure 4.3). Due to the employment of an increasing number of NTRs from different 
bacterial species, gene names are from here on (and in all remaining chapters) followed 
by the initials of the genus and species of origin, in parentheses (i.e. NfsA (E.c), NfsA 
(K.p) etc). 
 
 
Figure 4.3. HPLC analysis of products of YfkO (B.s) and NfsA (K.p)-catalysed reduction of 
CB1954. 
Reactions and HPLC conditions were set up and carried out as previously described (see Figure 3.8, 
section 2.16). Absorbance was measured at 262 nm.  
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Table 4.1. Kinetic parameters and end-products of CB1954 metabolism for each 
purified, His6-tagged candidate NTR.  
NTR Metabolite kcat (s
-1
) Km (µM) kcat / Km (M
-1
 s
-1
) 
NfsA (E.c)
a
 2-NHOH 16 ± 0.48 220 ± 18 73,000 ± 6,400  
NfsA (K.p)
b
 2-NHOH 37 ± 1.3 1,700 ± 150 22,000 ± 2,200 
NfsB (E.c)
a
 2-/4-NHOH 26 ± 2.6 3,600 ± 660 7,300 ± 1,500 
NemA (E.c)
a
 4-NHOH 0.22 ± 0.003 56 ± 2.2 3,900 ± 160 
YfkO (B.s)
b
 4-NHOH 60 ± 2.9 2,400 ± 250 25,000 ± 2,800 
aData taken from Table 3.1. 
bNADPH was used as co-substrate, at an initial concentration of 0.25 mM for all reactions. 
 
4.2.3. Generation and phenotypic characterisation of Δada Δogt, ΔmutS and 
ΔuvrB gene knockout strains of E. coli SOS-R1 
 
The genes encoding principal components of each DNA repair pathway under 
investigation were deleted, in-frame, from the SOS-R1 genome, resulting in a panel of 
reporter strains each with a unique DNA repair deficiency. These strains consisted of 1) 
a Δada and Δogt null mutant, deficient in both inducible and constitutive O6-
methylguanine methyl transferase activities, as well as deficient in the adaptive 
response; 2) a ΔmutS null mutant, deficient in mismatch repair; and 3) a ΔuvrB null 
mutant, deficient in nucleotide excision repair. Genetic verification of loss of the 
relevant genes was achieved through size analysis of PCR-amplified regions of genomic 
DNA flanking the affected gene (results not shown). To biochemically verify that the 
Δada Δogt dual gene knockout had the expected phenotypic effect, all three repair-
deficient and wildtype SOS reporter strains were assessed for SOS response induction 
following incubation with the known Ada response inducing agent N-methyl N-
nitrosourea (MNU) (305). As expected, SOS activity in the Δada Δogt strain was almost 
2-fold higher than in any other strain following 3 h challenge with this compound (see 
Figure 4.4). Appropriate drugs were not available to biochemically verify the other two 
mutant strains. 
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Figure 4.4. MNU-induced SOS responses from DNA repair-deficient and wildtype SOS-R1 strains.   
Wildtype SOS-R1 and strains deficient in certain DNA repair pathways carrying empty pUCX vector (x-
axis) were grown and challenged with the indicated concentrations of MNU for 3 h prior to SOS activity 
assessment. Data is the average ± 1 SEM of 2 independent assays. 
 
4.2.4. CB1954 SOS induction in DNA repair deficient and proficient strains 
of E. coli SOS-R1 
 
The genes encoding NfsA (K.p) and Yfko (B.s) were cloned into the MCS of pUCX, 
and individually transformed (together with pUCX constructs expressing the remaining 
three NTRs) into wildtype and each SOS-R1 repair-deficient reporter strain. 
Measurement of SOS response induction upon challenge with 50 µM CB1954 was then 
carried out as previously described. Results are displayed in Figure 4.5. No significant 
(p>0.05; t-test) increase or decrease in SOS response was observed between wildtype 
and Δada Δogt or ΔmutS strains, for any of the over-expressed NTRs. However, SOS 
induction was significantly enhanced in the ΔuvrB strain over wildtype when either 
NemA (E.c) or YfkO (B.s) (p=0.0182 and 0.0275 respectively; t-test), but not the 
remaining three enzymes, was over-expressed. To ensure that this difference was not 
due to alterations in enzyme expression levels between wildtype and ΔuvrB SOS-R1, 
SDS-PAGE was carried out on total cellular fractions remaining after a completed SOS 
assay. No substantial variation in over-expressed NTR levels was evident between the 
two strains (Figure 4.6).  
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Figure 4.5. CB1954-induced SOS responses in NTR over-expressing DNA repair proficient and 
deficient strains of SOS-R1. 
The relevant NTR over-expressing strains of wildtype (WT) and DNA repair-deficient SOS-R1 (x-axis) 
were grown and challenged with 50 µM CB1954 for 3 h prior to assessment of SOS activity. *p <0.05; t-
test. Data is the mean ± 1 SEM of 3 independent assays. 
 
Figure 4.6. Expression of candidate NTRs from wildtype and ΔuvrB strains of SOS-R1.  
 SDS-PAGE gel scan indicating relative levels of expression of each candidate NTR from pUCX in 
wildtype (left) and ΔuvrB (right) strains of SOS-R1. Samples for SDS-PAGE analysis were whole cell 
lysates taken directly from a completed SOS assay (50 µM IPTG, unchallenged cultures) and normalised 
for cell density (OD600) prior to electrophoresis. 
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 These results were further tested and validated by comparing SOS response 
induction upon application of pure synthetic reduction metabolites of CB1954 (the 2-
NH2, 4-NHOH, 4-NH2 and parental compound control (the 2-NHOH being too unstable 
as a purified compound to test in this manner (121)) to both SOS-R1 wildtype and 
ΔuvrB, in the absence of NTR over-expression (empty vector only; Figure 4.7). 
Although the 2-NH2 metabolite induced the highest overall SOS response in both 
strains, there was a significant increase in activity (p<0.05; t-test) with the 4-NHOH 
metabolite in the ΔuvrB strain over wildtype that was not observed with any of the other 
compounds. In contrast, SOS activity was slightly, but significantly (p<0.05; t-test) 
decreased in the ΔuvrB strain relative to wildtype upon challenge with 200 µM 2-NH2, 
although this difference was not observed at 100 µM 2-NH2.  
Therefore, in a NER-deficient genetic background, unique reduction of the 4-
NO2 of CB1954, but not the 2-NO2 or mixtures of both, appears to elevate SOS 
induction levels over wildtype. 
 
 
Figure 4.7. CB1954 reduction metabolite-induced SOS responses from wildtype and NER-deficient 
strains of SOS-R1. 
Wildtype (WT) and ΔuvrB strains of SOS-R1 (carrying empty vector) were grown and challenged for 3 h 
with the indicated pure CB1954 reduction metabolites at the indicated concentrations prior to SOS 
activity assessment. 2/4-NH2: 2/4-amino derivative. 4-NHOH: 4-hydroxylamino derivative. CB1954: 
parental prodrug. *p <0.05; t-test. Data are the mean ± 1 SEM of 2-5 independent assays. 
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4.2.5. Role of NER in processing adducts induced by alternative 
nitroaromatic prodrugs 
 
The ability to discriminate between NTR-catalysed reduction of either the 2- or 4-NO2 
of CB1954, through the use of multiple SOS reporter strains that differ in DNA repair 
proficiencies, suggested that the same system might be useful to determine genotoxic 
mechanisms of alternative compounds. This could be particularly useful, for example, in 
the analysis of environmental pollutants or for isolation of novel DNA-damaging 
antibiotic or anticancer agents from large-scale chemical libraries. Alternatively, it 
might be possible to increase the sensitivity of the SOS assay for specific metabolites by 
using a mutant reporter strain deficient in an adduct-specific DNA repair pathway. 
 These hypotheses were tested by comparing the SOS induction of SOS-R1 
wildtype and ΔuvrB strains, over-expressing the five candidate NTRs, following 3 h 
challenge with the 5-nitrofuran NFZ, the 5-nitroimidazole metronidazole (MTZ) or the 
DNBM prodrug PR-104A (the de-phosphorylated alcohol derivative of PR-104). Both 
of the former two compounds are established substrates for multiple bacterial NTRs 
(171; 176; 177; 306), while PR-104A has yet to be investigated in the context of 
bacterial NTR-catalysed reduction. Furthermore, all substrates require nitroreduction 
prior to onset of genotoxicity (57; 307; 308), and the reduced forms of both NFZ and 
MTZ have previously been shown to induce the SOS response (235; 309). Previous 
work has also established that nucleotide excision repair is the primary repair pathway 
involved in processing of NFZ-induced lesions (310), while the repair mechanism of 
MTZ-induced adducts is less well understood (311; 312). Repair of PR-104A-induced 
adducts has been shown to require multiple repair machineries, including NER and 
homologous recombination, in human cells (48). Accordingly, results from this study 
demonstrated that SOS induction was enhanced, on average, in NTR over-expressing 
ΔuvrB strains of SOS-R1, over wildtype, upon challenge with nitrofurazone or PR-
104A, while little to no difference was observed with metronidazole (Figure 4.8).  
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Figures 4.8A-C. SOS responses induced by alternative nitroaromatic prodrugs in NER-proficient 
and -deficient NTR over-expressing strains of SOS-R1.  
NTR over-expressing strains of wildtype (WT) and ΔuvrB SOS-R1 were grown and challenged with 
either (A) 5 µM NFZ, (B) 5 µM MTZ or (C) 200 µM PR-104A prior to analysis of SOS activity 
induction. Data are the average ± 1 SEM of 3 independent assays.  
 
 
 
 
 
 
 
 
  
107 
4.2.6. Mutagenicity of CB1954 reduction products 
 
The role of error-prone polymerases and TLS in repair of CB1954-induced adducts was 
assessed through a mutagenicity screen involving selection for rifampicin-resistant 
(Rif
R
) phenotypes following CB1954 challenge of NTR over-expressing SOS-R1 
reporter strains. Rifampicin (an inhibitor of bacterial RNA polymerase) resistance in 
many bacteria is obtained through specific mutations within the gene encoding RNA 
polymerase (rpoB) (313; 314). A large number of base pair substitutions (>60) across 
more than 30 nucleotide positions within the rpoB gene can induce a Rif
R
 phenotype, 
allowing detection of a wide variety of mutagens with this assay (315). Furthermore, as 
most of the mutational sites lie within a small (<1,000 base pair) region of the gene, 
characterisation of the mutational spectra (preferred substitution type and sequence 
specificity) of a test compound can easily be determined through PCR amplification and 
DNA sequencing of the relevant gene region.  
 Using this assay, mutagenicity of both the 2-NO2 and 4-NO2 reduction products 
of CB1954 (via NfsA (E.c) and YfkO (B.s) over-expression, respectively) was assessed, 
in both NER-proficient (wildtype) and -deficient (ΔuvrB) genetic backgrounds. Briefly, 
exponential phase cultures of the relevant strains were chilled, resuspended in PBS, and 
then challenged with CB1954 for 3 h at 30 °C, followed by dilution and recovery in 
fresh (LB) media overnight. The following day aliquots were spread onto LB agar plates 
containing either just ampicillin (for assessment of total viable cells) or both ampicillin 
and rifampicin (100 µg mL
-1
) and incubated at 37 °C for an additional 24 h. Colonies 
were then counted and the frequency of Rif
R
 isolates per 10
8
 cells calculated (Figure 
4.9). Both the 2- and 4-NO2 reduction products of CB1954 demonstrated mutagenic 
potential in this assay, illustrated by substantially higher (up to 4,000-fold) mutation 
frequencies compared with unchallenged isogenic cultures. Also, these compounds were 
significantly more mutagenic than the parental compound (comparison to empty vector; 
p<0.01; t-test). Furthermore, mutagenicity of both reduction products, as well as the 
parental compound, was significantly higher in the ΔuvrB strain compared to wildtype 
(p<0.05 for all three compounds; t-test). This difference was highest for the 2-NO2 
reduction product (22.5-fold difference compared to 3.3- and 5.5-fold for the 4-NO2 
reduction product and parental compound respectively). Due to catalytic differences 
between the two enzymes (see table 4.1) used for CB1954 reduction, the relative 
mutagenic potential of the two principal reduction products could not be confidently 
assessed.  
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Figure 4.9. CB1954-induced rifampicin resistance in wildtype and NER-deficient NTR over-
expressing strains of SOS-R1.  
Strains of wildtype (WT) and ΔuvrB strains of SOS-R1, over-expressing NfsA (E.c) (reduces 2-NO2 of 
CB1954), YfkO (B.s) (reduces 4-NO2 of CB1954) or no enzyme (Empty) were grown and challenged 
with CB1954 (0 or 100 µM) for 3 h, prior to dilution in fresh media and overnight recovery. Samples 
were then plated on solid media containing either just ampicillin (for calculation of total viable cells) or 
ampicillin and rifampicin (for detection of RifR mutants). Data is expressed as number of RifR colonies 
per 108 viable cells. *p <0.05. **p <0.01; t-test. Data is the average ± 1 SEM of 3 independent assays.  
 
4.2.7. Mutational spectra (nucleotide substitutions, sequence specificity) of 
CB1954 reduction products 
 
The region comprising nucleotides 1351 to 2224 of the rpoB genes (within which the 
majority of mutations that confer rifampicin resistance lie; (315)) from a selection of 
Rif
R
 colonies obtained through CB1954-induced mutagenesis were PCR amplified, 
sequenced and assessed for mutation specificity (results displayed in Table 4.2). In the 
wildtype strain, the predominant mutations induced by both 2- and 4-NO2 reduction 
products were GC → AT transitions, with the 2-NO2 reduction product also inducing a 
single instance of a GC → TA transversion. In the ΔuvrB strain, 2-NO2 reduction 
products only induced GC → AT transitions, while both GC → TA transversions (3 
total) and GC → AT transitions (2 total) were induced by 4-NO2 reduction products. 
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 Of the specific sites where mutagenesis occurred, 5 of the 10 sequenced 
mutations induced by the 2-NO2 reduction products and 4 of 10 induced by the 4-NO2 
reduction products were all at the same site: guanine 1546 (Table 4.3). No other 
mutational hotspot was observed for either of the two CB1954 reduction products, with 
mutations distributed equally (1-2 each) over a range of nucleotide sites. 
 
Table 4.2. Frequency and specificity of base pair substitutions within the E. coli 
rpoB gene induced by each CB1954 reduction product 
SOS-R1 strain Base pair change  2-NO2 reduction  
products
a
 
4-NO2 reduction  
products
b
 
Wildtype GC → AT 4 4 
GC → TA 1 0 
ΔuvrB GC → AT 5 2 
GC → TA 0 3 
aGenerated by challenging NfsA (E.c) over-expressing cells with CB1954 
bGenerated by challenging YfkO (B.s) over-expressing cells with CB1954 
 
 
Table 4.3. Frequency and sequence specificity of mutations within the E. coli rpoB 
gene  induced by the two principal reduction products of CB1954.  
Nucleotide site
a
 Surrounding sequence 
(5‟ → 3‟)b 
 2-NO2 reduction 
products 
4-NO2 reduction  
products 
1535 GCTGTCTCAGT 1 1 
1546 TTATGGACCAG 5 4 
1576 TTACGCACAAA 1 1 
1592 TATCTCCGCAC 1 0 
1595 CTCCGCACTCG 0 1 
1691 AACCCCTGAAG 0 1 
1721 CAACTCTCTGT 2 1 
aNucleotide numbering is relative to the adenine of the ATG start codon 
bNucleotide in bold indicates position of mutagenesis 
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4.3. Discussion 
 
The primary aim of this chapter was to investigate the roles of various E. coli DNA 
repair pathways, both SOS-dependent and -independent, on processing of the different 
DNA adducts induced by the principal reduction metabolites of CB1954. Results 
showed that SOS reporter strains deficient in either O
6
-methylguanine methyl 
transferase activity/adaptive response (Δada Δogt null mutants) or mismatch repair 
(ΔmutS null mutant) elicited levels of SOS response comparable to the wildtype strain, 
following challenge with any of the CB1954 reduction products (as generated by over-
expression of nitro group-specific CB1954-reductases). In contrast, NER (ΔuvrB) null-
mutants displayed enhanced SOS activity (relative to wildtype) in the presence of the 4-
NHOH metabolite, but not the 2-NO2 reduction products (as shown by both NTR-
catalysed generation of reduction products and with synthetic pure metabolites).  
These observations have several implications. Firstly, it is unlikely that the SOS-
independent adaptive response or mismatch repair pathways are involved in repair of 
any CB1954-induced adduct; or, if so, play only a very minor role, such that other repair 
pathways are able to compensate for their absence without necessitating increased SOS 
induction. Therefore the presence of these pathways in the E. coli reporter strains used 
throughout this work should not interfere with SOS assay results, in particular regarding 
the relative levels of SOS response induced by the different CB1954 reduction products. 
This is particularly relevant to the adaptive response, the activation of which has 
previously been shown to inhibit subsequent SOS induction in response to UV 
irradiation (301). However, other SOS-independent repair pathways, in particular BER, 
which were not investigated in this chapter may still be involved in CB1954 adduct 
repair and therefore warrant further study. For example, previous studies have shown 
that expression of the E. coli BER-linked DNA glycosylase Fpg in human cells reduces 
sensitivity to the toxic effects of both aziridine and the aziridinyl alkylating agent 
thiotepa (316; 317). This suggests a role for this enzyme in repair of aziridinyl-induced 
adducts, which could include certain lesions produced by CB1954  
 Secondly, the enhanced SOS response relative to wildtype observed in SOS-R1 
ΔuvrB strains over-expressing NemA (E.c) or YfkO (B.s) following challenge with 
CB1954 suggests a substantial role of NER in processing of 4-, but not 2-NO2 reduction 
metabolite-induced adducts in E. coli. This is analogous to results obtained in 
mammalian cells (121) and therefore implies that the role of NER in repairing CB1954-
induced DNA damage is similar in the two species. This lends support to the use of E. 
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coli as a model organism for studying CB1954 reduction. Furthermore, the improved 
sensitivity of the SOS-R1 ΔuvrB strain towards unique production of the 4-NHOH 
metabolite could be exploited as a screening tool for preferentially detecting over-
expressed NTRs that only reduce the 4-NO2 of CB1954. This may be beneficial in gene 
therapy targeting of tumours that are known to be deficient in NER and therefore more 
sensitive to the toxic effects of the 4-NHOH metabolite. Similarly, this strain could be 
used to improve overall sensitivity of the SOS assay towards alternative prodrugs whose 
principal adducts are processed by the NER machinery. This was demonstrated with the 
nitroaromatic prodrugs NFZ and PR-104A, which induced substantially higher SOS 
responses in NTR over-expressing ΔuvrB strains than in wildtype at equimolar doses. In 
contrast, metronidazole did not demonstrate a similar pattern of activity, no doubt due to 
differences in repair of the induced adducts compared with the former compounds. 
Together these data demonstrate that the SOS assay is able to detect different genotoxic 
mechanisms of test compounds, potentially aiding in identification of novel therapeutic 
drugs with specific modes of action (e.g. DNA interstrand crosslinking agents versus 
specific inhibitors of DNA replication machinery).  
This study also reports the first documented evidence of reduction of the DNBM 
prodrug PR-104A by bacterial NTRs, as demonstrated by enhanced SOS responses in 
SOS-R1 strains over-expressing NTRs relative to an empty vector control, following 
challenge with this prodrug. Previous work has established the ability of NfsB (E.c) to 
reduce the dibromo-derivative SN 27686 (56), in agreement with the results presented 
here. These preliminary findings therefore provide rationale for further testing of this 
clinically attractive nitroaromatic prodrug with bacterial NTRs in order to investigate its 
potential utility in GDEPT. 
Both the 2- and 4-NO2 reduction products of CB1954 were able to induce 
mutations in the E. coli genome, as illustrated by the significantly higher frequencies of 
rifampicin resistance in CB1954 challenged NTR over-expressing strains relative to 
unchallenged isogenic cultures. Mutagenic activity of alkylating agents and other DNA 
damaging species arises, in both bacteria and humans, primarily through the activity of 
damage-inducible error-prone polymerases, whose functions are to replicate DNA over 
the induced lesion (translesion synthesis), thereby rescuing replicative polymerases that 
have stalled at these positions (303). Error-prone polymerases and TLS have been 
associated with the repair of a number of different DNA lesions, in both mammalian 
and bacterial cells (303), and furthermore their activity has been directly linked to 
generation of drug resistance in cancer cells, most likely via mutational activation of 
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multi-drug resistance genes (318; 319). Studies have also demonstrated that down-
regulation of many translesion polymerases with antisense RNA technology can 
sensitize drug-resistant cancer cell lines to the toxic effects of alkylating agents (319; 
320). Therefore, as results presented in this chapter demonstrate that CB1954 induced 
lesions are substrates for translesion polymerases, clinical therapy with this prodrug 
may benefit from targeted inhibition of tumour cell translesion polymerases. 
 The mutagenicity of both 2- and 4-NO2 reduction products significantly 
increased in the absence of functional NER machinery, suggesting that TLS is 
compensatory to NER in repair of CB1954 induced adducts. This has previously been 
observed for a number of nitroaromatic mutagens (321). However, the increase in 
mutagenicity in the ΔuvrB strain was much greater in response to the 2-NO2 reduction 
products (22.5-fold difference over wildtype) than to the 4-NO2 reduction products (3.3-
fold difference). These observations indicate that 2-NO2 reduction product induced 
adducts may be preferentially repaired by NER, but are just as efficiently processed by 
TLS pathways in the absence of NER. In contrast, 4-NO2 reduction product-induced 
adducts may not be as efficient subsrates for TLS, therefore leading to enhanced SOS 
induction in the absence of a functional NER mechanism.  
 The majority of mutations induced by both 2- and 4-NO2 CB1954 reduction 
products were GC → AT transitions, which is in agreement with previous research that 
has shown that GC → AT transitions are the predominant mutation induced by a 
number of structurally diverse alkylating agents (322; 323). However, while the 
spectrum of mutations induced by the 2-NO2 reduction products was similar in both 
wildtype and NER-deficient strains, the 4-NO2 reduction products induced more GC → 
TA transversions in the ΔuvrB strain. Together, these results suggest that initial DNA 
binding of both 2- and 4-NO2 reduction metabolites is similar, the product of which 
(most likely a monoadduct) is able to be processed by NER (error-free) or certain TLS 
enzymes (introducing mainly GC → AT mutations ). If left unrepaired, the primary 
adduct formed by the 4-, but not the 2-, NO2 reduction metabolites is able to undergo a 
second reaction (due to bifunctional properties) to form intra- or interstrand crosslinks, 
which are primarily repaired by NER. However, in the absence of NER, persistent intra- 
or interstrand 4-NHOH lesions induce a higher SOS response, leading to up-regulation 
of alternative translesion polymerases that can then repair these adducts. The difference 
in base pair substitutions between NER-proficient and deficient cell lines may be due to 
the type of polymerases employed to repair either the initial monoadduct or the 
crosslink, as supported by both the differences in substrate specificity and mutational 
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bias that have previously been reported for differed TLS polymerases (303; 324). 
Further analysis of base pair substitutions and other mutations (insertions, deletions) 
induced by CB1954 will aid in understanding of the mechanisms of action of each 
reduction metabolite.  
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Chapter 5: Screening a phylogenetically diverse library of 
bacterial nitroreductases for nitroaromatic prodrug reduction 
 
5.1 Introduction 
 
The results gained in the previous two chapters have provided strong evidence for two 
principal hypotheses of this research: firstly, that a variety of phylogenetically diverse 
enzymes are able to bioreductively activate a range of structurally distinct DNA 
alkylating nitroaromatic prodrugs; and secondly, that our novel E. coli-based SOS assay 
is a generally applicable, accurate and moderately high-throughput screen for detection 
and quantification of NTR-mediated metabolism of these prodrugs. However, these 
studies have been performed using a very small (<15) panel of candidate enzymes, the 
majority of which are of E. coli origin. As previous GDEPT research has illustrated that 
prodrug-reductase activity can vary dramatically among homologues, whether close or 
distant, of prodrug-reducing enzymes (158; 206; 208), the next logical step in this 
research is to expand the breadth of candidate enzymes tested to include homologues of 
the most active NTRs, from a variety of genetic backgrounds. Not only will this 
potentially allow identification of more active nitroaromatic prodrug reducing NTRs, it 
will also enable further assessment of the ability of the SOS assay to function in a more 
high-throughput capacity, and allow insight into possible structure-activity relationships 
between prodrug and enzyme active site architecture. Lead NTR(s) could then be 
further enhanced for prodrug reducing activity via directed evolution/enzyme 
engineering approaches. 
The initial aim of the research described in this chapter was to identify, through 
database homology searches, a variety of bacterial NTRs with significant sequence 
homology to the previously tested E. coli enzymes. These enzymes formed the basis of 
a „core‟ library of NTRs that were subsequently examined, principally via the SOS 
assay, for their ability to reduce a number of structurally diverse nitroaromatic prodrugs 
with potential anti-cancer clinical applications. Finally, a selection of nitrobenzamide 
mustard prodrug analogues of PR-104A that induced strong SOS activity in the E. coli-
based screen were assessed for in vitro metabolism by recombinant human AKR1C3, in 
order to identify potential hypoxia and nitroreductase activated prodrugs with reduced 
aerobic off-target toxicity.     
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5.2. Results 
 
 5.2.1. Further optimisation of the SOS assay 
 
Prior to generation and screening of the expanded library of NTRs for nitroaromatic 
prodrug reduction, several modifications were made to the SOS assay to improve 
sensitivity and reduce potential background activity by native enzymes. Firstly, as 
results from Chapters 3 and 4 indicated small but significant roles of both AzoR (E.c) 
and NemA (E.c) in reduction of a variety of test drugs, the native genes of these two 
enzymes were deleted, in-frame (as previously described for NfsA (E.c) and NfsB (E.c)) 
from the SOS-R1 genome. The resulting strain was designated SOS-R1B. No 
observable growth disadvantages were detected between this strain and SOS-R1 (results 
not shown), indicating that these genes are not essential or important under standard 
laboratory conditions used for organism growth and maintenance. Secondly, 
enhancement of prodrug sensitivity was sought by investigating the role of a multi-drug 
efflux pump accessory protein (TolC) in promotion of resistance to the nitroaromatic 
prodrugs employed in this study. Higher sensitivity would guarantee lower prodrug 
concentrations able to be employed in the screens, preventing wastage of prodrugs that 
are either commercially expensive, or not commercially available and therefore supplied 
in limited amounts by generous donors. This is of particular relevance to PR-104A, of 
which very high concentrations (200 µM) were required to elicit moderate levels of 
SOS response induction in NTR over-expressing strains of SOS-R1 in the previous 
chapter (see Figure 4.8C). 
The outer membrane pore protein TolC is able to act in combination with at least 
four structurally distinct inner membrane pump systems (acrAB, acrEF, emrAB and 
macAB) to expel a wide array of low molecular weight compounds and proteins out of 
the cell (325). Inactivation of the tolC gene has been shown to be accompanied by 
greatly enhanced sensitivity to a variety of natural toxins and xenobiotics, including 
antibacterial drugs, in agreement with the important role this protein plays in expulsion 
of potentially harmful compounds (326-328). Furthermore, tolC mutants have been used 
widely in SOS reporter systems to improve assay sensitivity and decrease detection 
limits of genotoxic compounds (229-231). The role of TolC in efflux of the two 
principal nitroaromatic prodrugs studied in this work, CB1954 and PR-104A, was 
investigated through in-frame deletion of the tolC gene from the SOS-R1B genome. The 
resultant strain, termed SOS-R2, displayed a vastly enhanced sensitivity towards 
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reduction of PR-104A (from 2.3 to 7.2-fold induction, for otherwise isogenic tolC
+
 and 
tolC
-
 strains respectively, with NfsA (E.c)-over-expression and 50 µM PR-104A 
challenge; Figure 5.1). However, an increase in SOS response with the empty vector 
control was also noted in SOS-R2, suggesting a heightened sensitivity of this strain 
towards toxicity of the PR-104A parental prodrug. In contrast, no considerable 
difference in sensitivity towards CB1954 was observed between the two strains. Lack of 
a functional tolC gene did not affect cell growth rate (as compared to wildtype in the 
absence of prodrug; results not shown).  
In light of these data, SOS-R2 was chosen as the host strain of choice for all 
SOS and IC50 assays for the remainder of this work. 
  
 
Figure 5.1. Differences in nitroaromatic prodrug-induced SOS responses between tolC
+
 and tolC
-
 
strains of SOS-R1B.  
NTR over-expressing strains of SOS-R1B that either contained (tolC+) or lacked (tolC-) the outer-
membrane pore protein TolC were grown and challenged for 3 h with the indicated nitroaromatic prodrug 
at 50 µM final concentration, prior to analysis of SOS activity. Data is the average ± 1 SEM of 4 
independent assays. 
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  5.2.2. Generation and expression of a core library of bacterial NTRs  
 
NTRs that would form the basis of a core library to be screened for nitroaromatic 
prodrug-reductase activity were chosen from the NCBI protein database, through 
BLAST homology searches using each of the E. coli enzymes tested in Chapter 3 (as 
well as human NQO1 and B. amyloliquefaciens YwrO, see below) as query sequences. 
As such, the library was partitioned into separate NTR families, based around these key 
members. A total of 47 NTRs were chosen (plus the empty vector control), to facilitate 
assay screening of the entire library in duplicate in a single 96-well plate, at each 
prodrug concentration. NTRs were chosen from a range of bacterial species based on 
availability to our laboratory; this included both Gram positive and Gram negative 
strains, with the only other criteria for selection being a ≥25% amino acid identity to the 
key (query sequence) family member. Table 5.1 contains the complete list of enzymes 
chosen for the core library and their phylogenetic relationships are displayed in Figure 
5.2. As can be seen, emphasis was given to both the NfsA and NfsB families (12 
members each), as they were the most active enzymes with CB1954, as previously 
determined. Likewise, the AzoR and NemA families contain 4 members apiece, with 
the other families containing at least one homologue in addition to the E. coli enzyme. 2 
bacterial homologues of mammalian NQO1 were also included. Finally, based on the 
results of Anlezark et al. (207), a new family containing homologues of B. 
amyloliquefaciens YwrO, of which no E. coli enzyme with significant homology exists, 
was also introduced.  
NTR genes were PCR amplified from genomic DNA (strains used are listed in 
Table 2.3), cloned into pUCX and sequence-confirmed constructs were transformed into 
SOS-R2. SDS-PAGE was used to assess protein expression levels. High levels of 
expression were observed for most of the 47 NTRs tested, with only YwrO (B.s) and 
YwrO (V.f) failing to produce a visible band. Expression levels were consistent across 
the majority of NTRs, with the exception of a few for which expression was visibly 
lower (NfsA (V.f), EcD (P.p), YcdI (E.c), YcdI (K.p) and YdjA (E.c)). However, as the 
over-expressed NTR was the most prominent band in even these lanes, for simplicity of 
SOS response and IC50 data calculations, relative NTR expression levels were not 
analysed any further. 
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Figure 5.2. Phylogram of the 47 NTRs chosen for the core library. 
Gene names used throughout this work are those before the underscore (_). Letters after the underscore 
refer to the bacterial origin of each gene. Ec: E. coli. St: S. typhimurium. Ck: C. koseri. Es: E. sakazakii. 
Kp: K. pneumoniae. Vh: V. harveyi. Vv: V. vulnificus. Vf: V. fischeri. Bs: B. subtilis. Li: L. innocua. Pp: 
P. putida. Pa: P. aeruginosa. Ps: P. syringae. Table 2.3 contains more details on strains used, including 
ATCC number and/or substrain designation. Coloured lines indicate the different families that NTRs are 
divided into, with designated family names for each indicated to the right. Multiple sequence alignment 
and phylogram generation was performed using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/), 
on default settings.  
NemA 
SOS-R2: Δ NfsA, NfsB, AzoR, NemA 
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NQO1 
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Table 5.1. NTRs used in this study, 
NTR Family
a
 % ID
b
 % Sim
b
 Refs
c
 
NfsA (E.c) NfsA 100 100 (176; 189) 
NfsA (S.t) NfsA 87 95 (193) 
NfsA (C.k) NfsA 86 92  
NfsA (K.p) NfsA 83 92  
NfsA (E.s) NfsA 82 94  
NfsA (V.f) NfsA 52 68  
NfsA (V.v) NfsA 51 65  
Frp (V.h) NfsA 51 65 (179; 191) 
NfrA (B.s) NfsA 39 62 (167; 170) 
NfsA (L.i) NfsA 39 60  
EcD (P.p) NfsA 35 57  
YcnD (B.s) NfsA 35 56 (194; 329) 
NfsB (E.c) NfsB 100 100 (122; 177) 
NfsB (C.k) NfsB 88 95  
NfsB (S.t) NfsB 88 91 (197; 198) 
NfsB (K.p) NfsB 84 93  
NfsB (V.v) NfsB 61 75  
2432 (P.p) NfsB 52 71  
NfsB (E.s) NfsB 46 66  
FraseI (V.f) NfsB 34 53 (166) 
NfsB (V.h) NfsB 30 48  
YfkO (B.s) NfsB 29 46  
YdgI (B.s) NfsB 25 47 (208) 
5190 (P.a) NfsB 25 42  
AzoR (E.c) AzoR 100 100 (259; 260) 
AzoR (S.t) AzoR 87 95  
AzoR (V.v) AzoR 56 73  
4538 (P.p) AzoR 48 66  
NemA (E.c) NemA 100 100 (187; 190) 
NemA (S.t) NemA 92 96  
NemA (K.p) NemA 86 92  
NemA (V.v) NemA 47 65  
YwrO (B.s) YwrO 70
d
 82
d
  
YwrO (L.i) YwrO 42
d
 57
d
  
YwrO (V.f) YwrO 52
d
 68
d
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Table 5.1. continued. 
NTR Family
a
 % ID
b
 % Sim
b
 Refs
c
 
YieF (E.c) YieF 100 100 (184; 222) 
1204 (P.a) YieF 45 60  
MdaB (E.c) MdaB 100 100 (262; 330) 
MdaB (P.s) MdaB 60 74  
WrbA (E.c) WrbA 100 100 (263; 283) 
WrbA (P.s) WrbA 39 55  
YdjA (E.c) YdjA 100 100 (258) 
YdjA (K.p) YdjA 79 89  
3720 (P.p) NQO1 38
e
 57
e
  
4975 (P.a) NQO1 42
e
 55
e
  
YcdI (E.c) YcdI 100 100 (261; 315) 
YcdI (K.p) YcdI 76 85  
aNTR family names as designated in this study (based on homology groupings; see Figure 5.2) 
b% ID and % Sim. indicate amino acid identity and similarity, as calculated by the blastp program 
(“identities” and “positives”, respectively) of each NTR to the designated family lead member (the lead 
member is indicated as having 100 % ID and Sim) 
cPublications that report biochemical data for the respective NTR. 
dSim. and ID values for all YwrO family enzymes are relative to B. amyloliquefaciens YwrO (207) 
eSim. and ID values are relative to human NQO1 
 
 
Figure 5.3. Expression of core library NTRs in SOS-R2. 
SDS-PAGE analysis of expression levels of the 47 NTRs of the core library, from pUCX in SOS-R2. The 
order of enzymes is the same as that shown in Table 5.1 (the final sample, “E”, is the empty vector 
control). Samples for electrophoresis were whole cell lysates taken from a single replicate at the 
completion of an SOS assay. Samples were normalized for cell density (OD600) prior to gel loading.  
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 5.2.3. Screening the core library for CB1954-reductase activity 
 
 5.2.3.1. SOS assay 
 
The core library of NTRs was screened for CB1954-reductase activity using the SOS 
assay, employing prodrug concentrations ranging from 10-50 µM and a challenge time 
of 3 h (Figure 5.4). Consistent with previous results for the E. coli enzymes (Chapter 3), 
the NfsA and NfsB families elicited the highest average SOS responses, with smaller 
contributions from AzoR and NemA families. No substantial increase in activity above 
empty vector levels was observed for any NTR outside of these families. A lot of 
variation in SOS response induction was also observed within the NfsA and NfsB 
families. For example, within the NfsA family SOS fold inductions ranged from 2 to 
10.7 at the midrange CB1954 concentration of 20 µM, while within the NfsB family the 
equivalent range was between 2.6 and 8.3. Although on average the NfsA family 
elicited a higher SOS response across all CB1954 concentrations compared to the NfsB 
family (3.13, 5.4 and 8.4-fold SOS response induction compared with 2.8, 4.4 and 7.1, 
respectively, for the increasing concentrations of prodrug), there was no statistical 
significance between these differences (p>0.05; t-test). The highest overall response 
was obtained from the NfsA family enzyme YcnD (B.s), whose activity was roughly 2.5 
times higher (at both 10 and 20 µM CB1954) than that of NfsA (E.c) (6.7-and 10.7-fold 
compared to 2.4 and 4.3-fold, respectively). In fact, SOS response induction for YcnD 
(B.s) at the highest concentration tested (50 µM) was lower than at 20 µM, most likely 
due to the onset of growth inhibition (58% growth relative to unchallenged at 50 µM, 
whereas no other NTR induced growth inhibition below 70% of unchallenged levels; 
results not shown). Two other NfsA-family enzymes also showed significantly (p<0.05; 
t-test) higher SOS activity across all concentrations tested relative to NfsA (E.c), these 
being NfsA (V.v) and Frp (V.h). 
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 5.2.3.2. IC50s 
 
SOS assay results were next compared to IC50s of CB1954 for each over-expressed 
NTR in SOS-R2. Due to the large number of NTRs required to be tested and therefore 
high volume of CB1954 needed for extensive IC50 testing, the assay protocol was 
adjusted from that used in Chapter 3 to minimize prodrug requirements and usage. This 
involved both a change in the media used (M63 minimal media, compared to LB) and 
adaptation of the assay for use in 384-well plates. The justification for use of minimal 
media was that a slower growth rate would allow more pronounced CB1954-mediated 
toxic effects to show through and therefore produce lower overall IC50s. Growth was 
indeed slower overall in M63 relative to LB (results not shown) and subsequently IC50s 
in this section were on average 2-3-fold lower than those previously measured (i.e. 
Chapter 3). 
IC50 values for each NTR, calculated from these assays, are listed in Table 5.2. 
In agreement with SOS assay results, the most active NTRs (lowest IC50s) belonged to 
the NfsA and NfsB families, including 19 of the overall top 20 enzymes (NemA (E.c) 
taking 18
th
 place). Overall, a strong and significant (R
2
 >0.75, p<0.001) correlation 
between SOS (all concentrations tested) and IC50s was observed (see Figure 5.5). 
Correlations between results from just the NfsA and NfsB family enzymes were also 
high (R
2
 > 0.7; results not shown), demonstrating little correlation bias towards the 
many inactive enzymes. One consistent outlier was NfsA (S.t), which although eliciting 
only slightly higher SOS responses than NfsA (E.c) at all CB1954 concentrations tested 
yielded an IC50 value roughly 2-fold higher.  
 Figure 5.4. CB1954-induced SOS responses from NTR over-expressing strains of SOS-R2. 
NTR over-expressing strains of SOS-R2 were grown and challenged with CB1954 (at the indicated concentrations) for 3 h prior to analysis of SOS activity. Data is the average ± 1 
SEM of 4 independent assays 
1
2
4
 
Table 5.2. IC50s of CB1954 in NTR over-expressing strains of SOS-R2. 
IC50 values were calculated from growth measurements taken after 4 h challenge with increasing concentrations of CB1954. 
NTR IC50
a 
(µM) Rank SOS rank
b
 NTR IC50 (µM) Rank SOS rank NTR IC50 (µM) Rank SOS rank 
NfsA (E.c) 150 11 15 NfsB (V.v) 82.8 5 3 YwrO (B.s) 1,380 42 35 
NfsA (S.t) 305 25 10 2432 (P.p) 290 23 21 YwrO (L.i) 1,800 47 42 
NfsA (C.k) 154 13 16 NfsB (E.s) 183 15 7 YwrO (V.f) 1,600 44 36 
NfsA (K.p) 183 16 18 FraseI (V.f) 120 7 8 YieF (E.c) 1,750 46 40 
NfsA (E.s) 203 22 24 NfsB (V.h) 256 21 19 1204 (P.a) 1,290 39 32 
NfsA (V.f) 79.2 4 5 YfkO (B.s) 201 20 23 MdaB (E.c) 400 26 34 
NfsA (V.v) 83.9 6 4 YdgI (B.s) 127 8 13 MdaB (P.s) 832 32 37 
Frp (V.h) 70 3 2 5190 (P.a) 541 29 31 WrbA (E.c) 1,330 40 43 
NfrA (B.s) 46.1 2 6 AzoR (E.c) 866 33 30 WrbA (P.s) 944 35 38 
NfsA (L.i) 201 19 22 AzoR (S.t) 511 28 27 YdjA (E.c) 1,430 43 47 
EcD (P.p) 148 10 17 AzoR (V.v) 466 27 26 YdjA (K.p) 1,980 48 46 
YcnD (B.s) 29.1 1 1 4538 (P.p) 1,220 37 39 3720 (P.p) 1,330 41 33 
NfsB (E.c) 154 12 9 NemA (E.c) 188 18 20 4975 (P.a) 802 30 29 
NfsB (C.k) 157 14 12 NemA (S.t) 817 31 28 YcdI (E.c) 994 36 48 
NfsB (S.t) 188 17 14 NemA (K.p) 300 24 25 YcdI (K.p) 1,280 38 44 
NfsB (K.p) 136 9 11 NemA (V.v) 905 34 41 Empty 1,740 45 45 
aDegrees of error associated with IC50 values are omitted for clarity. Standard deviations did not exceed 17 % of the IC50 value, with the exception of YdjA (K.p) (23%) 
bSOS rankings are derived from the 20 µM CB1954 challenge data 
 
1
2
5
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Figure 5.5. Logarithmic correlations between SOS assay results and IC50s for CB1954-challenged 
NTR over-expressing SOS-R2 strains. 
 Data for SOS results were taken from Figure 5.4. Data for IC50s were taken from Table 5.2. The SOS 
value for 50 µM CB1954-challenged YcnD over-expressing SOS-R2 has been omitted, as growth 
inhibition impaired SOS output for this NTR at this concentration of prodrug.  
 
 5.2.3.3. In vitro kinetics of purified enzymes 
 
A selection of NTRs that performed strongly in both SOS and IC50 assays were further 
characterised for CB1954-reductase activity by measuring their in vitro kinetic 
parameters using purified recombinant enzymes. In addition to the 4 native E. coli 
enzymes previously screened in this way (Chapter 3), 16 new enzymes were chosen, of 
which 9 were NfsA and 7 NfsB homologues. Genes were cloned into the expression 
vector pET28a(+), transformed into E. coli BL21 (DE3), over-expressed, and purified 
by nickel-affinity chromatography. Although all enzyme preparations retained yellow 
colour upon elution, to compensate for partial loss of loosely bound flavin co-factors 
during the purification steps, all eluted enzymes were incubated with pure FMN prior to 
buffer exchange. Absorbance spectrophotometry on FMN-reconstituted samples 
indicated that flavin:enzyme monomer ratios were roughly equimolar (flavin:monomer 
ratios of recombinant enzymes directly after elution from nickel-affinity columns were 
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typically less than 0.5; results not shown), indicating roughly complete co-factor 
reconstitution by this method.   
The purity of recombinant protein preparations was assessed by SDS-PAGE, the 
results of which are displayed in Figure 5.6. All proteins were deemed to be >90% pure 
by scanning densitometry (results not shown).  
 
 
Figure 5.6. SDS-PAGE of purified, His6-tagged NTRs used in this chapter. 
Genes of the NTRs to be assessed were cloned into pET28a(+) vector, over-expressed in E. coli BL21 and 
recombinant His6-tagged NTR purified to homogeneity using nickel-affinity chromotography. Each lane 
corresponds to 2 µg of purified enzyme. 
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CB1954-reductase activity of purified enzymes was assessed as previously 
described (Chapter 3). All enzymes tested demonstrated clear activity towards this 
substrate (with the exception of NfsA (S.t), which exhibited no activity in vitro with any 
substrate tested, despite high heterologous expression levels and purified enzyme yield). 
As predicted by SOS and IC50s, catalytic efficiencies varied dramatically (see Table 
5.3). On average, NfsA-like enzymes were 10-fold more catalytically efficient than their 
NfsB counterparts (as measured by kcat/Km; averages of 174,000 M
-1
 s
-1
 and 17,500 M
-1
 
s
-1
 for NfsA and NfsB-families, respectively), similar to the previous results obtained 
with the 2 native E. coli representatives of these families. The basis of this difference 
appeared to be primarily due to substrate affinity rather than catalytic turnover, as NfsB-
family Km values were >25 times higher on average than those of NfsA-family 
enzymes. In contrast, NfsB kcat values were slightly higher, on average.  
Correlations between SOS assay results and kcat/Km values for the tested NTRs 
(see Figure 5.7A; R
2
 = 0.53 and 0.55) were not as strong as correlations observed 
between SOS assay results and IC50 values, likely due to the large difference (10-fold on 
average) in kcat/Km values between NfsA and NfsB family enzymes, which was not 
mirrored in either SOS assay results or IC50s.  
 
5.2.3.4. Identification of CB1954 reduction products  
 
As the reduction pathway (nitro group preference) taken by each enzyme has already 
been shown to have a considerable effect on SOS response induction, largely 
independent of kinetic efficiency (see Chapter 4), metabolite ratios produced upon 
reduction of CB1954 were analysed, via HPLC, for a selection of the tested enzymes 
(see last column of Table 5.3; see Appendix 2 for HPLC chromatograms). As was 
observed previously with the E. coli NTRs, all NfsA-family enzymes tested were only 
able to reduce the 2-NO2 to the hydroxylamino derivative, while NfsB-family enzymes 
produced a mixture of both the 2 and 4-NHOH, albeit in varying ratios. The only 
exception was YfkO (B.s), which generates only the 4-NHOH, as described previously 
(Chapter 4). Consistent with these observations, the correlation between kcat/Km and 
SOS induction increased sharply when only the NfsA-family enzymes (2-NHOH 
producers) were considered (see Figure 5.7B; R
2
 = 0.85 and 0.742, SOS response 
induction with 10 and 20 µM CB1954 respectively). 
The most active NTR based on kinetics data was YcnD (B.s); this result was 
consistent with SOS data and IC50s. NfsA (V.f), (V.v) and Frp (V.h) were also among 
  
129 
the top six most catalytically active enzymes (based on kcat/Km values), as predicted by 
both SOS and IC50s. Furthermore, NfsB (V.v), the lead NfsB-family member in both 
SOS assay results and IC50s, was also the most kinetically active NfsB-family enzyme, 
with a kcat/Km more than 4-fold higher than the majority of the NfsB-family enzymes.  
 
 
Table 5.3. Kinetic parameters for the reduction of CB1954 by purified, His6-
tagged NTRs. 
NTR Co-subs.
a
 kcat (s
-1
) Km (µM) kcat/Km  
(M
-1
 s
-1
) 
NO2  
pref.
b
 
NfsA (E.c)
c
 NADPH 16 ± 0.48 220 ± 18 73,000 ± 6,400    2 
NfsA (S.t) NADPH <1 ND
d
 NA
e
 2 
NfsA (C.k) NADPH 24.7 ± 0.96  163 ± 18 151,700 ± 17, 300  NT
f
 
NfsA (K.p) NADPH 37.1 ± 1.4 1,670 ± 150 22,270 ± 2,180  2 
NfsA (E.s) NADPH 25.7 ± 1.1 260 ± 28 98,880 ± 11,400  NT 
NfsA (V.f) NADPH 13.8 ± 0.7 52.5 ± 6.8 262,900 ± 36,500  NT 
NfsA (V.v) NADPH 45.2 ± 1.8 210 ± 21 215,700 ± 23,300  2 
Frp (V.h) NADPH 21.7 ± 0.7 99.6 ± 10 217,600 ± 22,900  2 
NfrA (B.s) NADPH 14.2 ± 0.8 147 ± 23 96,520 ± 15,900  2 
YcnD (B.s) NADPH 15.2 ± 0.4 35.4 ± 4.1 430,800 ± 51,300  NT 
NfsB (E.c)
c
 NADH 62 ± 11 11,000 ± 2,600 5,600 ± 1,660  2, 4 (50:50) 
NfsB (C.k) NADH 72.7 ± 12 12,200 ± 2,400 4,920 ± 1,230  NT 
NfsB (K.p) NADH 204 ± 76 21,140 ± 8,900 9,630 ± 5,440  2, 4 (50:50) 
NfsB (V.v) NADH 72.9 ± 5.2 1,260 ± 160 58,000 ± 8,470  2, 4 (25:75) 
FraseI (V.f) NADH 12.4 ± 3.3 903 ± 12 13,660 ± 3,640  NT 
YfkO (B.s) NADPH 60.2 ± 2.9 2,440 ± 250 24,740 ± 2,840  4 
YdgI (B.s) NADH 7.68 ± 0.5 1,780 ± 170 4,330 ± 493  2, 4 (60:40) 
AzoR (E.c)
c
 NADPH 0.15 ± 0.008 1,400 ± 160 110 ± 14  4 
NemA (E.c)
c
 NADPH 0.22 ± 0.003 56 ± 2.2 3,900 ± 164  4 
aPreferred co-substrates were used for all enzymes at an initial concentration of 0.25 mM.  
bPreferred nitro group (at 2 or 4 position) of CB1954 reduced by each enzyme, as determined by HPLC. 
Numbers in parentheses indicate relative percentages of each nitro group reduced  
cNative E. coli NTR kinetic parameters and nitro group (NO2) preference data taken from Chapter 3 
dND: not detected 
eNA: not applicable 
fNT: not tested 
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Figures 5.7A & B. Linear correlations between SOS assay results and purified NTR kinetic 
efficiency, CB954 as substrate. 
Data for SOS assay results were taken from Figure 5.4. Data for kinetic efficiencies (as measured by 
kcat/Km) were taken from Table 5.3. (A) All NTRs assessed kinetically. (B) Only 2-NO2 reducing 
enzymes. 
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5.2.4. Screening the core library for PR-104A-reductase activity 
 
 5.2.4.1. SOS assay 
 
Following on from CB1954-activity screening, the core library was next subjected to 
assessment of PR-104A-reductase activity. As previously, the first screen employed was 
the SOS assay (Figure 5.8). In contrast to CB1954, a family-specific pattern was less 
evident from these results, with NfsA, NfsB and AzoR families all displaying 
considerably higher activity than the empty vector control. Furthermore, a selection of 
individual members from other families (MdaB (E.c), WrbA (P.s), 4975 (P.a) and YcdI 
(K.p) also elicited responses greater than 1.5-times that of the empty vector with at least 
one of the prodrug concentrations tested. It is noteworthy that at 50 µM PR-104A, the 
highest concentration tested, considerable background SOS induction was observed, as 
is illustrated by the almost 3-fold induction of the empty vector control and at least 2-
fold induction of the majority (>85%) of the NTR-over-expressing strains at this 
concentration. Although background activity was still evident at the lower 
concentrations tested, the levels were overall much lower, with induction ratios only 
marginally above 1 for the empty vector control ( 1.1 and 1.36 for 10 and 20 µM 
respectively). As such, only 10 µM and 20 µM SOS data are considered in subsequent 
comparison and correlation analyses. 
The top 6 SOS-inducing NTRs with PR-104A all belonged to the NfsA family 
(in the order NfsA (S.t), NfsA (C.k), YcnD (B.s), NfrA (B.s), NfsA (E.c) and NfsA 
(K.p) at 20 µM prodrug). Likewise, the average fold-induction in SOS response across 
the NfsA family at both concentrations (2.57 and 4.43 at 10 µM and 20 µM PR-104A 
respectively) was significantly higher (p<0.05; t-test) than was the case for both the 
NfsB (1.78 and 2.70) and AzoR (1.42 and 2.26) families. In contrast, the average NfsB 
response was only significantly higher than the AzoR family at 10 µM PR-104A 
(p<0.05; t-test).  
 Within the NfsA family, substantial variation in SOS response was apparent, 
with fold-induction values ranging from 1.73 to 4.9 at 10 µM prodrug and 2.72 to 8.57 
at 20 µM. The most active NfsA family member, and the overall lead NTR from these 
results, NfsA (S.t), generated SOS responses almost twice that of the average NfsA 
response and 1.5-fold higher than the next best enzyme. Much less variation was 
observed within the NfsB family, with fold-induction values for the majority of 
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enzymes lying between 1.49 and 1.97 at 10 µM and between 2.21 and 3.16 at 20 µM. 
The only exception was YdgI (B.s), whose SOS fold induction values of 2.58 and 4.05 
were considerably higher than the average NfsB family response, and on a par with the 
average NfsA-family response.  
 
 5.2.4.2. IC50s 
 
The SOS data above were next compared to IC50s of PR-104A, obtained for all NTRs in 
SOS-R2 after a 4 h PR-104A challenge time. IC50 values are listed in Table 5.4. In 
contrast to SOS data, only 10 of the 20 lowest IC50s were obtained from NfsA or NfsB 
family enzymes. In fact, the two lowest overall IC50s came from alternative family 
enzymes: MdaB (E.c) and AzoR (S.t). On the other hand, NfsA (S.t), which elicited a 
considerably higher SOS response than any other enzyme tested, was much less active 
based on IC50 results, producing an IC50 on a par with many of the other NfsA-family 
enzymes (IC50 of 295 µM, compared to 292 µM for NfsA (E.c) and 290 µM for NfsA 
(C.k); see table 5.4). These discrepancies, among others, were evident in the overall, 
very weak correlations (for all enzymes) between SOS data and IC50s (R
2
 = 0.263 and 
0.337; see Figure 5.9A). However, much of this lack of correlation could possibly be 
attributed to the large degrees of error associated with many of the IC50 values, 
especially those at the higher end (less active), as is evident in the correlation graph. In 
fact, 21 of the 47 tested enzymes had standard deviations >20 % of the IC50 value, 
compared with just one IC50 value meeting this criteria among the CB1954 data. These 
large errors were likely a result of assay concentrations not reaching adequate levels to 
induce significant growth inhibition (due to both limited prodrug stocks and higher 
concentrations required, relative to CB1954), therefore preventing accurate calculation 
of IC50s for the less active enzymes. Indeed, by omitting many of these data points, the 
strength of correlations between IC50 and SOS assay results was substantially increased 
(in this case only focusing on NfsA and NfsB-family enzymes, R
2
 = 0.626 and 0.670; 
see Figure 5.9B).  
 Figure 5.8. PR-104A-induced SOS responses from NTR over-expressing strains of SOS-R2. 
NTR over-expressing strains of SOS-R2 were grown and challenged with PR-104A (at the indicated concentrations) for 3 h prior to analysis of SOS activity. Data is the average ± 1 
SEM of 4 independent assays
1
3
3
 
Table 5.4. IC50s of PR-104A in NTR over-expressing strains of SOS-R2. 
IC50 values were calculated from growth measurements taken after 4 h challenge with increasing concentrations of PR-104A. 
NTR IC50 (µM) Rank SOS rank
a
 NTR IC50 (µM) Rank SOS rank NTR IC50 (µM) Rank SOS rank 
NfsA (E.c) 292 5 5 NfsB (V.v) 496 27 13 YwrO (B.s) 492 26 35 
NfsA (S.t) 295 6 1 2432 (P.p) 407 17 20 YwrO (L.i) 539 39 37 
NfsA (C.k) 290 3 2 NfsB (E.s) 520 37 17 YwrO (V.f) 501 30 45 
NfsA (K.p) 378 11 6 FraseI (V.f) 511 33 25 YieF (E.c) 496 28 44 
NfsA (E.s) 384 12 15 NfsB (V.h) 516 35 28 1204 (P.a) 808 46 43 
NfsA (V.f) 529 38 16 YfkO (B.s) 480 25 27 MdaB (E.c) 205 1 8 
NfsA (V.v) 471 24 14 YdgI (B.s) 334 9 7 MdaB (P.s) 385 13 34 
Frp (V.h) 497 29 12 5190 (P.a) 601 44 24 WrbA (E.c) 517 36 39 
NfrA (B.s) 315 7 4 AzoR (E.c) 419 19 29 WrbA (P.s) 346 10 30 
NfsA (L.i) 511 32 9 AzoR (S.t) 263 2 21 YdjA (E.c) 544 40 47 
EcD (P.p) 433 20 10 AzoR (V.v) 388 14 31 YdjA (K.p) 588 43 40 
YcnD (B.s) 291 4 3 4538 (P.p) 449 21 26 3720 (P.p) 514 34 38 
NfsB (E.c) 418 18 19 NemA (E.c) 941 48 33 4975 (P.a) 400 16 23 
NfsB (C.k) 502 31 18 NemA (S.t) 927 47 46 YcdI (E.c) 321 8 42 
NfsB (S.t) 465 23 22 NemA (K.p) 585 42 48 YcdI (K.p) 390 15 32 
NfsB (K.p) 566 41 11 NemA (V.v) 456 22 36 Empty 666 45 41 
aSOS rankings are taken from 20 µM challenge data 
 
1
3
4
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Figures 5.9A & B. Logarithmic correlations between SOS assay results and IC50s for PR-104A-
challenged NTR over-expressing strains of SOS-R2. 
Data for SOS assay results were taken from Figure 5.8. Data for IC50s were taken from Table 5.4. (A) All 
NTRs tested. (B) Only NfsA and NfsB-family enzymes. 
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 5.2.4.3. Identification of PR-104A reduction products 
 
PR-104A, like CB1954, contains two nitro groups available for reduction (the para and 
ortho nitro groups, relative to the mustard nitrogen). Unlike CB1954, however, only 
reduction of the para nitro group yields a toxic derivative. Reduction of the ortho nitro 
group is accompanied by non-enzymatic intramolecular alkylation and cyclisation to 
form a non-toxic tetrahydroquinoxaline product (Product Y; see Figure 5.10) (57; 331).  
 
Figure 5.10. Different routes of reduction of PR-104A. 
Nitroreduction of PR-104A can occur via either the para nitro group, to form the DNA alkylating 
hydroxylamine PR-104H, or the ortho nitro group to form the unstable hydroxylamine X, which 
subsequently undergoes spontaneous intramolecular alkylation and cyclisation to form the non-toxic 
tetrahydroquinoxaline product Y. Figure adapted from Paterson et al. (57). 
 
In order to confirm that NTR-mediated reduction of PR-104A was occurring via the 
desired para nitro group pathway, reaction products obtained from incubation of 
purified enzymes, co-substrate and prodrug were analysed by HPLC-MS.  
 All enzymes tested in this manner were able to readily reduce PR-104A to 
HPLC-detectable metabolites (listed in final column of Table 5.5). No reduction 
products were observed in the absence of enzyme (see Figure 5.11E). Furthermore, all 
enzymes, with the exception of NemA (E.c), solely reduced the para-nitro group, as 
was demonstrated by both identical retention times (~13.8 min) of the major reaction 
metabolite with that of the synthetic pure compound (as exemplified by NfsA (E.c); see 
Figures 5.11A and F), and by mass spectrometry (primary species m/z = 485 and 487, 
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bromine isotope pattern; PR-104H molecular mass = 484 see Figure 5.11B). In contrast, 
reaction products formed by NemA (E.c) created no chromotographic peak 
characteristic of para-nitroreduction (including the hydroxylamine, amine and all minor 
electrophilic displacement products; see Paterson et al. (57) for details). Instead, a single 
peak (with low absorbance at 254 nm) was observed at around 9 min retention time (see 
Figure 5.11C). Mass spectrometry indicated a compound with a molecular mass of 388 
and a bromine isotope pattern (see Figure 5.11D) - properties matched only by the 
ortho-nitro group reduction and ring-closed product Y (see Figure 5.10), among all 
known products of PR-104A metabolism (Dianne Ferry, personal communication). 
Therefore it is likely that NemA (E.c) reduces solely the ortho-nitro group of PR-104A, 
while all other NTRs tested reduce the para-nitro group.  
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Figures 5.11A-F. HPLC and MS analysis of products of NTR-catalysed reduction of PR-104A. 
Reactions containing PR-104A (200 µM), preferred co-substrate (1 mM) and purified His6-tagged NTR 
(0.5-2 µM) were set up and incubated at room temperature for 10-30 min prior to chromatographic 
separation. (A) Chromatogram of NfsA (E.c)-mediated PR-104A reduction. (B) Mass spectrum of major 
metabolite, both with and without sodium adducts, identified in (A) at retention time of ~13.8 min (PR-
104H). (C) Chromatogram of NemA (E.c)-mediated PR-104A reduction. (D) Mass spectrum of major 
metabolite identified in (C) at ~9 min retention time. (E) Chromatogram of reaction products following 
incubation of substrates with inactivated (boiled) enzyme. (F) Chromatogram of synthetic PR-104A 
(parental), PR-104H (hydroxylamine) and PR-104M (amine) chemical species (1.5 µM). No authentic 
standards were available for ortho nitro group reduction products. Absorbance for all eluates was 
monitored at 254 nm. The first 5 minutes are omitted from each chromatogram for clarity (NAD(P)H 
species eluted during this retention time).  
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 5.2.4.4. In vitro kinetics of purified enzymes  
 
Assessment of reduction kinetics of PR-104A by purified His6-tagged enzymes was 
carried out in a similar manner to CB1954. Identification of a wavelength and extinction 
coefficient at which reduction could be monitored was achieved by comparing the 
absorption spectrum (from 330 to 550 nm) of the parental compound to the reduced 
para hydroxyamino derivative; the latter being generated by incubation of PR-104A 
with purified NfsA (E.c) protein and NADPH co-substrate. Excess NADPH in this 
reaction was removed automatically using the intrinsic low-level NADPH-oxidase 
activity of NfsA (E.c), by letting the reaction run until no further decrease in absorbance 
at 340 nm was evident. PR-104A displayed an absorbance spectrum with a single peak 
around 350 nm (see Figure 5.12A), which was lost upon reduction of the para nitro 
group to the hydroxylamine (PR-104H; see Figure 5.12C). Although not at its 
absorbance maximum, PR-104A reduction in this study was monitored as loss in 
absorbance at 400 nm (ε400 nm = 6,000 M
-1
cm
-1
), so as to minimize the impact and 
overlap of absorbance imparted by the nicotinamide co-substrates and their oxidation 
products (see Figure 5.12B). 
The kinetic parameters of candidate NTRs with PR-104A are listed in Table 5.5. 
NTR-family specific patterns are evident, including kcat/Km values of NfsA-family 
enzymes being on average almost 5-times higher than those of NfsB-family enzymes. 
As with CB1954, this difference appeared to be related largely to substrate affinity, 
based on substantially larger Km values for NfsB-family enzymes relative to NfsA-
family enzymes (mean Kms of 1770 µM compared to 88 µM, respectively). A major 
exception to this relationship was that of YdgI (B.s), whose kcat/Km was on a par with 
many NfsA-family enzymes. As previously, purified NfsA (S.t) displayed very low 
reductase activity with PR-104A as substrate. As this was most likely due to issues with 
the purified enzyme sample and not an intrinsic inability to reduce the prodrug (based 
on E. coli in vivo results), kinetic results for this enzyme were disregarded in all 
subsequent correlations and comparative analyses.  
 No kinetic data was extracted from NemA (E.c) due to its preference in 
reduction of the ortho nitro group, the product of which displays different 
spectrophotometric properties to PR-104H, and is unsuitable for anti-cancer therapy.  
 Overall, positive but very weak linear correlations were generated from 
comparisons of kcat/Km values and SOS data across all NTRs tested with PR-104A (R
2
 = 
0.247 and 0.242; see Figure 5.13A). Rationale for this poor correlation appeared to be 
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largely related to NfsA-family enzymes, as a distinct lack of correlation was observed 
when data for only these enzymes were compared (R
2
 <0.01; data not shown). In 
contrast, a vast improvement in the degree of correlation between SOS and kinetic 
results was observed when only NfsB-family enzymes were considered (R
2
 = 0.873 and 
0.859; see Figure 5.13B).  
 
 
 
 
Figures 5.12A-C. Calculation of extinction coefficient for spectrophotometric monitoring of PR-
104A reduction. 
Absorption spectra of (A) 100 µM PR-104A, (B) 100 µM NADPH and (C) 100 µM reduced PR-104A 
between 325 and 500 nm wavelength. PR-104A reduction was achieved by incubation of 100 µM PR-
104A, 400 µM NADPH and ~200 nM NfsA (E.c) at room temperature for ~10 min. The peak at 340 nm 
in (C) corresponds to excess NADPH in the reaction. Kinetic analysis of PR-104A reduction was 
monitored at 400 nm due to no interference by NAD(P)H or its oxidation products at this wavelength. 
The extinction coefficient for PR-104A at 400 nm was calculated to be 6,000 M-1 cm-1 (abs400nm M
-1 cm-1 
of PR-104A – abs400nm M
-1 cm-1 of reduced PR-104A), rounded up to the nearest 1,000 M-1 cm-1.  
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Table 5.5. Kinetic parameters for the reduction of PR-104A by purified His6-
tagged NTRs  
NTR Co-subs. kcat (s
-1
) Km (µM) kcat/Km (M
-1
 s
-1
) NO2 pref.
a
 
NfsA (E.c) NADPH 12.1 ± 0.51 101 ± 11  119,900 ± 14,000  para 
NfsA (S.t) NADPH <1 ND
b
 NA
c
 para 
NfsA (C.k) NADPH 17.1 ± 0.92 155 ± 19 110,300 ± 14,600  NT
d
 
NfsA (K.p) NADPH 29.5 ± 1.9 245 ± 30 120,400 ± 16,700  para 
NfsA (E.s) NADPH 22.0 ± 1.3 99.5 ± 19 220,800 ± 44,600  NT 
NfsA (V.f) NADPH 6.2 ± 0.18 18.8 ± 2.0 329,800 ± 36,400  NT 
NfsA (V.v) NADPH 24.4 ± 0.73 77.7 ± 7.8 314,000 ± 32,900  para 
Frp (V.h) NADPH 17.6 ± 0.35 61.3 ± 4.3 287,800 ± 21,000  para 
NfrA (B.s) NADPH 10.1 ± 0.39 25.5 ± 3.8 397,600 ± 61,200  para 
YcnD (B.s) NADPH 5.15 ± 0.13 10.8 ± 1.1 479,100 ± 50,500  NT 
NfsB (E.c) NADH 60 ± 23 4,490 ± 2,000 13,280 ± 7,760  para 
NfsB (C.k) NADH 34.8 ± 6.9 2,060 ± 530 16,880 ± 5,480  NT 
NfsB (K.p) NADH 90 ± 7.5 1,930 ± 210 46,610 ± 6,440  para 
NfsB (V.v) NADH 54.5 ± 3.8 541 ± 58 100,700 ± 12,900  para 
YfkO (B.s) NADPH 15.1 ± 6.8 2,537 ± 1,400 5,970 ± 4,280   para 
YdgI (B.s) NADH 33.7 ± 1.5 244 ± 26 137,900 ± 15,800  para 
MdaB (E.c) NADPH 0.14 ± 0.09 4,290 ± 3,000 33 ± 31  NT 
AzoR (E.c) NADPH 0.076 ± 0.017 1,320 ± 430 57 ± 23  NT 
NemA (E.c) NADPH ND ND ND ortho 
aPreferred nitro group (para or ortho) of PR-104A reduced by each enzyme, as determined by HPLC (see 
section 5.4.2.3). 
bND: not detected 
cNA: not applicable 
d
NT: not tested 
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Figures 5.13A & B. Linear correlation between SOS assay results and purified NTR catalytic 
efficiency, PR-104A as substrate. 
Data for SOS assay results were taken from Figure 5.8. Data for kinetic efficiencies (as measured by 
kcat/Km) were taken from Table 5.5. (A) All enzymes tested. Only 20 µM SOS data is used for clarity. 
Enzyme families are colour coded for reference. (B) Only NfsB-family enzymes, with both 10 and 20 µM 
SOS data shown. All correlations are statistically significant (p<0.01). 
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5.2.5. Activity screening of human AKR1C3 and select core library NTRs 
with mononitrobenzamide mustard prodrugs 
 
A significant disadvantage of PR-104A (as well as several other DNBM prodrugs we 
have tested; results not shown) is its ability to act as a substrate for the aerobic (human) 
reductase AKR1C3 (62). As previously mentioned, such activity is undesirable for both 
hypoxia-selective and gene-therapy approaches for the treatment of human tumours, as 
it is implicated in off-target toxicity and therefore lower therapeutic efficiency.   
 Structural analogues of DNBMs are currently being investigated in order to 
identify compounds that demonstrate diminished AKR1C3 activity (Adam Paterson, 
personal communication). One promising class of compounds is the 
mononitrobenzamide mustards (MNBMs), which may be less efficient AKR1C3 
substrates than their DNBM analogues by virtue of their lower reduction potentials 
(154) and/or diminished affinity for the AKR1C3 active site (Adam Patterson, personal 
communication). 
In this section, the catalytic efficiency of AKR1C3 towards a panel of MNBM 
and DNBM prodrugs was experimentally investigated. The open reading frame 
encoding AKR1C3 was firstly PCR amplified from the vector pF527:AKR1C3 (62) 
using restriction site-containing AKR1C3-specific primers and cloned into pET28a(+). 
The enzyme was then over-expressed from pET28a(+) in E. coli BL21, purified to 
homogeneity and kinetically tested with a selection of DNBM and MNBM prodrugs 
(shown in Figure 5.14). Results are shown in Figure 5.15 and kinetic parameters listed 
in Table 5.6. In agreement with theoretical expectations, AKR1C3 was both less 
catalytically active and had lower substrate affinity for the MNBM prodrugs relative to 
the DNBMs, with overall catalytic efficiencies for the former being 5-7 fold lower than 
the latter.  
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Figure 5.14. Structures of mono- and dinitrobenzamide mustard prodrugs tested in this section. 
 
Figure 5.15. Kinetic activity of AKR1C3 with mono- and dinitrobenzamide prodrugs. 
Plots of catalytic rate of reduction (initial rate, v / enzyme concentration, [E]) versus substrate 
concentration for purified, His6-tagged recombinant human AKR1C3 with two examples each of DNBM 
(red) and MNBM (green) prodrugs. Each data point is the average ± 1 SD of at least 4 individual replicate 
assays. Extinction coefficients used for monitoring reduction of prodrugs are as follows: SN 27686: ε400 nm 
= 7,000 M
-1
 cm
-1; SN 30444: ε400 nm = 7,000 M
-1
 cm
-1; SN 29176: ε400 nm = 4,000 M
-1
 cm
-1
. 
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Table 5.6. Kinetic parameters for the reduction of selected DNBM and MNBM 
prodrugs with purified his6-tagged AKR1C3.  
Substrate
a
 kcat (s
-1
) Km (µM) kcat/Km (M
-1
 s
-1
) 
PR-104A 0.114 ± 0.007  73.6 ± 13 1,540 ± 288 
SN 27686 0.162 ± 0.007 128 ± 18 1,270 ± 187 
SN 30444 0.059 ± 0.009 241 ± 93 244 ± 101 
SN 29716 0.092 ± 0.02 451 ± 160 204 ± 84 
aNADPH (0.25 mM) was used as co-substrate. 
 
 Next, the ability of MNBMs to act as substrates for bacterial NTRs, and 
therefore as potential prodrugs for GDEPT strategies, was assessed by SOS assay using 
the prototypical MNBM SN 30444. Due to limited prodrug stocks, only a small 
selection of NTRs were able to be tested; however, results (shown in Figure 5.16) 
clearly demonstrate that this MNBM can be reductively activated by both NfsA and 
NfsB-family enzymes, although not by AzoR (E.c) or NemA (E.c).  
 
 
Figure 5.16. SN 30444-induced SOS responses from NTR over-expressing strains of SOS-R2. 
NTR over-expressing strains of SOS-R2 were grown and challenged with the MNBM prodrug SN 30444 
(10 µ) for 3 h prior to analysis of SOS activity. Data is the average ± 1 SEM of 3 independent assays. 
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5.2.6. SOS screening of the core library with alternative nitroaromatic 
prodrugs 
 
Many different classes of nitroaromatic prodrugs have been developed for clinical 
application to date, based on a wide variety of core chemical structures, including 
nitroimidazoles, nitrochloromethylbenzindolines  and nitrobenzamides, among others 
(37; 44; 57; 332). This section has so far only dealt with those belonging to the latter 
family, yet the diversity of compounds available suggests that NTR specificity may 
differ considerably between different chemical classes. Furthermore, the majority of 
nitroaromatic compounds developed to date have been for hypoxia activation therapy 
and therefore their application in GDEPT has been largely unexplored (44; 51; 332). 
Many of these compounds display distinct properties, such as improved hypoxia 
selectivity (e.g. the nitrochloromethylbenzindolines; (332)) or radio-sensitising 
properties (nitroimidazoles; (40)) that could render them more attractive than the 
nitrobenzamides in certain clinical applications. Therefore it would be beneficial to test 
the compatibility of such nitroaromatic prodrugs for nitroreduction by diverse bacterial 
NTRs, in order to assess their utility in GDEPT strategies. To this end, the SOS assay 
was once again used to evaluate the NTR specificity of two alternative nitroaromatic 
prodrugs, the 5-NI MTZ and the 2-NI RB 6145. 
 
 5.2.6.1. MTZ 
 
MTZ has already been introduced in this study (see Chapter 4), where it was shown to 
be selectively reduced by certain members of a small panel of NTRs, the products of 
which were detectable by SOS assay. Screening this compound against the full core 
library therefore allowed greater understanding of NTR specificity.  
Results of SOS assay screening are presented in Figure 5.17. Both NfsA- and 
NfsB-family enzymes readily reduced MTZ; however no NTR from any of the other 
represented families elicited SOS responses above background levels. Even within the 
NfsA and NfsB families, a wide variety of SOS responses was elicited, ranging from 
less than 2-fold, to 7-fold above unchallenged levels at the lowest concentration of MTZ 
tested (1.25 µM). Mean responses between NfsA and NfsB families, at both MTZ 
concentrations tested, did not significantly differ (e.g. mean SOS fold inductions of 5.47 
for the NfsA family and 4.26 for the NfsB family, for 2.5 µM MTZ challenge data; 
p>0.05; t-test), demonstrating broad acceptor specificity for this compound. The highest 
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overall responses were obtained from NfsB (V.h), although these did not differ 
considerably, especially at the lower concentration tested, from those of YcnD (B.s) and 
NfsA (V.f).  
 
5.2.6.2. RB 6145 
 
RB 6145 is a hypoxia-activated nitroimidazole prodrug that has previously been 
investigated as a sole agent for use in clinical anti-cancer therapy (43). No reports exist 
however (to the best of our knowledge) on the ability of this prodrug to act as a 
substrate for bacterial NTRs.  
 Results from SOS assays employing RB 6145 and the core library of NTRs 
demonstrated that NfsA-family enzymes were (on average) the most active RB 6145-
reductases (e.g. mean SOS fold inductions of 5.5 for the NfsA family and 3.0 for the 
NfsB family, for 5 µM RB 6145 challenge data; see Figure 5.18). In particular, NfsA 
(S.t) and Frp (V.h) induced SOS responses substantially higher than any other over-
expressed NTR. With a couple of exceptions (WrbA (E.c) and YfkO (B.s), 5 µM RB 
6145), no other NTR induced an SOS response more than 1.5-fold that of the empty 
vector control.   
 
 
 
 Figure 5.17. MTZ-induced SOS responses from NTR over-expressing strains of SOS-R2. 
NTR over-expressing strains of SOS-R2 were grown and challenged with MTZ (at the indicated concentrations) for 3 h prior to analysis of SOS activity. Data is the average ± 1 
SEM of 4 independent assays. 
1
4
8
 
 Figure 5.18. RB 6145-induced SOS responses from NTR over-expressing strains of SOS-R2. 
NTR over-expressing strains of SOS-R2 were grown and challenged with RB 6145 (at the indicated concentrations) for 3 h prior to analysis of SOS activity. Data is the average ± 1 
SEM of 3 independent assays 
1
4
9
 
  
150
5.3. Discussion 
 
The ultimate aim of this section was to screen multiple, phylogenetically diverse NTRs 
for their ability to reduce a variety of nitroaromatic prodrugs, in order to identify lead 
candidate enzymes that would form the basis of further improvement work via enzyme 
engineering and directed evolution. 
 With CB1954 as substrate, correlations between results from the different assays 
employed were generally strong (R
2
 >0.7), with the overall most efficient enzyme 
across all screens being the NfsA-family member YcnD (B.s). Other NfsA-family 
members, including NfsA (V.f), NfsA (V.v) and Frp (V.h) also featured within the top 
six of each screen, demonstrating a clear NfsA family-superiority towards CB1954, 
consistent with results from Chapter 3 and elsewhere (189). It is noteworthy that these 
latter three enzymes are all from Vibrio species and consequently share close protein 
sequence homology with one another (>80 % sequence similarity). This therefore 
suggests a structural basis for the improvement in CB1954 activity over, for example, 
NTRs with closer homology to NfsA (E.c) (e.g. NfsA (S.t), NfsA (C.k), NfsA (K.p); see 
Figure 5.2).  
 NfsA family enzymes also induced the highest SOS response and were the most 
catalytically active (highest kcat/Km), on average, towards the DNBM PR-104A. 
However, in contrast to CB1954, no significant level of correlation existed between 
SOS assay results and kcat/Km values of the NfsA-family members with PR-104A as 
substrate (R
2
 <0.01), leading to greater ambiguity in overall enzyme rankings. 
Furthermore, SOS assay results did not correlate with purified enzyme kcat values (R
2
 < 
0.01); positive correlations have previously been observed between toxicity of several 
DNBMs in an NfsB (E.c) over-expressing cancer cell line and the kcat value of the 
purified enzyme with each substrate (151). In the absence of additional mammalian cell 
PR-104A toxicity data for these enzymes, it is difficult to ascertain which set of results 
(SOS or kinetics) to be the more globally meaningful. Although IC50 values for each 
over-expressed NfsA-family NTR correlated more closely with SOS results than 
kinetics (data not shown), this was likely due to the shared E. coli in vivo conditions 
employed for each assay. Nevertheless, the ability of each NfsA-family NTR to induce 
strong, dose-dependent SOS responses with PR-104A as substrate indicates that 
discrepancies between SOS results and kinetics between NfsA-family members should 
not impact on the ability to use the SOS assay for screening of improved mutants of a 
specific NfsA-family enzyme. 
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Unlike the NfsA family, NfsB-family enzymes displayed a strong correlation 
between SOS and kinetics results with both CB1954 and PR-104A as substrates. 
Although ultimately less catalytically efficient in terms of kcat/Km than their NfsA 
counterparts, NfsB-like enzymes may be preferable as therapeutic proteins for gene 
therapy, depending on the administered prodrug and target cell type. For example, 
despite a lack of mammalian cell data in this chapter, results from Chapter 3 indicate 
that NfsB (E.c) performs better than NfsA (E.c) with CB1954 in the colon carcinoma 
cell line HCT-116. Furthermore, despite substantially lower in vitro purified enzyme 
activity measurements, NfsB-family enzymes elicited SOS responses with CB1954 and 
PR-104A only marginally lower than those of NfsA-family enzymes; these observations 
suggest that factors independent of catalytic ability may affect enzyme activity in vivo 
(for example co-substrate availability, or the reduction pathway taken), as has been 
discussed previously. Whatever the bases of these observations are, results here have 
demonstrated that NfsB-family enzymes that are superior to the well characterised E. 
coli representative exist, and could therefore provide improved alternatives for clinical 
use. Of particular note is NfsB (V.v), which produced the highest SOS response 
inductions out of all NfsB enzymes for CB1954 (at a level comparable to many NfsA 
enzymes) and also ranked among the highest for both PR-104A and MTZ activity by 
this same assay. Furthermore these results were validated at the purified enzyme level, 
illustrating the clear catalytic superiority of this enzyme among the NfsB-family 
members. The relatively high sequence homology of this enzyme to more well 
characterised enzymes (such as NfsB (E.c); 61% identity, 75 % similarity), for which 
multiple crystal structures and biochemically characterised mutants are available, could 
also facilitate investigations into specific residues involved in prodrug recognition and 
catalysis; this being fundamental knowledge required for any attempts at further 
improvement of enzyme activity through rational protein engineering techniques. 
 Another interesting observation from the results of this chapter was the 
alternative pathway taken by NemA (E.c) in the reduction of PR-104A. While all other 
enzymes clearly reduced the para nitro group of this compound to the hydroxylamine, 
HPLC-MS tentatively identified the major metabolite of NemA (E.c)-mediated 
reduction as being the tetrahydroquinoxaline product Y (see Figure 5.10; m/z = 388, 
positive scan mode), which is known to form spontaneously from the ortho-
nitroreduction product of DNBM prodrugs via intramolecular alkylation and cyclisation 
(331). Furthermore, SOS assay and IC50 results with NemA (E.c) were roughly 
consistent with the formation of a product less toxic than both the para hydroxylamine 
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and the parental compound itself (lower SOS response induction and higher IC50 
relative to the empty vector control; see Figure 5.8 and Table 5.4). As it has been well 
established that the tetrahydroquinoxaline is of a very low cytotoxic potency by virtue 
of the loss of bifunctionality, these results support an ortho-nitroreduction mechanism 
of action for NemA (E.c). This is of interest as no specific enzyme able to uniquely 
reduce the ortho nitro group of a DNBM has previously been identified, and suggests a 
novel substrate-binding and catalytic mechanism for this enzyme. Furthermore, 
although ultimately ineffective as a PR-104A activating enzyme for tumour cell 
targeting, its ability to deactivate this prodrug, and potentially other DNBMs, could 
render it useful in gene therapy approaches where protection from prodrug activation is 
the desired outcome. In this way, NemA (E.c) could be over-expressed in certain 
healthy non-malignant tissue types that are particularly prone to off-target toxicity from 
alkylating agents (for example the bone marrow and liver), therefore enhancing 
resistance of these tissues to the prodrug. Such strategies have previously been trialled 
in vitro with moderate success, for example through the expression of the multi-drug 
resistance gene MDR-1 in hematopoietic stem cells (333), therefore demonstrating the 
feasibility of such an approach. 
 Other than the nitrobenzamide prodrugs already discussed, this study also 
investigated the ability of NTRs to activate two nitroimidazole prodrugs: MTZ and RB 
6145. The first, MTZ, is most commonly employed as an antibiotic for the treatment of 
anaerobic pathogens; however MTZ has also been studied in the context of targeted cell 
ablation in developmental studies, in combination with NfsB (E.c) as an activating 
enzyme. MTZ is an ideal prodrug in this context due to its distinct lack of bystander 
effect (54; 114), permitting highly specific targeted cell killing. Furthermore, lack of 
bystander-mediated cell killing has also been proposed as an attractive property for 
specific ablation of tumour vasculature in the treatment of cancer (334). Results shown 
here indicate that NfsB (E.c), although a proven effective MTZ reducing enzyme, is not 
the most efficient NTR available. In fact, NfsB (E.c), along with the very close relative 
NfsB (C.k), induced the lowest SOS activity out of all NfsA and NfsB-family enzymes 
tested. Therefore significant improvements in MTZ-based gene therapy could 
potentially be achieved through the use of an alternative NTR, such as NfsB (V.h) or 
YcnD (B.s).  
The second prodrug, RB 6145, is a 2-NI, which along with the structurally and 
mechanistically similar RSU1069, has been extensively studied as a hypoxia-activated 
cytotoxin (37; 39; 43). Although ultimately ineffective as anti-cancer agents due to their 
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high systemic cytotoxicity, their structural relatedness to another class of compounds, 
the 2-NI positron emission tomography (PET) imaging agents, could render them useful 
as model drugs for the study of NTR-mediated activation of the latter. 2-NI PET 
imaging agents, such as F-MISO (335) and EF5 (336) are hypoxia-selective compounds 
that once reduced, are retained intracellularly due to reactivity with cellular 
macromolecules. In this way their mechanism of action is akin to the hypoxia-activated 
prodrugs described previously, except that they lack DNA alkylative activity, and 
therefore toxicity. They can however be radio-labelled via their incorporated fluorine 
groups, enabling PET imaging of their presence and location within a patient, once 
reduced, without the requirement of invasive procedures (337). The ability of these 
compounds to also undergo NTR-mediated reduction, as demonstrated here, could 
permit their use as imaging agents to assess the temporal and spatial aspects of 
transgene expression, in GDEPT procedures, prior to prodrug administration. However, 
their lack of DNA-reactivity renders them ineffective as substrates for the SOS assay, or 
any toxicity-based screen. As results described in this chapter show that RB 6145 
activation can be effectively monitored by way of the SOS assay, this compound could 
be used as a replacement molecule, in order to employ the SOS assay as a screening 
procedure, to indirectly assess NTR-mediated reduction of 2-NI imaging agents. 
Validation of this approach is currently ongoing in the Ackerley laboratory.  
 
Figure 5.19. Structures of RB 6145 and selected 2-NI imaging agents.  
 
 In summary, NfsA-family enzymes were found to be the most active NTRs with 
all prodrugs tested in this section, across all screens employed. More specifically, YcnD 
(B.s) was the overall superior enzyme with CB1954 as a substrate, followed by NfsA 
(V.f), (V.v) and Frp (V.h), while it was less clear as to the identity of the lead enzyme 
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with PR-104A as substrate. However, YcnD (B.s) had the highest kcat/Km and produced 
a substantial SOS response with this prodrug, suggesting this enzyme as a lead 
candidate for further mutagenesis and enzyme engineering studies. Furthermore, this 
enzyme displayed high SOS activity with the 5-NI nitroaromatic prodrug MTZ and 
moderate SOS activity with the 2-NI RB 6145. Alternatively, NfsA (S.t), which induced 
the highest SOS response for PR-104A and RB 6145 could equally be considered a lead 
NTR candidate, despite an inability to extract active purified enzyme of this NTR.  
  
155 
Chapter 6: Improving the PR-104A-reductase activity of 
Bacillus subtilis YcnD: Saturation mutagenesis of the active 
site. 
 
6.1. Introduction 
 
The previous chapter characterised the nitroaromatic prodrug reductase activity of a 
variety of bacterial NTRs. In this chapter, one of the most active of these NTRs, YcnD 
(B.s), was selected for further enhancement of PR-104A reductase activity through site-
directed mutagenesis of the enzyme active site. Protein mutagenesis, when coupled with 
an effective screening or selection process, is a powerful tool for enhancing specific 
properties of an enzyme, such as catalytic efficiency. This has previously been shown to 
be an effective means of maximising rates of prodrug activation by GDEPT enzymes 
(156; 213; 218; 223; 338). The only prior mutagenesis work carried out for NTR 
GDEPT has focused on NfsB (E.c) with CB1954 as substrate (218; 221; 225); this 
chapter therefore presents the first reported case of mutagenesis of an NfsA-family 
enzyme towards improved activity with a DNBM prodrug. 
YcnD (B.s) was chosen for mutagenesis in this chapter due to its high level of 
native reductase activity towards a variety of nitroaromatic prodrugs (including 
CB1954, PR-104A, MTZ and RB 6145, as determined by SOS assay and in vitro 
purified enzyme kinetics). PR-104A was selected as the substrate towards which 
enzyme activity was to be screened and enhanced due to its greater clinical appeal 
(increased potency, hypoxia activation, strong bystander effect) than CB1954 and many 
other nitroaromatic anticancer prodrugs. Lastly, site-directed mutagenesis of active site 
residues was used to create enzyme variants, as opposed to other commonly used 
methods of enzyme engineering such as full sequence random mutagenesis or DNA 
shuffling, for several reasons: a) previous work has demonstrated site-directed 
mutagenesis to be effective in generating mutant NfsB (E.c) variants with improved 
CB1954-reductase activity (218; 225); b) a crystal structure in complex with the flavin 
co-factor was available for YcnD (B.s) (194) allowing insight into active site 
architecture; and c), the lower number of sites targeted with SDM techniques compared 
to full gene sequence mutagenesis is compatible with the lacZ SOS screen developed in 
this work, which is more amenable to “medium” than high throughput screening 
applications. 
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 In summary, this chapter investigated the effects of individually mutating 10 
active site residues of YcnD (B.s), identified by structural analysis, on the PR-104A 
reductase activity of this enzyme. Double site mutants, created through pairwise 
combination of the most active single mutations, as identified by SOS assay, were 
subsequently tested for further PR-104A activity improvement by SOS assay. A 
selection of the overall most active YcnD (B.s) variants were finally subjected to IC50 
and in vitro kinetic analysis with PR-104A and SOS response induction with alternative 
nitroaromatic prodrugs. 
 
6.2. Results 
 
 6.2.1. Generation of a positive selection vector 
 
PCR-based mutagenesis techniques, such as the one used in this chapter, typically 
generate a pool of variant gene sequences in a single PCR reaction, by substituting the 
codon of interest with a primer-encoded degenerate oligonucleotide sequence. This pool 
of gene variants is then cloned into the desired expression vector, transformed into the 
host organism, and a suitable number of colonies picked and screened to ensure 
coverage of all possible mutations. When using restriction enzyme and ligase-based 
cloning techniques it is often the case that a proportion of transformants carry vectors 
that either have no insert (due to, for example, degradation of restriction enzyme-
generated „sticky‟ DNA ends by contaminating exonucleases, followed by re-annealing 
of blunt ended DNA (339)) or that are the parental plasmid (due to insufficient 
restriction digestion prior to insert ligation). To account for the likely presence of these 
undesirable products, library sizes need to be increased, greatly enhancing workload and 
substrate usage during screening. One way to overcome this limitation is to use a 
positive-selection vector, whereby successful (in frame) cloning of a desired gene 
confers a selectable phenotype (for example antibiotic resistance) to the host organism. 
The feasibility of this type of cloning has been demonstrated in several publications 
(339-342), however many of the positive selection vectors described in these examples 
are limited in their scope of use due to either the requirement of unique restriction 
enzymes (340; 341), dependence on a specific selectable marker (340), or generation of 
translational fusions between the cloned gene product and selectable marker (342). The 
first aim of this chapter was therefore to develop and test a positive selection vector that 
was compatible with the cloning methods used in the lab and that also permitted 
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inducible expression of inserted genes, enabling its use in SOS assays and other activity 
screens.  
 The resultant plasmid, pUCXKT (short for pUCX Kan
R
-Truncated; for full map 
and scheme outlining its use see Figures 2.3 and 6.1), was generated by the insertion of 
a truncated kanamycin resistance (kan
R
) gene, missing the initial (N-terminal) 4 codons, 
between the SalI and HindIII restriction sites of pUCX. The lack of a start (ATG) 
codon, in addition to two stop codons introduced (in-frame) between the ATG codon of 
the pUCX NdeI site and the start of the truncated kan
R
 gene prevented expression of this 
gene in host cells carrying this vector. A SacI site was also introduced directly upstream 
of and in-frame with the kan
R
 gene, in effect constituting the 3
rd
 and 4
th
 codons of this 
gene. Plating tests indicated that this plasmid did not confer kanamycin resistance on 
host cells (SOS-R2), based on the inability of transformants to grow on LB agar plates 
containing 50 µg mL
-1
 kanamycin (results not shown). 
 Kanamycin resistance, and therefore positive selection, is provided by this 
plasmid only in the event of successful, in-frame cloning of a gene of insert, between a 
restriction site of the pUCX MCS (NdeI was used in all instances in this study) and the 
SacI site of the kan
R
 gene. Initial PCR amplification of this gene requires the use of a 
unique reverse primer (pUCXSacIRv) that contains a SacI site followed directly by the 
first 2 codons of the kan
R
 gene, as well as a „linker‟ region containing a ribosome 
binding site. The resultant plasmid, termed pUCXKG (pUCX Kan
R
 Gained) therefore 
contains the desired insert (NTR gene) directly downstream of the native pUCX 
promoter region, followed by a linker region containing a second ribosome binding site 
directly upstream of the reconstituted kan
R
 gene. Both genes are therefore transcribed as 
a single operon; however translation of each gene is disengaged by virtue of the 
individual ribosome binding sites for each gene. The reconstituted kan
R
 gene contains 
the SacI sequence (GAGCTC) in place of the native 3
rd
 and 4
th
 codons (sequence of 
GAACAA), therefore inducing a single amino acid change at position 4 from a 
glutamine to a leucine (the sequence change at codon three, GAG to GAA, is silent as 
both codons encode glutamic acid). Nevertheless, both agar plating methods (as 
described above) and growth in liquid media demonstrated that this plasmid conferred 
kanamycin (at 50 µg mL
-1
) resistance to transformed SOS-R2 host strains (results not 
shown), indicating that the kan
R
 gene was positively expressed from this plasmid and 
that the Q4L amino acid substitution had little effect on Kan
R
 enzyme activity.  
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Figure 6.1. Overview of cloning mechanism of pUCXKT and PUCXKG.  
See text (sections 2.18 and 6.2.1) for details. 
 
The cloning efficiencies of pUCXKT and pUCXKG were tested by transforming 
E. coli SOS-R2 with either NdeI-SacI digested pUCXKT that had been treated just with 
ligase, or with ligase plus NdeI-SacI digested PCR product that had been generated 
using the pUCXSacIRv primer. Transformation mixes were plated onto solid media 
containing ampicillin and kanamycin. With one exception, in this control experiment 
and all subsequent cloning experiments with this system, transformation of NdeI-SacI 
digested pUCXKT that was re-ligated without insert yielded no colonies on kanamycin-
containing solid media (results not shown). The single case recorded to date of Kan
R
 
colonies appearing after this treatment was found (upon sequence confirmation) to be 
due to ligation of a NdeI-SacI recognition site-flanked 105 bp region of the E. coli F 
plasmid into the respective site of pUCXKT (results not shown). This therefore did not 
constitute a case of kanamycin resistance afforded by transformation of parental 
plasmid (pUCXKT) or through degradation and re-ligation of digested plasmid sticky 
ends, the most common causes of appearance of false positives. In contrast, 
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transformation of digested pUCXKT that was ligated with the relevant insert 
consistently yielded colonies, at high efficiency, on solid media containing ampicillin 
and kanamycin. PCR screening of a selection of these colonies yielded only bands 
corresponding to correctly sized and oriented inserts (results not shown). 
 To ensure that pUCXKG permitted expression of functional inserted genes, a 
selection of NTRs with a range of CB1954-reductase activities were cloned into this 
vector and transformed into SOS-R2. These strains were then compared to SOS-R2 
strains expressing the NTRs from pUCX for both SOS induction and recombinant 
protein expression levels following challenge with or without CB1954. To maintain 
equivalence in assay conditions between the two vectors, kanamycin was not included 
in media used for strains harbouring pUCXKG (ampicillin being sufficient to maintain 
plasmid propagation in host cells). Overall, SDS PAGE analysis demonstrated that 
native sized NTRs were expressed from pUCXKG, although expression levels were 
much lower at equimolar IPTG concentrations (results not shown). Further assay 
optimisation established that raising the IPTG concentration to 250 µM when 
expressing from pUCXKG achieved roughly equal NTR expression to that obtained 
from pUCX at 50 µM IPTG (see Figure 6.2). No visible bands corresponding to the 
kanamycin resistance gene product (29.1 kDa) encoded by pUCXKG were observed on 
SDS-PAGE gels, suggesting that translational regulation of the insert and kan
R
 gene is 
separate. 
SOS responses following CB1954 challenge were similar when NTRs were 
expressed from either pUCX or pUCXKG in SOS-R2, provided that IPTG was 
employed at the respective concentrations (50 µM for pUCX, 250 µM for pUCXKG; 
see Figure 6.3). 
Based on these results, pUCXKT was used for cloning of all mutant YcnD (B.s) 
variants in this chapter and the resulting pUCXKG plasmids used for gene expression in 
SOS and IC50 assays (250 µM IPTG in all instances). 
 
  
160
 
Figure 6.2. Relative NTR expression levels from pUCX and pUCXKG. 
SDS PAGE gel scan demonstrating expression levels of various NTRs from either pUCX (indicated by 
„WT‟) or pUCXKG (indicated by „KG‟) in SOS-R2, following the completion of an SOS assay. Strains 
harbouring pUCX constructs were induced for protein expression at 50 µM IPTG, those with pUCXKG at 
250 µM IPTG. Whole cell lysates were normalised for culture density (OD600) prior to gel loading. The 
kanamycin resistance gene product encoded on pUCXKG is unable to be distinguished in any lane 
(molecular weight is 29.1 kDa) 
 
Figure 6.3. Relative SOS response induction using either pUCX or pUCXKG for NTR over-
expression. 
Strains of SOS-R2 over-expressing NTRs from either pUCX (left side of graph) or pUCXKG (right) were 
grown and challenged with the indicated concentrations of CB1954 for 3 h prior to analysis of SOS 
activity. Strain harbouring pUCX were induced for protein expression with 50 µM IPTG; those with 
pUCXKG were induced with 250 µM IPTG. Data is the average ± 1 SEM of 3 independent assays. 
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 6.2.2. Selection of YcnD (B.s) targeted residues 
 
The availability of a crystal structure of YcnD (B.s) facilitated selection of active site 
residues for targeted mutagenesis (194); however, the absence of any data for substrate 
binding within the active site of this enzyme complicated the process of assigning roles 
to specific residues. Therefore, the YcnD (B.s) active site structure was superimposed 
onto that of the homologous enzyme Frp (V.h), of which a crystal structure in complex 
with an nicotinamide adenine dinucleotide (NAD) inhibitor has previously been solved 
(179). Although amino acid sequence similarity between these two enzymes is only 54 
%, structural homology is strong, with the root mean square deviation (a measure of 
structural similarity) of α carbon atoms across the entire sequence being 1.0 Å (194)). 
This therefore allows mapping of potential interactions of YcnD (B.s) active site 
residues with substrates by using Frp (V.h) as a model structure. Sites in YcnD (B.s) to 
be targeted were therefore chosen based on equivalent Frp (V.h) residues that formed 
hydrogen bonds with the NAD molecule, or that had potential roles in substrate and 
active site stabilisation, as previously reported for a selection of NfsA-family enzymes 
(see Figures 6.4A and B) (179; 194; 343). The YcnD (B.s) active site differed 
significantly at one region relative to Frp (V.h), around amino acids 227-233 
(corresponding to amino acids 219-225 in Frp (V.h)). In particular, four tyrosine 
residues (Y227, Y228, Y232 and Y233) extend into the active site of YcnD (B.s) that 
are not present in Frp (V.h) or any other NfsA-family enzyme structure solved to date. 
Two of these residues, Y227 and Y233, were chosen as targets based on their closer 
proximity to the assumed substrate binding site. It is noteworthy that Y233 is in the 
position corresponding to R225 of Frp (V.h), which is able to hydrogen bond with NAD 
in this enzyme. Furthermore, the equivalent residue in NfsA (E.c) has been shown to be 
important for substrate binding and catalysis with a number of nitroaromatic 
compounds, based on mutagenesis work performed in our laboratory (Dr. Janine Copp, 
personal communication). 
 In total, 10 sites in YcnD (B.s) were selected for mutagenesis. These were R15, 
I41, G65, Q67, W69, E105, R139, G140, Y227 and Y233 (displayed in Figure 6.4). 
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Figures 6.4A & B. Comparison of active site architecture between Frp (V.h) and YcnD (B.s).  
 Residues surrounding the active site of (A) Frp (V.h) and (B) YcnD (B.s) are displayed. FMN co-factors 
are coloured in orange, while the NAD molecule is coloured in blue. Positioning of the NAD molecule in 
the YcnD active site was achieved by superimposing the active site of Frp (V.h) on that of YcnD 
(therefore no hydrogen bonds are displayed between YcnD residues and the NAD molecule, due to an 
inability of the employed software to compute them). Residues targeted in this chapter are shaded in dark 
red in the YcnD structure, with the equivalent residues of Frp (V.h) shaded in dark green. Protein 
structural alignments and images were generated in Swiss-Pdb Viewer (DeepView) 
(http://www.expasy.org/spdbv) 
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6.2.3. Creation of mutant libraries and initial SOS screening 
 
Targeted residues of YcnD (B.s) were individually mutated using an overlap PCR 
protocol with primers that led to the incorporation of the degenerate oligonucleotide 
sequence NNK, where N designates any nucleotide and K is either thymine or guanine, 
in place of the targeted codon. The codon NNK is able to code for all 20 proteinogenic 
amino acids in just 32 codons, permitting coverage of all possible amino acid 
substitutions at a single site. Following transformation of pUCXKG:ycnD (B.s) mutant 
constructs into SOS-R2, gene variant libraries of 92 clones (per targeted site; analysis of 
92 clones providing an estimated 94 % chance of obtaining full library coverage (344)) 
were picked and grown in 96 well plates. Each plate also contained 2 wells of SOS-R2 
over-expressing wildtype YcnD (B.s) and a single well with an empty vector control. 
The remaining well was left blank as a control for media contamination. Prior to activity 
screening, plasmids were extracted from several randomly selected clones for each 
library and sequenced, with results confirming that variation was being introduced into 
the correct codon for each library (results not shown). All 10 libraries were then 
screened for SOS response induction following 3 h challenge with 10 µM PR-104A. 
Results are shown in Figures 6.5A-J. To facilitate screening of the large number of 
libraries, unchallenged cultures were not tested. Therefore all SOS responses are 
reported as net SOS response (as measured in Miller units) rather than fold inductions. 
Preliminary screening of unchallenged cultures for several libraries revealed very little 
difference in basal SOS responses (Miller units) between individual clones of a specific 
library (results not shown), indicating that net SOS response was a suitable substitute 
for fold induction in this instance. 
 The majority of libraries contained clones that induced SOS responses 
significantly higher than wildtype YcnD (B.s), in particular those encoding variants for 
sites I41, G65, R139, Y227 and Y233. At least one third of the clones within each of 
these libraries were superior to wildtype YcnD (B.s) in SOS response induction, with 
the greatest activities being 1.7-2.3-fold higher. In contrast, wildtype YcnD (B.s) ranked 
in the top five SOS inducers for R15, Q67 and E105 mutant libraries, while slightly 
more clones induced higher SOS responses than wildtype in W69 and G140 mutant 
libraries, although fold improvements were not as substantial as those previously 
mentioned (highest activities were 1.2 and 1.4-fold higher than wildtype for W69 and 
G140 libraries, respectively). 
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 To gain a better understanding of the comparative activities of different site-
specific mutants of YcnD (B.s), as well as to strengthen the data set already obtained, 
the top 9 hits of each of the I41, G65, R139, Y227 and Y233 mutant libraries and the 
top 4 hits of the W69 and G140 mutant libraries were combined in a single 96 well plate 
and screened (alongside wildtype YcnD (B.s) and empty vector controls) for PR-104A 
induced SOS activity. Only the middle 60 wells of the plate were used so as to prevent 
edge effects from influencing results (a phenomenon that was observed to a moderate 
degree with the initial mutant library testing; results not shown). In agreement with the 
previous data, results demonstrated that the majority of mutants tested induced higher 
SOS responses than wildtype, the only exceptions being two of the Q67 mutants (Figure 
6.6). The most active clones overall originated from the I41, G65, R139 and Y227 
mutant libraries, which altogether constituted the top 20 hits. Plasmids were 
subsequently extracted from these twenty clones and the ycnD (B.s) gene inserts 
sequenced to identify the introduced mutations. These are displayed in Table 6.1. In 
total, 11 different mutations were represented by these 20 clones, with 5 specific 
mutations occurring more than once. These five mutations were I41G, I41M, G65I, 
G65V and Y227G. Of particular note were the I41G mutations, which appeared three 
times within the top 5 hits, and the Y227G mutations, which appeared five times in 
total. The remaining mutations were at sites R139 (Phe, His and Leu substitutions), 
Y227 (Phe and Cys substitutions) and G65 (Glu substitution). It is noteworthy that two 
of these sequenced mutants, encoding G65E and Y227C amino acid substitutions 
respectively, contained nucleotide mutations elsewhere in the gene leading to amino 
acid changes (see Table 6.1 for details). These double mutants were, however, not 
investigated and further, due to both their modest activity profiles relative to the most 
active single mutants identified, and an already substantial yield of genuine single 
mutants with improved function that was sufficient for further experimentation.   
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Figures 6.5A-J. SOS responses of SOS-R2 strains over-expressing YcnD (B.s) variants following 3 h 
challenge with 10 µM PR-104A.  
Single site mutants of YcnD (B.s) were created by PCR amplification of the ycnD (B.s) gene, using 
primers that substituted the targeted wildtype codon for the degenerate sequence NNK. Libraries of 92 
clones were created for each targeted site to ensure close to 95 % probability of obtaining all possible 
codon variants (344). The site targeted is indicated at the top of each individual graph. SOS responses are 
displayed as total Miller units instead of fold induction, because unchallenged samples were not measured 
(to facilitate efficient library screening). Each graph is the mean ± 1 SEM of at least 2 independent assays 
(each performed in duplicate).  
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Figure 6.6. PR-104A induced SOS responses from strains of SOS-R2 over-expressing the most 
active YcnD (B.s) single-site variants.   
The most active YcnD (B.s) over-expressing clones identified previously (see Figures 6.5A-J), along with 
wildtype YcnD (B.s) and empty vector controls, were combined in a single 96 well plate (middle 60 wells 
to avoid edge effects) and assessed for SOS activity following 3 h challenge with 10 µM PR-104A. Bars 
are colour coded to indicate the mutation specificity (library of origin) of each tested clone. Data is the 
mean ± 1 SEM of 3 independent assays (each performed in duplicate).   
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Table 6.1. Amino acid substitutions of the 20 most active single-site variants of 
YcnD (B.s) with PR-104A.  
Activity is based on SOS response induction, as displayed in Figure 6.6. Specific 
mutations that occurred multiple times are colour coded. 
Clone
a
 Original 
amino acid 
Altered codon 
sequence 
Amino acid 
substitution 
139_43 Arg TTT Phe 
41_80 Ile GGG Gly 
41_57 Ile GGG Gly 
41_15 Ile GGG Gly 
139_15 Arg CAT His 
41_72 Ile ATG Met 
227_90 Tyr GGT Gly 
41_9 Ile ATG Met 
227_5 Tyr TTT Phe 
65_32 Gly ATT Ile 
227_39 Tyr GGG Gly 
65_90 Gly ATT Ile 
227_73 Tyr GGT Gly 
227_47 Tyr GGG Gly 
65_88
b
 Gly GAG Glu 
65_72 Gly GTG Val 
65_24 Gly GTT Val 
139_88 Arg TTG Leu 
227_87 Tyr GGG Gly 
227_3
c
 Tyr TGT Cys 
aClones are listed in descending order of activity, based on results displayed in Figure 6.6. Numbers 
before the underscore of each clone designation indicate the targeted residue; numbers after the 
underscore refer to the relative position on original screening plates. 
bYcnD (B.s) gene also carried an Asp to Gly substitution at codon 71 
cYcnD (B.s) gene also carried a Trp to Arg substitution at codon 211.  
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 6.2.4. Pairwise combinations of beneficial single mutations 
 
In order to further improve PR-104A reductase activity of YcnD (B.s), beneficial single 
mutations identified in the previous section were combined (pairwise) on the same gene 
to create various combinations of YcnD (B.s) double mutants. Firstly, due to the 
multiple amino acid substitutions at site R139 that led to heightened SOS activity with 
PR-104A, new NNK libraries (92 clones) of R139 were created using either I41G or 
Y227G gene variants as templates. Secondly, an NNK library of I41 was created using 
the Y227G gene variant as template, due to the different beneficial mutations available 
at site I41. These three libraries, along with internal controls consisting of wildtype and 
parental single mutant YcnD (B.s) expressing clones, were screened for SOS response 
induction, as previously described, following challenge with PR-104A. Few clones in 
the I41G R139 NNK and Y227 R139 NNK libraries demonstrated improved activity 
over the respective single mutant parents (see Figures 6.7A and B); however more than 
a third of the Y227G I41 NNK library elicited substantially heightened SOS responses 
relative to the Y227G single mutant (see Figure 6.7C). pUCXKG:ycnD plasmids were 
purified and the ycnD (B.s) gene insert sequenced from the top 5 hits of the Y227G I41 
NNK library and the top 3 hits of the I41G 139 NNK library. All three sequenced clones 
from the I41G 139 NNK library coded for glycine at site 139, while three of the five 
sequenced clones from the Y227G I41 NNK library coded for glycine at position 41. 
The remaining two sequenced Y227G I41 NNK clones coded for alanine at amino acid 
41.  
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Figures 6.7A-C. PR-104A-induced SOS responses of SOS-R2 strains over-expressing double site 
variants of YcnD (B.s). 
Selected YcnD (B.s) single-site mutants (with improved PR-104A reductase activity over wildtype) were 
used as templates for further PCR-based (NNK codon substitution) site-saturation mutagenesis. Targeted 
residues included (A) R139 in an I41G genetic background, (B) R139 in an Y227G genetic background, 
and (C) I41 in an Y227G genetic background. Mutant libraries were created as previously described and 
each one individually assessed for SOS activity induction following 3 h challenge with 5 µM PR-104A. 
Data displayed is the mean ± 1 SEM of 3 independent assays. 
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Four additional double mutants of ycnD (B.s) were generated through pairwise 
combinations of I41G or Y227G mutations with either G65I or G65V mutations 
(resultant variants were I41G G65I, I41G G65V, Y227G G65I and Y227 G65V). These 
four double mutants, along with the I41G R139G, I41A Y227G and I41G Y227G 
double mutants identified previously, the individual single mutant parents of the above 
(where available), a selection of other single site mutants that demonstrated improved 
activity over wildtype, and wildtype YcnD (B.s) were combined on a single 96 well 
plate for comparative activity testing with PR-104A by SOS assay. Results 
demonstrated that the overall most active YcnD (B.s) variants were the double mutants 
I41A Y227G and I41G Y227G, followed very closely by the double mutants I41G G65I 
and I41G G65V (Figure 6.8). These enzymes elicited significantly higher (p<0.05; t-
test) SOS responses than wildtype YcnD (B.s); however the difference between the SOS 
response inductions of these enzymes and the most active parental single mutant I41G 
(or I41A) was not significant (p>0.05; t-test). Likewise, the Y227G G65I/V double 
mutants elicited SOS responses no higher than the parental Y227G single mutant.  
 
Figure 6.8. PR-104A-induced SOS responses from SOS-R2 strains over-expressing the most active 
single and double-site variants of YcnD (B.s). 
Relevant strains were grown and challenged with 5 µM PR-104A for 3 h prior to analysis of SOS activity. 
Data is the mean ± 1 SEM of 4 independent assays. 
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6.2.5. IC50 determination and in vitro enzyme kinetics of lead candidate 
YcnD (B.s) variants 
 
To verify the results observed in the SOS assays, IC50 values of PR-104A were 
calculated for a selection of YcnD (B.s) variants following 3 h challenge with increasing 
concentrations of prodrug. Results are displayed in Table 6.2. The enzymes that 
conferred the highest sensitivity to PR-104A were the double mutants I41A Y227G and 
I41G Y227G; IC50 values from these variants were roughly 2.5-fold lower than that 
obtained for wildtype YcnD (B.s). Furthermore, these IC50 values were significantly 
lower than those obtained from the I41G and Y227G single mutants (p<0.05; t-test). 
Expression levels in SOS-R2 of all the YcnD (B.s) variants tested were equivalent, as 
measured by SDS-PAGE (results not shown). Overall, the correlations between SOS 
assay results and IC50s were very strong (R
2
 > 0.95; Figure 6.9). 
 
Table 6.2. IC50 values of PR-104A in SOS-R2 over-expressing wildtype and active 
site mutants of YcnD (B.s). 
YcnD (B.s) variant IC50 (µM)
a
 
Wildtype 226 ± 9.9 
I41G 112 ± 7.9 
G65I 177 ± 4.4 
G65V 176 ± 9.1 
Y227G 141 ± 6.4 
I41G G65I 107 ± 12 
I41G G65V 101 ± 8.6 
I41A Y227G 88.5 ± 11 
I41G Y227G 88.9 ± 9.9 
aIC50 values were calculated from growth measurements taken after 4 h challenge with increasing 
concentrations of PR-104A. 
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Figure 6.9. Logarithmic correlations between SOS assay results and IC50 values for PR-104A-
challenged strains of SOS-R2 over-expressing YcnD (B.s) single and double-site variants. 
Data for SOS results was taken from Figure 6.8. IC50 values were taken from Table 6.2.  
 
The highly active (based on SOS and IC50 results) YcnD (B.s) double mutant 
I41G Y227G, along with its parental single site mutants I41G and Y227G, were further 
investigated for PR-104A reductase activity through in vitro purified enzyme kinetics. 
Genes were cloned into the expression vector pET28a(+), transformed into E. coli BL21 
and recombinant His6-tagged enzymes over-expressed and purified as described 
previously. Wildtype YcnD (B.s) was also re-purified and tested alongside the single 
and double-site mutants for consistency. All enzymes were deemed to be >95 % pure 
based on densitometric analysis of bands after SDS PAGE of purified enzyme 
preparations (results not shown).  
Spectrophotometric analysis of PR-104A reduction kinetics was assessed for 
each purified enzyme as previously described, using NADPH as co-substrate in all 
instances. In contrast to SOS assay and IC50 results, the catalytic activity of the mutant 
YcnD (B.s) enzymes (based on kcat/Km values) was on average considerably lower than 
that of the wildtype enzyme (see Table 6.3 and Figure 6.10). The I41G and I41G 
Y227G mutants displayed the lowest activity (3-4-fold lower kcat/Kms than wildtype), 
while the Y227G mutant yielded a kcat/Km roughly equal to that of wildtype (248,000 M
-
1
 cm
-1
 compared to 255,000 M
-1
 cm
-1
, kcat/Kms for Y227G mutant and wildtype YcnD 
(B.s), respectively). Further testing revealed that co-substrate preferences among the 
  
176
mutant YcnDs had not been substantially altered relative to wildtype, as rates of 
reduction of PR-104A with NADH as co-substrate were consistently less than 50 % of 
rates achieved with NADPH (at equimolar PR-104A concentrations) for all four 
enzymes (see Figure 6.11). Lastly, the in vitro activity of these enzymes with two 
alternative nitroaromatic compounds, CB1954 and NFZ, was also tested. Results 
(displayed in Figures 6.12A and B) demonstrated that relative levels of reduction 
between the four enzymes were highly consistent among the different substrates tested 
(i.e. Wildtype>Y227G>I41G>I41G Y227G), and furthermore that these relative levels 
of activity also correlated with those seen with PR-104A as substrate (as illustrated in 
Figure 6.11).   
 
Figure 6.10. Kinetic characterisation of YcnD (B.s) and three active site mutants with PR-104A.  
Catalytic rate of reduction (initial rate, v / enzyme concentration, [E]) plotted against substrate 
concentration. NADPH was used as co-substrate, at 0.25 mM, for all reactions. Reduction of PR-104A 
was monitored as the decrease in absorbance at 400 nm (ε = 6,000 M-1 cm-1). Results are the mean ± 1 SD 
of at least 4 replicates for each PR-104A concentration tested. 
 
Table 6.3. Kinetic parameters for the reduction of PR-104A by purified His6-
tagged wildtype and evolved YcnD (B.s). 
See legend of Figure 6.10 for more details. 
YcnD (B.s) variant kcat (s
-1
) Km (µM) kcat / Km (M
-1
 s
-1
) 
Wildtype 4.10 ± 0.11 16.1 ± 1.7 255,000 ± 28,000 
I41G 1.2 ± 0.08 20.9 ± 5.5 57,400 ± 16,000 
Y227G 2.4 ± 0.11 9.66 ± 2.2 248,000 ± 58,000 
I41G Y227G 0.57 ± 0.08 7.37 ± 6.0 77,300 ± 64,000 
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Figure 6.11. Reduction of PR-104A by purified His6-tagged wildtype and mutant YcnD (B.s), using 
NADH or NADPH as co-substrate. 
Catalytic rates of PR-104A reduction by purified His6-tagged YcnD (B.s) and select mutants was 
measured as described previously, using PR-104A at 50 µM and either NADH or NADPH as co-substrate 
(at 0.25 mM fixed concentration). Data is the mean ± 1 SD of at least 4 replicate assays for each enzyme-
co-substrate condition tested. 
 
 
 
Figures 6.12A & B. Reduction of alternative nitroaromatic prodrugs by purified His6-tagged 
wildtype and mutant YcnD (B.s).  
Catalytic rates of reduction of either (A) NFZ (50 µM) or (B) CB1954 (100 µM) by purified his6-tagged 
YcnD (B.s) and select mutants were measured as previously reported for these substrates. NADPH was 
used as co-substrate (0.25 mM). Data is the mean ± 1 SD of at least 4 replicate assays for each enzyme-
prodrug combination tested.  
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 6.2.6. SOS activity with alternative nitroaromatic prodrugs 
 
The effect of active site mutations on the ability of YcnD (B.s) to reduce nitroaromatic 
prodrugs other than PR-104A was tested next. The same panel of SOS-R2 strains over-
expressing single and double-site YcnD (B.s) mutants that was used to generate data for 
Figure 6.8 was assessed for SOS response induction following challenge with either 
CB1954, MTZ or RB 6145. Overall, results shown in Figures 6.13A-C demonstrate that 
activity of mutant YcnD (B.s) enzymes differed substantially, relative to wildtype, 
across the different substrates tested. For example, the double mutants I41A/G Y227G, 
which demonstrated the highest SOS activity and lowest IC50s with PR-104A, elicited 
lower SOS responses than wildtype across all three substrates tested in this section, with 
a particularly large difference (more than 2.2-fold lower SOS responses relative to 
wildtype) observed with MTZ as substrate. Furthermore, the R139H/F mutations caused 
a significantly higher SOS response than wildtype and the majority of mutants upon 
challenge with RB 6145, while these same R139 mutants produced decreased responses 
relative to wildtype upon challenge with CB1954 and MTZ. Overall, no YcnD (B.s) 
variant elicited an SOS response substantially higher than wildtype with either CB1954 
or MTZ as substrate. In fact, with MTZ as substrate, the majority of mutations tested 
appeared to diminish activity relative to wildtype.  
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Figures 6.13A-C. SOS induction of wildtype and mutant YcnD (B.s) over-expressing strains of SOS-
R2 following challenge with alternative nitroaromatic prodrugs. 
Strains of SOS-R2 over-expressing wildtype or mutant (most active single- and double-site variants) 
YcnD (B.s) were grown and challenged for 3 h with either (A) 5 µM CB1954, (B) 1.25 µM MTZ, or (C) 
2.5 µM RB 6145, prior to analysis of SOS activity. Each data set is the mean ± 1 SEM of 4 independent 
assays. 
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6.3. Discussion 
 
The overall aim of the experiments described in this chapter was to improve the PR-
104A reductase activity of the Bacillus subtilis NTR YcnD through site directed 
mutagenesis of residues considered to be involved in substrate binding and catalysis. 
Using the SOS assay as a screening tool, 10 active site amino acids identified by 
analysis of crystal structure data were individually mutated and tested for PR-104A 
reductase activity. Double mutants containing paired combinations of beneficial single 
mutations were subsequently created and also tested for PR-104A reductase activity. 
The most active variants generated, the double mutants I41G/A Y227G, elicited SOS 
responses 2.5-fold higher than the wildtype enzyme, following challenge of the relevant 
SOS-R2 over-expression strains with 5-10 µM of PR-104A. A similar difference in 
activity between these two strains was also observed in IC50 values, confirming the 
results gained with the SOS assay. 
 However, these results were not matched in vitro by purified enzyme kinetics. 
By this metric, the I41G Y227G mutant was judged to be approximately 3-fold less 
active (as measured by kcat/Km) as the wildtype enzyme, with diminished in vitro 
activity also observed for the two parental single mutants relative to their SOS activity 
profiles. It is unclear as to why the in vitro and E. coli in vivo results in this chapter 
were contradictory; however the purified mutant enzymes also displayed less activity 
with the alternative substrates CB1954 and NFZ relative to wildtype YcnD (B.s). This 
may be due to an unexplained issue with the mutant protein preparations, or may 
indicate that the mutant proteins are less stable or less active under the specific in vitro 
assay conditions employed in this chapter. Alternatively, assuming that the purified 
enzyme kinetic parameters measured in this chapter were an accurate measure of the 
enzyme activity, one possible explanation is that the mutant enzymes may nonetheless 
exhibit greater activity than wild type YcnD (B.s) in vivo due to significantly decreased 
catalytic activity with alternative substrates that are present naturally in E. coli. If YcnD 
has high affinity for such substrates, they could potentially compete with PR-104A in 
vivo; whereas the mutants may exhibit less activity with PR-104A in isolation, but 
higher effective activity in vivo due to reduced competitive inhibition. A similar theory 
was suggested as the rationale for the lower in vitro activity, but more than 1,000-fold 
higher sensitivity conferred towards rat glioma cells in vivo, of a mutant HSVtk enzyme 
with the prodrug substrate GCV, compared to the wildtype enzyme (345). In this case, 
the mutant enzyme demonstrated an even greater decrease in catalytic activity (as 
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determined in vitro, relative to the decrease observed with GCV) with the native 
substrate thymidine, considered to be a competitive substrate for GCV (212). In the case 
of YcnD (B.s), the competing substrates could be quinones, which are naturally found in 
abundance in E. coli and other bacteria and are known substrates for many bacterial 
NTRs (167; 260; 286; 330; 346). Further investigation of this phenomenon could be 
achieved through kinetic analysis of quinone reduction by mutant and wildtype 
enzymes, as well as observing the effects on SOS induction and IC50s upon addition of 
exogenous quinones to cell cultures during relevant assays. Unfortunately, attempts at 
over-expressing YcnD (B.s) and mutant variants in the human carcinoma cell line 
HCT116 were unsuccessful, preventing analysis of the relative activities of these 
enzymes with PR-104A in a more clinically relevant mammalian cell system. 
A recurring motif in the mutagenesis results presented here was the substitution 
of relatively bulky amino acids (e.g. isoleucine, arginine, tyrosine) by glycine, resulting 
in improved SOS activity with PR-104A as substrate. Mutation of sites I41, Y227 and 
R139 to glycine all conferred beneficial effects on PR-104A reductase activity, with 
further improvement afforded by the combination of two of these changes (I41G 
Y227G). A possible reason for this pattern is that enlargement of the active site by 
decreasing resident amino acid side chain size (see Figures 6.14A & B) results in 
greater affinity for bulkier substrates. PR-104A (molecular weight 498 g mol
-1
) is a 
substantially larger molecule than many quinones (molecular weights 100-200 g mol
-1
), 
the latter widely considered to be natural substrates of NTRs. Furthermore, an I41A 
mutant was almost indistinguishable in SOS activity from the I41G mutant (see Figure 
6.8), which is consistent with smaller side chains being beneficial in that residue 
position. A similar scenario was observed during mutagenesis of NfsA (E.c) towards 
improved reductase activity of flavins, where the greatest improvement in activity was 
conferred by an E99G mutation (188). It is noteworthy that other work in our lab has 
demonstrated that this same mutation in NfsA (E.c) substantially improves PR-104A 
reductase activity of this enzyme; however the analogous mutation in YcnD (B.s) 
(E105G) was not identified as being able to confer improved activity towards PR-104A 
in this study. In published site-directed mutagenesis work on NfsB (E.c), substitutions 
for glycine at either sites Y68 or S40 were demonstrated to be among the most 
beneficial mutations at these sites for improving CB1954 reductase activity of this 
enzyme (218; 219).  
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Figures 6.14A & B. Mutagenesis-induced alterations in YcnD (B.s) active site topography. 
Representation of the molecular surfaces of the substrate binding pockets of (A) wildtype and (B) I41G 
Y227G double mutant YcnD (B.s). Amino acids belonging to the separate monomeric YcnD (B.s) 
subunits are coloured in cyan and magenta, respectively, and the FMN co-factor is coloured blue. The 
approximate locations of other active site residues are shown in (A). Molecular surfaces were calculated 
and imaged with Swiss-PdB Viewer (Deepview), using lowest-energy conformations.     
 
In contrast, for YcnD (B.s), substituting glycine by either isoleucine or valine at 
amino acid 65, or arginine by phenylalanine, leucine or histidine at amino acid 139 all 
appeared to enhance PR-104A reductase activity of this enzyme relative to wildtype. 
This suggests that enlargement of the active site is not the only alteration required for 
improved PR-104A catalysis, but that remodelling of active site architecture is also 
necessary.  
It is noteworthy that many of the mutations that improved activity with PR-104A had 
either little effect, or were deleterious for activity of YcnD (B.s) with alternative 
nitroaromatic prodrugs (CB1954, MTZ and RB 6145). In fact, the only mutation that 
substantially improved activity (more than 1.5-fold) of YcnD (B.s), relative to wildtype, 
towards any of these substrates was R139H, conferring a modest 1.65-fold increase in 
SOS response activity over wildtype with RB 6145. These data suggest that 
mechanisms of binding and catalysis of YcnD (B.s) vary widely for different 
nitroaromatic substrates, and that development of a single lead mutant enzyme for 
optimal reduction of one prodrug may not be ideal for others. It might therefore be 
beneficial to develop a panel of mutant YcnD (B.s) enzymes for GDEPT clinical use, 
with the prodrug being administered ultimately determining which YcnD (B.s) variant is 
employed. 
Overall, the best single and double mutant YcnD (B.s) enzymes described in this 
work (I41G and I41A/G Y227G) were 2 and 2.5-fold improved, respectively, over the 
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wildtype enzyme (based on SOS and IC50 results), for PR-104A reduction. This is 
modest in comparison with enzyme engineering work performed elsewhere, in 
particular that of active site mutagenesis of NfsB (E.c). For this enzyme, the best single 
and double mutant variants identified were roughly 8 and 12-fold improved 
(respectively) for CB1954 reductase activity over wildtype (219). Although our results 
are not directly comparable to those of Searle and colleagues due to fundamental 
differences in the enzymes, substrates and experimental methodology, the differences in 
fold-improvement observed between the two enzymes following active site mutagenesis 
is worth discussing. In particular, the high PR-104A reductase activity exhibited by 
wildtype YcnD (B.s) suggests that native active site architecture may already be very 
good for reduction of this prodrug, and that small alterations (e.g. single or double 
mutations) are not going to substantially improve activity. Wildtype NfsB (E.c), on the 
other hand, has a kcat/Km almost 50-fold lower than that of YcnD (B.s) for both CB1954 
and PR-104A (see Chapters 3 and 5), indicating a greater capacity for this enzyme to 
undergo catalytic improvement through active site mutagenesis. Alternatively, 
catalytically important residues of YcnD (B.s) may have been missed in this study, as 
the targeted sites were only chosen based on their proposed interactions with an NAD 
molecule following superimposition of the active site with that of the homologous NTR 
Frp (V.h). Binding of PR-104A and nitroaromatic substrates within the YcnD (B.s) 
active site could differ to that carried out by co-substrates, or additionally, binding of 
both substrates and co-substrates could differ between YcnD (B.s) and Frp (V.h). A 
more extensive site-directed mutagenesis study of YcnD (B.s) active site residues may 
therefore identify mutations that are more beneficial for PR-104A reduction than those 
identified in this study.  
As previously mentioned, YcnD (B.s) contains four tyrosine residues (Y227, 
Y228, Y232 and Y233) within the active site that are absent in all other NfsA-family 
enzymes (based on sequence and structural alignments). Alteration of one of these 
residues, Y227, to a glycine significantly improved the PR-104A-reductase activity of 
YcnD (B.s) in this study, based on SOS and IC50 results. The rationale for this 
observation could be that steric hindrance of PR-104A binding and product release 
conferred by the phenyl ring of the tyrosine residue is alleviated upon conversion to a 
less bulky amino acid. This theory has previously been suggested in a mutagenesis 
study with NfsB (E.c), where it was demonstrated that mutation of a phenylalanine 
residue at site 124 to any of 14 alternative amino acids significantly improved the 
CB1954-reductase activity of this enzyme (218). Although no Y233 mutations 
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conferred substantially higher PR-104A reductase activity over the wildtype enzyme, 
the remaining two tyrosines (Y228 and Y232) that were not investigated in this chapter 
present attractive candidates for future mutagenesis studies, based on the positive results 
obtained with alterations to residue Y227. 
The site directed mutagenesis work performed in this chapter was greatly 
facilitated by the creation and employment of the positive selection vector pUCXKG. 
Using the pUCXKT-KG vector system has so far resulted in close to 100 % efficiency 
in selection of transformants carrying correctly constructed vectors. The principal 
advantage of this system over other commonly used cloning techniques (such as 
blue/white selection or toxic allele replacement) is the complete reduction in frequency 
of false positive clones, the latter being principally generated through self-ligation of 
digested parental plasmid, following degradation and blunt ending of DNA ends by 
contaminating exonucleases (339). This situation is precluded in the pUCXKT/KG 
system due to the absolute requirement on incorporation of primer-encoded DNA 
sequences and regulatory regions into the parental plasmid, in order to confer the 
selective property (kanamycin resistance) on host cells.  
Other positive selection vectors that work on similar principals to pUCXKG 
have previously been developed. For example, positive selection afforded by the vector 
RHP-AmpS designed by Haag and Ostermeier (2009) involves the reconstitution of a 
truncated antibiotic resistance gene, the β-lactamase encoding bla gene, by in frame, 
correctly oriented cloning of a PCR product that includes (and correctly restores) the 
final C-terminal codon (W290) of this gene (340). As described in the publication, this 
system is able to function due to the essentiality of residue W290 to the catalytic 
function of the β-lactamase enzyme. Therefore, although effective, this system is 
limited to the use of β-lactamase activity as the selective property. Additionally, both 
the inserted gene and bla are expressed in complementary directions (towards each 
other), suggesting (although not mentioned by the authors) the possibility of 
translational inhibition of both enzymes through generation of antisense RNA during 
transcription of each gene. pUCXKG overcomes both of these limitations, because it 
does not depend on essential residues for regulating activity of the selective enzyme, 
and the expression of both genes in the same orientation and from different RBSs allows 
separate translational control of each gene product. Selective functions other than 
kanamycin resistance are therefore able to be employed in the pUCXKG system, 
widening its potential utility.  
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Chapter 7: Summary, conclusions and future directions. 
 
7.1. Research motivation 
 
To date, the E. coli NTR NfsB is the best studied nitroaromatic prodrug reducing 
enzyme for GDEPT, having already been employed, in combination with the 
prototypical nitroaromatic prodrug CB1954, in phase I/II clinical trials for the treatment 
of prostate cancer (100; 136; 138). The observed clinical benefits of this system in 
aiding tumour regression have however been modest, with a likely contributing factor 
being insufficient catalytic turnover of CB1954 (at its MTD) by NfsB (122; 136). 
Therefore, the discovery and design of novel nitroaromatic drugs and activating 
enzymes with improved clinical efficacy are attractive areas of research (36; 199; 219). 
Identification of alternative nitroaromatic prodrug reducing enzymes is facilitated by the 
vast availability and diversity of naturally occurring bacterial NTRs (162). Additionally, 
nitroaromatic prodrug reductase activity of NTRs can be enhanced through enzyme 
engineering methods, enabling unique tailoring of enzyme-prodrug combinations (218; 
221). This avenue of research has been limited, however, by a lack of effective and 
flexible methodologies for high throughput screening of candidate NTRs that exhibit 
improved nitroaromatic prodrug activation. The research described in this thesis has 
addressed many of these issues, in particular through the development of a moderately 
high throughput screen for NTR-catalysed nitroaromatic prodrug reduction, and its 
application in identification and engineering of novel bacterial NTRs for enhanced 
activity towards several key nitroaromatic prodrugs. 
   
7.2. Key findings 
 
 7.2.1. Development of a screen for nitroaromatic prodrug reduction 
 
The first outcome of this research was the development and validation of a microtitre 
plate-based screen for the detection and relative quantification of nitroaromatic prodrug 
reduction catalysed by candidate NTRs. The screening system chosen was based on the 
previously reported SOS chromotest, an E. coli-based bioassay that employs a 
genetically engineered reporter strain containing a reporter gene (in this case the β-
galactosidase-encoding gene lacZ) under the control of an SOS responsive promoter (in 
this case the sfiA promoter) (231; 250). Expression of the reporter gene in this host is 
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therefore directly linked to activation of the SOS response, which in turn is up-regulated 
by accumulation of DNA damage within the cell. Consequently, the relative rates of 
nitroaromatic prodrug reduction by candidate NTRs over-expressed in this host 
organism can be indirectly assessed by measuring the degree of SOS response induced 
by DNA adducts caused by the activated prodrugs.  
 Over-expression of NfsB (E.c) in the SOS reporter strain SOS-R1 (sfiA::lacZ) 
led to a dose-dependent increase in SOS response relative to an empty plasmid control, 
following challenge with CB1954 (Figure 3.2), proving the feasibility of this approach 
for monitoring nitroaromatic prodrug reduction. Further testing with a panel of ten 
additional native E. coli candidate NTRs identified three enzymes (NfsA, AzoR and 
NemA) also capable of inducing SOS responses substantially higher than empty vector 
levels (Figure 3.4). Furthermore, one of these NTRs, NfsA, displayed superior SOS 
activity to NfsB. SOS assay results were consistent with both IC50 values of E. coli 
grown in the presence of CB1954 and in vitro kinetics using His6-tagged purified 
enzymes (Figure 3.5, Table 3.1). In contrast, cytotoxicity studies in the human 
carcinoma cell line HCT-116 demonstrated an apparent (over 2-fold) superiority of 
NfsB over NfsA in conferring CB1954 sensitivity to host cells; otherwise, results were 
consistent with those obtained in E. coli regarding relative rankings of NTRs (Table 
3.2). Although the basis for the discrepancy between NfsA and NfsB results observed in 
HCT-116 and E. coli is not clear, it is possible that it was related to either different co-
substrate availability between the cell types (NfsA is NADPH-dependent, NfsB has no 
preference), different sensitivities to the various CB1954 reduction products (NfsA 
reduces the 2-NO2, NfsB reduces both the 2 and 4-NO2 of CB1954; Figure 3.8) or other 
as yet unknown differences between the cell types employed. Overall however, the 
metabolic heterogeneity of different cancer types and cell lines suggests that results 
obtained in HCT-116 may not be representative of cancer as a whole. Therefore E. coli 
may provide a valid, as well as simple, rapid and more generally applicable, alternative 
to human cell lines for studying nitroaromatic prodrug reduction. 
 
7.2.2. Roles of various DNA repair pathways in processing and 
mutagenicity of CB1954-induced DNA adducts. 
 
CB1954 can be reduced by NTRs at either the 2- or 4-NO2 (but not both) resulting in 
metabolites (hydroxylamino- and amino-derivatives) with disparate cytotoxic properties 
(110; 121). Previous work in mammalian cells has demonstrated that the 4- NO2 
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reduction product can induce DNA interstrand crosslinks, which are significantly more 
lethal in cells deficient in NER than in wildtype cells (121). The 2-NO2 reduction 
products on the other hand are generally presumed to form far less toxic mono-adducts 
(109), although toxicity of the 2-NH2 and 4-NHOH metabolites were very similar in an 
NER-proficient cell line (121). These differences led us to investigate the roles of both 
SOS-dependent and -independent DNA repair pathways in E. coli in CB1954-induced 
DNA lesion repair, and how the presence or absence of these pathways may affect SOS 
inductions in response to CB1954. SOS-R1 strains deficient in either O
6
-methylguanine 
transferase activity, the adaptive response to DNA alkylation damage, or DNA 
mismatch repair induced SOS responses of equal magnitude to wildtype strains upon 
challenge with either 2- or 4-NO2 reduction products of CB1954, suggesting little to no 
role for these pathways in CB1954 adduct repair. In contrast, strains lacking the uvrB 
gene, essential for NER to function, induced SOS functions significantly higher than 
WT strains in response to the 4-NO2, but not the 2-NO2 reduction products of CB1954 
(Figure 4.5). Therefore, NER is likely to be a critical pathway for repair of 4-NO2 
reduction product induced adducts, similar to results observed in mammalian cells 
(121). Likewise, reduced forms of other nitroaromatic prodrugs (NFZ, PR-104A) that 
generate adducts also known to be repaired by NER (in bacteria and/or mammalian 
cells) induced SOS responses in SOS-R1 ΔuvrB strains substantially higher than in WT 
strains (Figure 4.8). Mutagenicity testing of each of the CB1954 reduction products in 
SOS-R1 wildtype and ΔuvrB strains demonstrated that error-prone polymerases, 
through TLS repair pathways, are likely to be involved in repair of DNA adducts 
formed by both metabolites. Furthermore, CB1954-induced mutagenicity was higher in 
the ΔuvrB strain relative to wildtype, particularly in response to the 2-NO2 reduction 
products (Figure 4.9). These results suggest that NER may be the primary repair 
pathway for adducts induced by both CB1954 reduction metabolites; however, in its 
absence, adducts induced by 2-NO2, but not 4-NO2 reduction products are equally 
capable of being repaired through the TLS pathway. 
 
7.2.3. Testing an expanded library of bacterial NTRs for CB1954 and PR-
104A reductase activity 
 
To identify novel NTRs with improved nitroaromatic prodrug reductase activity, a core 
library of 47 bacterial NTRs of diverse origins and sequence/structure were selected for 
activity screening (Figure 5.2). Prior to screening, the SOS reporter strain was optimised 
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for enhanced sensitivity to nitroaromatic prodrugs by in-frame deletion of the outer 
membrane channel-encoding gene tolC. This resulted in up to 3-fold higher SOS 
responses relative to tolC
+
 strains upon challenge with equimolar concentrations of PR-
104A (Figure 5.1), greatly reducing levels of prodrug consumed in SOS assays. The 
library of NTRs was screened for CB1954 and PR-104A reductase activity, initially via 
the SOS assay and subsequently through IC50 assays and in vitro measurement of 
purified enzyme kinetics. Results correlated positively and strongly across all assays 
with CB1954 (Figures 5.4 to 5.7), with NfsA family enzymes being the most active 
class of NTRs on average, in agreement with results achieved in Chapter 3. Although 
correlations between results of the various assays with PR-104A as substrate were not 
as strong as those with CB1954 (Figures 5.8, 5.9 and 5.13), overall results indicated a 
superiority of NfsA-family enzymes in metabolism of this substrate. NfsA-family 
enzymes were also, on average, the most active enzymes (in terms of SOS response 
induction) with the nitroimidazole prodrugs MTZ and RB 6145 (Figures 5.17 and 5.18, 
respectively). 
A potential clinical weakness of PR-104A and related DNBMs is their ability to 
undergo metabolism by the endogenous human oxygen insensitive reductase AKR1C3, 
resulting in off-target toxicity in healthy cells. Seeking to identify alternative 
nitrobenzamide mustard prodrugs that do not share this limitation, two mono 
nitrobenzamide mustards (MNBMs) were tested with AKR1C3 in vitro and found to be 
poor substrates for this enzyme (Figure 5.15). Furthermore, SOS testing with a selection 
of NTRs demonstrated that MNBMs are efficient substrates for NfsA and NfsB-family 
NTRs (Figure 5.16), suggesting a potential application in GDEPT for these compounds.  
 
7.2.4. Improving the PR-104A reductase activity of YcnD (B.s) through 
active site mutagenesis. 
 
YcnD (B.s) was identified in Chapter 5 as an ideal candidate NTR, based on high 
CB1954 and PR-104A reductase activity, for further enhancement of nitroreductase 
activity by site saturation mutagenesis of active site residues. Using the SOS assay as a 
screen, YcnD (B.s) variants randomly mutated at one of ten active site residues (chosen 
through analysis of the solved enzyme structure; (194)) were screened for improved PR-
104A reductase activity (Figure 6.5). Individual mutations that conferred the highest 
improved activity were combined, pairwise, within the same gene and the subsequent 
double site variants subsequently tested for PR-104A reductase activity. The most active 
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single and double mutants (I41G and I41A/G Y227G) that were identified through these 
assays induced SOS responses that were on average 2- and 2.5-fold higher than 
wildtype YcnD (B.s), respectively, at equimolar concentrations of PR-104A (Figure 
6.8). These results were in agreement with IC50 measurements of the same strains 
(Table 6.2). Among the amino acid substitutions that conferred enhanced PR-104A 
reductase activity to YcnD (B.s), many involved changes to glycine, suggesting that 
enlargement of the active site cavity was beneficial in enzyme catalytic activity with 
PR-104A. However, purified His6-tagged recombinant enzymes of three of the most 
active YcnD (B.s) variants demonstrated lower PR-104A reductase activity in vitro, on 
average, relative to the wildtype enzyme (Figure 6.10). This pattern was also observed 
with other nitroaromatic substrates (Figure 6.12), suggesting that the low mutant 
enzyme activity observed in vitro was a product of poor quality or unstable purified 
enzyme preparations. Alternatively, the introduced mutations may have lowered the 
activity of YcnD (B.s) with alternative substrates that naturally occur within the E. coli 
host (e.g. quinones). Therefore, mutant enzymes, although kinetically inferior to 
wildtype YcnD (B.s) in reduction of PR-104A, may have demonstrated superior activity 
in vivo due to substantially reduced competition from endogenous substrates. If this 
hypothesis is correct, the evolved enzyme variants may only prove superior to native 
YcnD in GDEPT models if these competing substrates are also present in human cells.   
 To facilitate mutant library creation and screening, a novel positive selection 
expression vector, pUCXKT, was developed and used for over-expression of variant 
YcnD (B.s) enzymes in this section. The cloning efficiency (frequency of correctly 
formed constructs among all transformants) of this vector was close to 100 %; 
substantially higher than success rates typically encountered with restriction 
digestion/ligation based cloning techniques. Therefore, these results indicate that this 
vector is a useful tool for efficient preparation of large expression libraries for protein 
evolution and engineering studies. 
 
7.3. Critical evaluation and possible experimental improvements 
 
 7.3.1. SOS assay improvements 
 
A significant component of this thesis was the development and employment of the 
SOS assay as a rapid and reliable screening technology for detection and relative 
quantification of nitroaromatic prodrug reduction by candidate NTRs. Despite its 
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obvious advantages, the screening potential of this assay is largely limited by the 
necessity of working in 96-well plates and the extra handling steps (cell lysis, addition 
of reporter substrates) that are required prior to measurement of SOS activity. For a 
single researcher working without automated liquid-handling robots it would be difficult 
to use this assay to screen more than 1,000 variants per day, an inadequate number if 
more comprehensive enzyme evolution and engineering studies were to be performed. 
One approach for obtaining higher assay throughput could be the replacement of the 
colorimetric LacZ substrate ONPG for one of the many available cell-permeable 
fluorescent LacZ substrates (e.g. MUG, FDG) (347; 348). This would not only obviate 
the need for cell lysis prior to SOS response detection, thereby decreasing manual 
screening labour, but also permit real-time assessment of SOS induction, providing 
deeper insight into the kinetics of SOS induction in response to different drugs. A 
particularly attractive property of fluorescent reporter substrates is their potential 
application in flow cytometry and FACS, which would provide a substantially more 
efficient means of screening, and selecting, for improved enzymes. However, the high 
cost associated with many of these fluorescent substrates could render the screen 
economically unviable; instead, replacement of the SOS-controlled lacZ gene with that 
for green fluorescent protein (gfp) is potentially a more cost-effective means of applying 
fluorescence-based screening to the detection of active enzymes. Although an inherently 
less sensitive reporter molecule than β-galactosidase (349; 350), Gfp signal production 
and detection can be enhanced by incorporating the SOS reporter gene fusion into a 
multi-copy plasmid (229). Attempts to improve SOS screening using this method are 
ongoing in our laboratory (Janine Copp, personal communication).  
 Alternatively, it might be possible to place selectable markers such as genes that 
confer antibiotic resistance or that complement null mutations in essential metabolic 
pathways (e.g. amino acid biosynthesis) under SOS control, permitting ultrahigh-
throughput selection of active NTR over-expressing clones on prodrug-containing 
selective-solid media. However, SOS response induction caused by antibiotic-mediated 
cellular damage (351) or nutrient starvation (352; 353) could potentially impact the 
effectiveness of these techniques.  
 
7.3.2. Validation of E. coli as model organism 
 
Another credible limitation of the experimental procedures employed in this thesis was 
the use of E. coli as a model organism. Although prokaryotic models provide significant 
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advantages in enzyme activity screens, such as rapid growth time, ease of genetic 
manipulation and robust enzyme expression, fundamental genetic and physical 
differences between E. coli and human cells raise issues concerning the reliability and 
applicability of results gained in the former in the context of actual therapeutic 
performance in human GDEPT. The contrasting results observed with CB1954 toxicity 
between NfsA (E.c) and NfsB (E.c) over-expressing E. coli and HCT-116 carcinoma 
cells (see section 3.4.5) suggest potential discrepancies between the different cell types. 
More comprehensive cytotoxicity testing of prodrugs in NTR over-expressing 
mammalian cell lines, however, is required before definite conclusions can be reached; 
such studies are currently underway at the ACSRC (Adam Patterson, personal 
communication). On the other hand, many other GDEPT studies that have used E. coli 
as a model organism, including those investigating NfsB (E.c) variants for improved 
CB1954-reductase activity, describe positive correlations between enzyme activity 
results gained in this organism and mammalian cells (156; 213; 218). It should be noted, 
however, that divergent results may be less likely to be reported in the literature. 
Nevertheless, if E. coli is to remain a core component in screening of NTRs for prodrug 
reduction, more detailed knowledge of prodrug metabolism in this species is required 
before results can be regarded with confidence. In particular, properties such as 
intracellular co-substrate levels, the ultimate fate of drug reduction products, resistance 
mechanisms to drugs and their metabolites, and the nature and repair of induced DNA 
lesions should ideally all be investigated and compared to the same properties in 
mammalian cells. This way, the basis of any differences in results observed between the 
organism types can be understood. 
A method of avoiding the potential pitfalls of E. coli could be to use fast-
growing eukaryotic microorganisms as host strains for testing prodrug reduction. Thus, 
screening would retain the benefits of short assay time, but also gain the significant 
advantage of using an organism more closely related to the final application. One 
attractive candidate is the yeast S. cerevisiae, which has been well-characterised at the 
biochemical and genetic levels and is often employed in high throughput enzyme 
screens (354; 355) and as a model organism for anticancer drug testing (356). 
Furthermore, DNA damage reporter strains of this species have been developed (357-
360), which would allow transfer of the screening benefits of the E. coli SOS assay to 
this new organism. 
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7.3.3 Alternative screens to the SOS assay 
 
It is important to note that SOS response induction in the SOS assay is an indirect effect 
of prodrug reduction; as such, internal or external factors independent of prodrug 
reduction and associated DNA damage could potentially influence SOS activity. More 
importantly, NTR-specific properties that may affect the SOS response (stress arising 
from heterologous protein expression or NTR activity with competing substrates, for 
instance) could have confounding effects on relative activity rankings. For example, 
many, but not all biochemically characterised NTRs have demonstrated NAD(P)H 
oxidase activity, whereby NAD(P)H is oxidised at the expense of molecular oxygen, 
leading to the formation of hydrogen peroxide (170; 171; 329). As H2O2 is itself a 
harmful oxidant with DNA damaging properties, generation of this species by over-
expression of such NTRs in host cells could impact on their SOS and cytotoxicity 
measurements relative to NTRs that lack such oxidase activity. As such, NTR activity 
screens that directly test for the desired end product of prodrug reduction (i.e. the 
hydroxylamino/amino derivatives) may be advantageous and, overall, more accurate 
and reliable in the assessment of relative NTR prodrug reductase activity. As an 
example of such a screening mechanism, the replacement of prodrugs with non-toxic 
fluorescent analogues in a whole cell assay would permit direct measurement of NTR 
activity via fluorescence spectrophotometry or flow cytometry/FACS, a technique that 
has previously been employed in the evolution of other enzymes (223; 361; 362). 
However, the cost and effort involved in design and synthesis of such analogues could 
be a limiting factor. Also, catalytic activity of enzymes towards such analogues may not 
precisely reflect activity towards the prodrugs of interest, due to subtle structural 
differences between the compounds. Alternatively, reagents that can react directly and 
selectively with reduced prodrug derivatives, producing a detectable signal in the 
process (e.g. colour change, fluorescence), would permit rapid and direct quantification 
of prodrug reduction by candidate enzymes. As already mentioned, a similar screen has 
previously been applied successfully to the detection of hexavalent chromium reduction 
(222; 363). Such a technique may be particularly relevant to nitroaromatic prodrug 
reduction due to the reactive nature of the reduced (hydroxylamino) species. Examples 
of reagents that are able to detect the presence of aromatic amines in complex mixtures 
have already been reported (164; 364-366), although interactions of these reagents with 
aromatic hydroxylamino compounds – the typical end product of NTR-catalysed 
reduction of nitroaromatic compounds – have not been examined. Furthermore, it is 
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expected that cell lysis and other handling steps would still be required prior to reagent 
addition and product detection, which would hinder assay efficiency. 
 
7.4. Future experiments  
 
 7.4.1 Structure-activity relationship studies: NTRs and prodrugs 
 
An appropriate future direction for this research would be the continuation of YcnD 
(B.s) active site mutagenesis to further enhance PR-104A reductase activity. Although 
this study included a comprehensive coverage of active site single-residue variants of 
YcnD (B.s), the highest activity improvement detected was modest (ca. 2-fold over 
wildtype). Previous research has demonstrated that multiple simultaneous mutations 
within the active site can have synergistic effects on enhancement of the desired 
activity; activity improvements beyond those that might be predicted by addition of the 
effects of the individual single mutants (367; 368). Therefore more detailed 
investigations into double or triple site mutants of YcnD (B.s) may uncover unexpected 
improvements in enzyme activity. Additionally, random mutagenesis techniques that 
target the entire gene sequence could identify mutations outside of the active site that 
improve enzyme activity and/or stability that would be difficult or impossible to predict 
based on structural analyses alone (369). This would however require more efficient 
methods for high-throughput screening, as discussed above. Finally, determination of 
crystal structures of both native enzymes and improved mutant NTRs in complex with 
prodrug substrates could provide highly valuable information regarding key residues 
involved in prodrug binding and catalysis and therefore enable more rational design of 
improved biocatalysts for prodrug reduction. 
 Understanding the role of competing substrates (e.g. quinones) in vivo on the 
prodrug-reductase activity of NTRs is also an important direction for further research.  
This is underscored by the likely heterogeneity in intracellular quinone pool 
composition between different human tumour types (370-372), which could lead to 
varied success rates of NTR-GDEPT between different cancers depending on the degree 
of competition by quinones on NTR activity. A similar scenario has previously been 
observed for mutant HSVtk enzymes, whose success in conferring GCV sensitivity to 
different human cell types depended on intracellular thymidine (competitive substrate) 
concentrations (345; 373). Furthermore, differences in the composition of quinone pools 
between E. coli and human cells could constitute a source of discrepancy between NTR 
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activity results (e.g. SOS, IC50) gained from the two organisms. Firstly however, a role 
of quinone competition on NTR prodrug reductase activity needs to be firmly 
established, through purified enzyme and in vivo assays. If confirmed, NTRs would then 
ideally need to be engineered to lose quinone affinity but retain or gain prodrug affinity; 
in this case a high throughput screen with the ability to detect quinone reduction would 
need to be developed and employed alongside prodrug reduction assays.  
  
 7.4.2. Alternative uses for NTRs 
 
The biotechnological use of NTRs has been reported in areas of research other than 
cancer therapy. In particular, NTRs have been well-studied for their ability to reduce 
environmental contaminants such as hexavalent chromium (184; 374), azo dyes (286; 
375) and nitroaromatic by-products of industrial processes (162), thereby aiding in the 
detoxification and eventual removal of these compounds from the environment. As 
such, the native and evolved NTR libraries generated in this thesis may be of 
significance for the identification of enzymes with improved catalytic activity towards 
any of these alternative substrates. However, as reduced species of many of these 
compounds do not display strong genotoxic properties, the SOS assay is not likely to be 
an effective means of screening for enzyme activity. Instead, an assay based on 
NAD(P)H consumption that uses tetrazolium salts as indicator dyes of nicotinamide co-
substrate concentration (such as NBT or INT; (247; 376)) could be used as a generic 
screening tool for evaluation of NTR reductase activity. Validation of this technique is 
ongoing in the Ackerley laboratory (Elsie Williams, personal communication). 
Alternatively, a moderate throughput screen has previously been developed for 
evaluation of chromate reduction (363), while assessment of azo-dye reduction is 
facilitated by the change in visible colouration that accompanies this process. An 
alternative and potentially very high throughput screen for assessing rates of 
nitroaromatic compound reduction could be to couple NTR activity with dioxygenase 
enzymes that are able to release nitrite from aromatic amines, many of which have 
previously been characterised (377; 378); as such, reaction products of NTR directed 
catalysis of nitroaromatic compounds would become substrates for the dioxygenase 
enzymes. When performed in an E. coli host, nitrite released from the latter reaction 
could act as a source of nitrogen for cell growth, thereby providing a selective 
mechanism for detection of active NTR enzymes by growing cells on solid media with 
the nitroaromatic compound as the sole nitrogen source. However, a dioxygenase 
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enzyme with wide substrate specificity (yet lacking parental nitroaromatic compound 
dioxygenase activity) would first need to be identified, or as is more likely, engineered 
for this technique to function efficiently. If feasible, such a selection strategy could also 
be employed in assessing nitroaromatic prodrug reduction, thereby greatly enhancing 
rates of detection of improved enzymes.     
 Apart from bioremedial processes, NTRs have also been employed in 
developmental research, most notably by exploiting the ability of NfsB (E.c) to reduce 
the non-bystander prodrug MTZ, thereby presenting a strategy for targeted ablation of 
NTR over-expressing transgenic cell lines (379). This thesis presents evidence 
indicating not only that alternative NTRs may be better suited for MTZ reduction, but 
also that other NTR-prodrug combinations that do not overlap with MTZ reduction 
could be identified or developed, thereby enabling the study of multiple transgenic cell 
lines simultaneously. Work to this end, along with identification of fluorescent 
nitroaromatic reporter compounds for imaging of separate NTR over-expressing cell 
lines, is ongoing in the Ackerley laboratory (Claire Horvat, personal communication).     
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7.5. Concluding remarks 
 
This thesis has described both the development of techniques for evaluation of enzyme-
catalysed genotoxic prodrug reduction, and the assessment of novel bacterial NTRs for 
their ability to reduce a range of clinically attractive nitroaromatic prodrugs. In 
particular, NTRs superior to NfsB, the „gold-standard‟ of NTR GDEPT, with CB1954 
as well as other nitroaromatic prodrugs of interest, were identified. These results are not 
only relevant to the field of cancer gene therapy, but also hold significance for other 
areas of research that require efficient NTR-mediated catalysis, such as bioremediation, 
targeted cell ablation and reporter compound development. Similarly, the novel SOS 
assay developed in this study has the potential to be applied to the discovery of enzymes 
that activate other genotoxic prodrugs, such as cyclophosphamide and 5-FC, or simply 
to the discovery of novel DNA-damaging antimicrobial or anti-cancer agents from 
large-scale chemical libraries. However, deeper investigation is required before this 
assay and the E. coli host organism can confidently be viewed as a model system for 
drug metabolism in cancer.  
 GDEPT presents a novel strategy for combating cancer, with the particularly 
attractive property of limiting toxicity to cancerous cells. While improving activity of 
prodrug activating enzymes is one method for enhancing clinical efficacy of the system, 
there is likely to be an upper limit to the extent to which the catalytic rate of the 
activating enzyme can be improved before other factors, such as prodrug diffusion and 
toxicity, and gene delivery/transfection rates become the principal limitations in 
therapeutic efficacy of the treatment regimen. It is therefore pertinent that research into 
these other avenues is continued, to maximise the chances of GDEPT becoming a major 
anti-cancer therapy system.  
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Appendix 1: NTR accession numbers and sequences 
 
NCBI accession numbers of NTRs employed throughout this thesis are listed, 
alphabetically by NTR name, in Table A1.1. The sequences the accession numbers refer 
to were used for design of oligonucleotide primers for PCR amplification of the 
respective genes. However, due to the use of non-type strains, in many instances, for the 
amplification and extraction of NTR genes, many gene and protein sequences of NTRs 
used throughout this work were divergent from those given in the NCBI database. 
Where this is the case, accession numbers are coloured in red in Table A1.1, and the 
actual nucleotide and amino acid sequences are listed below. All others (coloured in 
blue), refer to gene and protein sequences that were identical to those used in this study.  
 
Table A1.1. NCBI database accession numbers of NTRs used throughout this 
work. 
See text for details on colour coding.  
NTR Accession 
 number 
NTR Accession 
 number 
NTR Accession 
 number 
1204 (P.a) NP_249895 NemA (S.t) NP_805105 NfsB (V.v) NP_762888 
2432 (P.p) NP_744580 NemA (V.v) NP_762994 WrbA (E.c) AP_001635 
3720 (P.p) NP_745853 NfrA (B.s) CAB15837 WrbA (P.s) YP_275866 
4538 (P.p) NP_746647 NfsA (C.k) YP_001453815 YcaK (E.c) AP_001531 
4975 (P.a) NP_253662 NfsA (E.c) AP_001482 YcdI (E.c) AP_001639 
5190 (P.a) NP_253877 NfsA (E.s)
c YP_001438568 YcdI (K.p) YP_001334699 
AzoR (E.c) AP_002037 NfsA (K.p) GU726296.1 YcnD (B.s) CAB12194 
AzoR (S.t) NP_805329 NfsA (L.i)
d NP_470273 YdgI (B.s) CAB12385 
AzoR (V.v) NP_761189 NfsA (S.t) NP_455401 YdjA (E.c) AP_002384 
EcD (P.p) AAL09699 NfsA (V.f) YP_002158635 YdjA (K.p) YP_001334868 
FraseI (V.f)a BAA04595 NfsA (V.v) NP_763284 YfkO (B.s) GU726295.1 
Frp (V.h)b AAA21331 NfsB (C.k) YP_001454141 YieF (E.c) AP_004074 
KefF (E.c) AP_000710 NfsB (E.c) AP_001223 YwrO (B.s) NP_391480 
MdaB (E.c) AP_003578 NfsB (E.s) YP_001437964 YwrO (L.i) NP_471232 
MdaB (P.s) YP_273002 NfsB (K.p) YP_001334233 YwrO (V.f) YP_002157853 
NemA (E.c) AP_002272 NfsB (S.t) NP_806031   
NemA (K.p) YP_001335650 NfsB (V.h) ZP_01985918   
aOur fraseI nucleotide sequence contained 1 base pair change from the database sequence: C→T at 
position 651. This was a silent mutation (codon change from ATC→ATT, both coding for Ile) 
bOut Frp nucleotide sequence was synthesized to contain all optimal E. coli codons. Protein sequence was 
identical to that given by the indicated accession number. 
cThe initial 17 amino acids indicated in the database sequence were not incorporated into the NfsA (E.s) 
sequence used in this work. 
dInitial codon was changed from GTG to ATG for the sequence used in this work. 
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AzoR (V.v) 
 
Nucleotide sequence: 
ATGTCTCGTTTACTAGTATTAAAATCAAGCATCCTTGGTGATTACTCTCAATCAAACAAACTGGTTGACG
AGTTCATCAATAAATTCGACCAACAAGACGTTGTCGTTCGTGATCTGGCCCAGCAACCATTGCCTGTTTT
AGATTTCCAAGTGGCGACAGCATTGCGCGCAAGCGGTGATTTAAGTGAAGCGCAACAGGCTATTGTTGAT
CTTTCTGACCAACTGATTGCCGAAATCAAACACGCTGACACCTTAATTATTGCTGCCCCTATGTACAACT
TCACCGTCCCGACCCAGCTTAAAAACTGGATCGATTTGATTGCTCGTGCTGGCGTTACCTTCACTTATAC
CGAGCAAGGTCCGAAAGGACTGATCGAAGGTAAGAAAGCGGTTGTTGTAACGACTCGTGGTGGTATTCAT
AAAGACGCAGCGAGTGACATCATCACTCCATACCTAAAAACCGTATTAGGGTTTGTTGGTATCACAGAGG
TTGAATTTGTTTACGCTGAAGCACTCAACATGGGTGAAGACTTTGCCTCTAAAGGCTTGGCTTCAGCAAG
TGAGCACCTTGCAGCGCTAACAGCTTAA 
 
Amino acid sequence: 
MSRLLVLKSSILGDYSQSNKLVDEFINKFDQQDVVVRDLAQQPLPVLDFQVATALRASGDLSEAQQAIVD
LSDQLIAEIKHADTLIIAAPMYNFTVPTQLKNWIDLIARAGVTFTYTEQGPKGLIEGKKAVVVTTRGGIH
KDAASDIITPYLKTVLGFVGITEVEFVYAEALNMGEDFASKGLASASEHLAALTA 
 
NemA (K.p) 
 
Nucleotide sequence: 
ATGTCGGAAGCAAAATTATTCAGCCCACTGAAAGTCGGTGCGGTCACCGTCCCTAATCGCGTATTTATGG
CGCCGTTGACGCGTCTGCGCAGCATTGAGCCGGGCGATATCCCTACTCCGCTGATGGGCGAATACTACCG
CCAGCGCGCCAGTTCCGGGCTGATCATCACCGAAGCGACGCAGATCTCCGCGCAGGCCAAAGGCTACGCC
GGCGCGCCTGGGCTGCACAGCCCGGAGCAGATTGCCGCCTGGCAGAAAATCACCGCCGGCGTTCATGCCG
AAAACGGTCATATCGCCGTCCAGCTGTGGCACACCGGGCGTATTTCCCATAGCAGCCTGCAGCCTGGCGG
CGCCGCCCCGGTAGCGCCTTCCGCGCTGAGCGCGGGCACCCGTACCTCACTGCGTTACGAAAACGGCCAC
GCCATTCGCGTCGACACCTCAATGCCCCGCGCCCTGGAAACCGCAGAGATCCCAGGGATCGTCAACGATT
TCCGTCAGGCGGTCGGCAATGCCCGTGACGCCGGCTTCGATCTGGTCGAGCTGCACTCAGCCCACGGCTA
TCTGCTGCACCAGTTCCTCTCGCCATCGGCGAACCAGCGTACCGATCAGTACGGCGGCAGCGTGGAGAAC
CGTGCCCGTCTGGTGCTGGAAGTGGTTGACGCCGTGAGTCAAGAGTGGAGCGCCGAGCGCATTGGCATCC
GCGTGTCGCCGATTGGCAGCTTCCAGAATGTGGATAATGGCCCGAACGAAGAAGAAGACGCGCTGTATCT
GATTAGCGAGCTGGCGAAACGCGGTATCGCCTATCTGCACATGTCCGAGCCGGACTGGGCGGGCGGCAAA
CCTTACAGTGAAGCTTTCCGTCAGAAAGTCCGCGACCGCTTCCCGGGGGTGATCATTGGCGCTGGCGCTT
ACACAGTAGAAAAAGCCAACGATCTTATCAATAAAGGGCTGATTGATGCCGTGGCATTTGGCCGCGATTA
CATCGCCAACCCGGATCTGGTGGCTCGCCTGCAGAAAAAAGCGGCGCTTAACCCGCAACGCCCGGAATCC
TTCTACGGCGGCGGCGCGGAAGGCTACACCGATTACCCGACTCTGTAA 
 
Amino acid sequence: 
MSEAKLFSPLKVGAVTVPNRVFMAPLTRLRSIEPGDIPTPLMGEYYRQRASSGLIITEATQISAQAKGYA
GAPGLHSPEQIAAWQKITAGVHAENGHIAVQLWHTGRISHSSLQPGGAAPVAPSALSAGTRTSLRYENGH
AIRVDTSMPRALETAEIPGIVNDFRQAVGNARDAGFDLVELHSAHGYLLHQFLSPSANQRTDQYGGSVEN
RARLVLEVVDAVSQEWSAERIGIRVSPIGSFQNVDNGPNEEEDALYLISELAKRGIAYLHMSEPDWAGGK
PYSEAFRQKVRDRFPGVIIGAGAYTVEKANDLINKGLIDAVAFGRDYIANPDLVARLQKKAALNPQRPES
FYGGGAEGYTDYPTL 
 
NemA (S.t) 
 
Nucleotide sequence: 
ATGTCATCAGCAAAACTGTTTACCCCCCTCAAGGTGGGTGCCATCACGGCGACAAGTCGCGTATTTATGG
CGCCTTTGACGCGTTTGCGGAGTATTGAACCGGGCGACATTCCTACGCCGTTAATGGCGGAATATTACCG
TCAACGCGCCAGCGCCGGATTGATCATCAGCGAAGCCACACAAATCTCCGCGCAGGCGAAAGGCTATGCC
GGCGCACCGGGATTACACAGCGATGAGCAGATCGCCGCCTGGAAAAAAATCACTCAGGGAGTCCATGCCC
AGGGCGGCCATATGGCGGTGCAACTGTGGCATACGGGCCGTATTTCACACGCCAGCCTGCAACCAGGCGG
ACAAGCGCCCGTCGCGCCATCCGCTATCAATGCGGGAACCCGCACCTCTTTGCGTGACGAAAACGGCCAG
GCCATCCGCGTAGAAACTTCCACGCCGCGCGCGCTGGATACTCATGAGATCCCCGGGATCGTCAACGATT
TCCGCCAGGCTATCGCCAATGCCCGAGAGGCAGGCTTTGATCTGGTGGAGCTGCACTCCGCGCACGGTTA
TCTGCTGCACCAGTTCCTCTCACCGTCTTCTAATCACCGTACCGATCGGTACGGCGGCAGCGTAGAGAAT
CGCGCCCGTCTGGTGCTGGAGGTGGTTGATGCCGGCATTAAGGAATGGGGCGCGGACCGTATCGGCATCC
GCCTTTCTCCTGTCGGCACTTTCCAGAATGTCGATAACGGCCCGAATGAAGAAGCTGACGCCCTTTATCT
GATTGAAGCGTTAGGCAAACGCGGCATCGCTTATCTGCATATGTCTGAACCAGACTGGGCGGGCGGCGAA
CCGTACAGCGACGCGTTCCGTGAAAAAGTGCGCGCGCGTTTCCACGGTCCCATCATCGGCGCTGGCGCCT
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ATACGCCAGAAAAAGCGGAAGATCTGATCGAAAAAGGGCTGATTGACGCCGTGGCGTTTGGTCGCGATTA
CATCGCTAACCCGGATCTGGTGGCGCGTCTGCAACGTAAAGCGGAACTTAATCCACAGCGTCCCGAAAGT
TTTTATGGTGGCGGCGCGGAAGGCTACACAGACTACCCTACTCTGTAA 
 
Amino acid sequence: 
MSSAKLFTPLKVGAITATSRVFMAPLTRLRSIEPGDIPTPLMAEYYRQRASAGLIISEATQISAQAKGYA
GAPGLHSDEQIAAWKKITQGVHAQGGHMAVQLWHTGRISHASLQPGGQAPVAPSAINAGTRTSLRDENGQ
AIRVETSTPRALDTHEIPGIVNDFRQAIANAREAGFDLVELHSAHGYLLHQFLSPSSNHRTDRYGGSVEN
RARLVLEVVDAGIKEWGADRIGIRLSPVGTFQNVDNGPNEEADALYLIEALGKRGIAYLHMSEPDWAGGE
PYSDAFREKVRARFHGPIIGAGAYTPEKAEDLIEKGLIDAVAFGRDYIANPDLVARLQRKAELNPQRPES
FYGGGAEGYTDYPTL 
 
NemA (V.v) 
 
Nucleotide sequence: 
ATGAGCAAACTGTTTGAACCAACACAGCTAAAACAACTGGATCTACTAAACCGTGTGGTGATGGCGCCAA
TGACCCGAGCTCGCACTAGTCAACCGGGAAACATTCCAAACCAAATGATGGCGACTTACTACAAGCAGCG
CGCTACCGCAGGCTTGATCATCTCTGAAGCCACCCAGATTTCCGATGATTCACAAGGCTACTCCTTCACA
CCCGGCGTTTATACCGATGAACAAGTGGCCGGTTGGAAGTTAGTCACTCAAGCGGTGAAATCACAAGGCG
CCGCCATGTTCTGCCAGCTTTGGCATGTGGGCCGAGTATCGCACCCAGTTTTCCAAAAAGGTGAACAGCC
CATCGCACCATCTGCGCTTGCTCCGGTAGAGACTAAAGTGTGGATCGCCGATGAGCAAGGCAACGGCAAT
ATGGTCGATTGTGTAGAGCCACGAGCCATGACTCAAGCGGATATTGACCGTGTTGTGAGTGATTTTGCCT
ATGCCGCGAAACGGGCGATTGAAGCAGGCTTCGATGGCATCGAAATCCACGGCGGCAATGGTTACCTGAT
TGACCAGTTCCTACGTACCAATTCAAACCACAGAACCGACAACTACGGCGGTACTCGAGAAAATCGACTT
CGCTTTTTGTTAGAAGTGGTCGATGCGGTGAGTAAAGCCATAGGTGCCAACAAAGTAGGAGTACGACTCG
CGCCTTTCATCACTTTCAAGGACATGAACTGCCCAGACATTGTGCCAACCATCCTCGATGCATCGAAACA
ACTTCAAGCTCGTGATATCGCGTACTTGCATCTGTCTGAAGCGGATTGGGACGACGCGCCCGTGATTCCA
GAGAGTTTCCGCATCGAATTGCGTGAATACTTCACCAACACCATTATCGTCGCTGGCAGTTACACTCAAG
CGAGAGCCGATGAGGTACTTGAGAAGGGGTATGCAGATTTAGTGGCGTTTGGCCGCCCATTTGTCTCTAA
TCCAGATTTGGTGGCACGCTTAAAGCATCAACAACCTCTGGCAGAACTGGATGGAGCAACCCTATTTGGC
GGCAATGAACGAGGTTATACAGATTACACCGCTTTGCATGTGTGA 
 
Amino acid sequence: 
MSKLFEPTQLKQLDLLNRVVMAPMTRARTSQPGNIPNQMMATYYKQRATAGLIISEATQISDDSQGYSFT
PGVYTDEQVAGWKLVTQAVKSQGAAMFCQLWHVGRVSHPVFQKGEQPIAPSALAPVETKVWIADEQGNGN
MVDCVEPRAMTQADIDRVVSDFAYAAKRAIEAGFDGIEIHGGNGYLIDQFLRTNSNHRTDNYGGTRENRL
RFLLEVVDAVSKAIGANKVGVRLAPFITFKDMNCPDIVPTILDASKQLQARDIAYLHLSEADWDDAPVIP
ESFRIELREYFTNTIIVAGSYTQARADEVLEKGYADLVAFGRPFVSNPDLVARLKHQQPLAELDGATLFG
GNERGYTDYTALHV 
 
NfrA (B.s) 
 
Nucleotide sequence: 
ATGAATAACACAATCGAAACCATTTTAAATCATCGGTCGATCCGGTCTTTTACTGATCAGCTTCTGACAG
CTGAAGAAATTGATATATTAGTGAAGAGTGCGCAGGCTGCGTCTACGTCCAGCTATGTACAGGCGTATTC
GATTATCGGGGTTTCCGATCCTGAGAAAAAACGTGAGCTGTCTGTGCTTGCCGGAAATCAGCCTTACGTT
GAGAACAACGGGCACTTTTTTGTATTTTGCGCGGACTTGCACCGCCACCAAAAACTGGCTGAGGAAAAAG
GCGAAAATATTTCTGAGCTGCTCGAAAATACGGAAATGTTTATGGTTAGCTTAATTGATGCAGCGCTGGC
AGCGCAAAATATGAGCGTTGCCGCTGAATCTATGGGGCTTGGCATTTGTTATATCGGCGGCATTCGGAAT
GAACTGGACAAGGTGACAGAGGTGTTGCAAACGCCTGACCATGTGCTTCCGCTTTTCGGTCTGGCAGTAG
GCCATCCTGCGAACCTATCCGGCAAAAAACCAAGATTGCCAAAGCAGGCTGTCTATCATGAGAATACGTA
TAATGTAAACGCAGACGATTTCCGCGACACCATGAATGCGTATGATCAAACCATTTCTGATTATTATAGA
GAAAGAACAAACGGACAGCGGGAAGAAACGTGGTCTGATCAGATTCTGAACTTTATGAAGCAGAAGCCGC
GTACCTATTTAAATGACTATGTGAAGGAAAAGGGCTTTAATAAAAACTAA 
 
Amino acid sequence: 
MNNTIETILNHRSIRSFTDQLLTAEEIDILVKSAQAASTSSYVQAYSIIGVSDPEKKRELSVLAGNQPYV
ENNGHFFVFCADLHRHQKLAEEKGENISELLENTEMFMVSLIDAALAAQNMSVAAESMGLGICYIGGIRN
ELDKVTEVLQTPDHVLPLFGLAVGHPANLSGKKPRLPKQAVYHENTYNVNADDFRDTMNAYDQTISDYYR
ERTNGQREETWSDQILNFMKQKPRTYLNDYVKEKGFNKN 
 
 
  
200
NfsA (C.k) 
 
Nucleotide sequence: 
ATGACTCCAACCATTGATTTAATCCGTGGTCACCGTTCTATTCGTCATTTTACCGATGAGCCGATTTCCG
ATGCGCAGCGTGAGTCGATTATTGCCGCCGCGCGGGGAACCTCAAGCTCCAGTTTTTTACAGTGCAGTTC
CATTATCCGCATTACCGATAAAGCCATGCGCGAAGCGCTGGTGCCCCTGACGGGCGGGCAAAAGCACGTT
GCGCAGGCCGCGGAATTTTGGGTTTTCTGCGCTGATTTTAATCGTCACTTACAGATTTGCCCGGACGCGC
AGCTCGGGCTGGCGGAACAGCTGCTGCTGGGCACGGTCGATACGGCGATGATGGGGCAAAATGCGCTGAC
CGCTGCCGAATCCCTGGGGCTGGGCGGCGTCTACATCGGCGGTATCCGCAATCATATTGAAGCGGTTACG
GAACGGCTGAAATTACCGAAATATGTCCTGCCGCTGTTTGGACTGTGCCTCGGCTGGCCTGCGGATAACC
CTGGCGTTAAGCCGCGTTTGCCCGCAGAACTGGTGGTGCATGAAAATCACTATCAGCCTGTGGATGCCGC
GCTGTTGGCGCAATATGATGAGCAGATCGCGGAGTATTACCTGACCCGCGACAGCAATACGCGCCGCGAT
ACCTGGAGCGATCATATCCGTCGTACCATCATCAAAGAGAATCGCCCGTTTATTCTGGACTATTTGCATA
AACAGGGTTGGGCGACGCGCTAA 
 
Amino acid sequence: 
MTPTIDLIRGHRSIRHFTDEPISDAQRESIIAAARGTSSSSFLQCSSIIRITDKAMREALVPLTGGQKHV
AQAAEFWVFCADFNRHLQICPDAQLGLAEQLLLGTVDTAMMGQNALTAAESLGLGGVYIGGIRNHIEAVT
ERLKLPKYVLPLFGLCLGWPADNPGVKPRLPAELVVHENHYQPVDAALLAQYDEQIAEYYLTRDSNTRRD
TWSDHIRRTIIKENRPFILDYLHKQGWATR 
 
NfsA (E.s) 
 
Nucleotide sequence: 
ATGAGCCCATCAGCGACGCCCAGCGTGAAGCGATTATCCACGCGGCGCAGTCCGCCTCCAGCTCCAGTTT
CCTGCAGTGCAGCTCCATTATTCGTGTAACCGACCGCGCGATGCGTGAGCAACTGGTGACGCTGACCGGC
GGTCAGCCGCACGTCGCGAAAGCCGCCGAGTTCTGGGTTTTCTGCGCCGATTTCAACCGTCATCTGCAAA
TCTGCCCGGATGCGCAACTGGGGCTGGCTGAACAGCTTTTGCTTGGCGTGGTAGATACCGCGATGCTCGG
ACAAAACGCGCTGGTCGCGGCGGAATCGCTTGGCCTCGGCGGGGTTTACATCGGCGGTATTCGTAACAGC
ATTGAAGCGGTCACAGAACTGCTGGGCCTGCCGAAACATGTGCTGCCGCTGTTTGGCCTGTGCCTCGGCT
GGCCGGCGGACAATCCGCAGGTGAAACCGCGTATGCCTGCGGGCCTGATGGTGCACGAAAACCGCTACCA
GCCGGTCGACCGTGAACTGCTTGCTGAATATGACGAAGAGATAGCCGACTACTACCTGCATCGCGACAGC
AACGCCCGCCGCGACACCTGGAGCGATCAGATCCGCCGCACCATCATTAAAGAGAACCGTCCGTTTATTC
TCGACTATCTGCACAAGCAGGGCTGGGCGACACGCTAA 
 
 
Amino acid sequence: 
MTPTIELLCSHRSIRHYTDEPISDAQREAIIHAAQSASSSSFLQCSSIIRVTDRAMREQLVTLTGGQPHV
AKAAEFWVFCADFNRHLQICPDAQLGLAEQLLLGVVDTAMLGQNALVAAESLGLGGVYIGGIRNSIEAVT
ELLGLPKHVLPLFGLCLGWPADNPQVKPRMPAGLMVHENRYQPVDRELLAEYDEEIADYYLHRDSNARRD
TWSDQIRRTIIKENRPFILDYLHKQGWATR 
 
NfsA (V.f) 
 
Nucleotide sequence: 
ATGAACCCTGTTATCGATACTATTTTAGAGCATCGCTCTATTCGCTCTTTTACTAATGAACCTATCTCTA
AAGAGCAATTAGATACCATCATCAGTGCGGGTATTGCAGCCTCTTCTTCTAGCTTGCTCCAAGTCAATTC
TATTATTCGAATTACCGATAAGGAAAAACGAAAAGCATTAGTTGAGCTATCAGGAGGCCAGCCTTATGTT
GAAGGTGCGGCGGAGTTTCTTGTTTTCTGTATTGATTTTCAACGTCATTATGAAATGAACCCGGAGATCA
AAGCCGAATTTACCGAACTTACTCTTATTGGTGCTGTTGATGCAGGTATTATGGCGCAAAATTGTCTTTT
AGCTGCAGAATCTATGGGATTAGGAGGTGTGTATATCGGTGGGTTACGTACAAACGCACAAGGTGTCGAT
GATTTATTAGAACTGCCAAAAAACACAGCTGTTTTGTTTGGTATGTGCCTAGGTTACCCAAATCAAGCGC
CTCAAAAAAAGCCACGTTTAAGTCCTGATGTTATTGTTCATGAAAATAGTTATCAGCCACTGGATAAAAG
TAAAATTGATGAATATGACGAAATAATGCAAAGCTACTATGCAACGCGCTCGACGAATCAAAAACAAAGT
TCATGGTCAGAGCAAATTACAGGAAAACTATCTCAAGAATCTCGCCCTCACATTAAAGGCTACTTAAATA
ATAAAGGCCTAGCTATTAAGTGA 
 
Amino acid sequence: 
MNPVIDTILEHRSIRSFTNEPISKEQLDTIISAGIAASSSSLLQVNSIIRITDKEKRKALVELSGGQPYV
EGAAEFLVFCIDFQRHYEMNPEIKAEFTELTLIGAVDAGIMAQNCLLAAESMGLGGVYIGGLRTNAQGVD
DLLELPKNTAVLFGMCLGYPNQAPQKKPRLSPDVIVHENSYQPLDKSKIDEYDEIMQSYYATRSTNQKQS
SWSEQITGKLSQESRPHIKGYLNNKGLAIK 
  
201 
 
NfsA (V.v) 
 
Nucleotide sequence: 
ATGAACGCTGTTATTGACACTCTGCTTTCCCACCGTTCTATTCGCAAATTTACCGACCAAGCGATAACGC
CAGAGCAACTCGACACCATCATTCGAGCAGGGCTAGCCGCTTCTTCTTCCAGTTTGCTACAAGTGGTCTC
AATCATTCGCATTACCGATCCAGCCAAACGTCAGCAGCTTGCCGAGCTCGCGGGGCCACAACACTATGTC
GAAACGGCTGCCGAATTCCTCGTGTTTTGCATTGATTATCAACGCCACGCCACCCTCAACTCAGAAGTAC
AAGCGGGCTTTACCGAGCTGACATTGATCGGCGCGGTGGATGCCGGCATCATGGCGCAAAACTGCTTATT
GGCCGCAGAGTCGATGGGGTTAGGTGGCGTTTACATCGGTGGGCTGAGAAACAAAGCCGCCGAGGTGGAT
GCCCTTCTCGAACTGCCTCCATTCAGTGCCGTCTTGTTTGGTATGTGCTTAGGCCATCCAGACCAAGACC
CTGATCTCAAACCACGGCTGCCCGCGGAGGTCATTCTCCACGAGAACCACTATCAGCCGCTCGATCTCAA
TAAAGTAGAGCAATACGATCAAACCATGCTCGACTACTATGGCAAGCGTTCATCAAACCAAAAACAGGCC
AGCTGGTCTGAACAAGTAACGGGCAAGCTGGCGGGGGAATCTCGCCCTCATATCTTGCCTTATTTACACA
GCAAAGGCTTGGCGACAAAGTAA 
 
Amino acid sequence: 
MNAVIDTLLSHRSIRKFTDQAITPEQLDTIIRAGLAASSSSLLQVVSIIRITDPAKRQQLAELAGPQHYV
ETAAEFLVFCIDYQRHATLNSEVQAGFTELTLIGAVDAGIMAQNCLLAAESMGLGGVYIGGLRNKAAEVD
ALLELPPFSAVLFGMCLGHPDQDPDLKPRLPAEVILHENHYQPLDLNKVEQYDQTMLDYYGKRSSNQKQA
SWSEQVTGKLAGESRPHILPYLHSKGLATK 
 
NfsB (C.k) 
 
Nucleotide sequence: 
ATGGATATCGTTTCTGTCGCCTTAAAACGCTACTCCACTAAGGCGTTCGATCCCAGCAAACAACTGACCG
CAGACGAAGCGGAAAAACTCAAAACATTGCTGCAATATAGCCCTTCCAGCACCAACTCTCAGCCGTGGCA
TTTCATCGTCGCCAGTACCGAAGAAGGGAAAGCGCGCGTTGCGAAATCCGCCGCCGGTAATTTCGTGTTT
AACGAGCGCAAAATGCTGGATGCTTCCCATGTCGTCGTGTTTTGCGCAAAAACCGCAATGGATGACGCCT
GGCTGGATCGCGTTGTCGATCAGGAAGATGCCGATGGCCGTTTTGCCACGCCGGAAGCCAAAGCGGCAAA
TAACAAAGGCCGTCGCTTTTTCGCGGATCTGCACCGCCGCGACCTGAAAGATGACGATCAGTGGATGGCG
AAACAGGTATACCTGAACGTTGGCAACTTCCTGCTGGGCGTCGCCGCGATGGGTCTGGACGCCGTACCGA
TTGAAGGCTTCGACGCTGCGGTTCTTGACGCTGAATTTGGCCTGAAAGAGAAAGGTTATACCAGCCTGGT
CGTGGTGCCTGTCGGCCATCACAGCGTAGAAGATTTTAACGCTGCGCTGCCGAAATCCCGCCTGCCGCAG
GAAACCACCCTGACGGAAGTCTGA 
 
Amino acid sequence: 
MDIVSVALKRYSTKAFDPSKQLTADEAEKLKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGNFVF
NERKMLDASHVVVFCAKTAMDDAWLDRVVDQEDADGRFATPEAKAANNKGRRFFADLHRRDLKDDDQWMA
KQVYLNVGNFLLGVAAMGLDAVPIEGFDAAVLDAEFGLKEKGYTSLVVVPVGHHSVEDFNAALPKSRLPQ
ETTLTEV 
 
NfsB (E.s) 
 
Nucleotide sequence: 
ATGAACCTTAATGAGATCATTCGCACTCGCCATACCAGCAAAGCCTACGATAACAGCCGTAAACTGACGG
CCGAACAGCAGCAGGAGCTGCTGGATCTGCTGCGTTTTAGCCCCTCTTCCGTCAACTCACAGCCGTGGCA
CTTTTTTGCCGTGACTACTGAAGAAGGCAAAGCGCAGATCCTGCCAGCGCTGATGGACGCTAATCAGGTA
AAAGCGAAAAACGCCGCCATGACCGTCGTGTTCACCATTAAAGAAGAGCTGAACGAAGCGCACCTGCTGC
AACTGCTGGAAAAAGAGCAGCAGGATGGTCGCTACGACGGCGAGGAAGCGCGCGCCGCGAACGATAAAGG
CCGCCGCTTTTTTGTGGGTCTGAACAGCGAAACGCCGGAGCAGCAGCGCGAATGGATGACCCGTCAGGCC
TATCTGGCGCTCGGTTTCCTGCTGCTGGGCGCAGCCGCGATGGGCCTCGACGCGACGCCTATCGAAGGTT
TCCATCCGGAGAAAATGGATGAAGTGCTGGGCCTGAAAGAAAAAGGTCTACGCAGCGTGGTGGTAGCGAC
CATCGGTTATCGCAGCGATGCCGACTTCAACGCCACACTGCCGAAATCCCGTCTGGATCAGGATGTGGTG
ATCACGCAGCTCTGA 
 
Amino acid sequence: 
MNLNEIIRTRHTSKAYDNSRKLTAEQQQELLDLLRFSPSSVNSQPWHFFAVTTEEGKAQILPALMDANQV
KAKNAAMTVVFTIKEELNEAHLLQLLEKEQQDGRYDGEEARAANDKGRRFFVGLNSETPEQQREWMTRQA
YLALGFLLLGAAAMGLDATPIEGFHPEKMDEVLGLKEKGLRSVVVATIGYRSDADFNATLPKSRLDQDVV
ITQL 
 
  
202
NfsB (K.p) 
 
Nucleotide sequence: 
ATGGATATCGTATCGGTCGCTTTGAAGCGCTATTCCACCAAGGCCTTTGACGCCACGAAAAAGCTGACTG
CCGGGGAAGCGGAACAGCTGAAAACGCTGCTGCAGTACAGCCCGTCTAGCACCAACTCCCAGCCGTGGCA
CTTTATTGTCGCCAGCACCGATGAAGGCAAAGCTCGCGTGGCGAAAGCCGCCAGCGGCACCTACGTGTTC
AACGAACGTAAAATTCTCGACGCCTCGCACGTGGTGGTGTTCTGCGCGAAAACCGCGATGGACGACGCCT
GGCTGCAGCGCGTGGTGGATCAGGAAGAGGCCGATGGCCGTTTCGCCACCCCGGACGCAAAAGCCGCTAA
CCACAAGGGTCGCACCTTCTTTGCCGATATGCACCGCAAAGAGCTGAAAGATGACGATCAGTGGATGGCG
AAACAGGTGTATCTCAACGTCGGCAATTTCCTGCTGGGCGTAGCGGCGATGGGTCTCGACGCCGTGCCGA
TTGAAGGGGTCGATTTTGCGATCCTCGATGAGGAATTTGACCTGAAAGCCCAGGGCTACACCAGCCTGGT
GGTGGTCCCGGTCGGCCACCATAGCGTAGAAGATTTCAACGCTACCCTGCCGAAGTCGCGTCTGCCGCAG
TCGACGACCATTACCGAGATTTAA 
 
Amino acid sequence: 
MDIVSVALKRYSTKAFDATKKLTAGEAEQLKTLLQYSPSSTNSQPWHFIVASTDEGKARVAKAASGTYVF
NERKILDASHVVVFCAKTAMDDAWLQRVVDQEEADGRFATPDAKAANHKGRTFFADMHRKELKDDDQWMA
KQVYLNVGNFLLGVAAMGLDAVPIEGVDFAILDEEFDLKAQGYTSLVVVPVGHHSVEDFNATLPKSRLPQ
STTITEI 
 
NfsB (V.h) 
 
Nucleotide sequence: 
ATGTCTCATCAAATCATTACAGACCTAAACAACCGTTACACAGCTAAAAAATACGACGAAGAGAAACGCA
TCTCTCAAGAAGATATGGCAATCATCAAAGAAGCAATCCGCCTATCTGCGTCTTCTATCAACTCTCAGCC
TTGGAAATTCATCGTAATTGAGAGCGACGAAGCGAAACAGCGTTTCCATGACACGTTTGCTAACATGCAC
CAGTTCAACCAACCGCACGCGAAAGCAGCATCCCACACTATTCTGCTAGCGTACGATCCAAAATTCACTA
AAGAGAAATTTGCGAAGCGTGTTGATGCTGAAGTAACTTCTGGTCACCTACCAGCAGACATGTACGACAT
GTTCATGGGTGCTTACGCATTTGCTGAAGCAAACACAGATGAAAACGGCTACAACGGCGGCTGGACGAAA
GCGCAAGTTTATATCGCGCTTGGTAACCTACTGCACACACTAGCGCGTCTAGGTATCGACTCTACTCCAA
TGGAAGGTGTTGACCCAACACTGATCGGCGAAGAGTTCAAAGCAGAACTAGACGGTCACGTATGTGAAGT
TGCACTAGCAATCGGCTACCACAAAGACGGCGAAGACTACAACCACGGTCTACCAAAAGCACGTCTAAAC
ATGGATGACGTAATTACTACTCTTTAA 
 
Amino acid sequence: 
MSHQIITDLNNRYTAKKYDEEKRISQEDMAIIKEAIRLSASSINSQPWKFIVIESDEAKQRFHDTFANMH
QFNQPHAKAASHTILLAYDPKFTKEKFAKRVDAEVTSGHLPADMYDMFMGAYAFAEANTDENGYNGGWTK
AQVYIALGNLLHTLARLGIDSTPMEGVDPTLIGEEFKAELDGHVCEVALAIGYHKDGEDYNHGLPKARLN
MDDVITTL 
 
NfsB (V.v) 
 
Nucleotide sequence: 
ATGACTATTGTTCAAGCTGCCCAATCCCGCTATTCCACGAAAGCCTTTGATGCTTCGCGCAAATTGCCTG
AAGAAAAAGTCGCGGCAGTGAAAGAGTTAATCCGCATGAGTGCGTCCAGTGTCAACTCGCAACCTTGGCA
TTTCATTGTCGCGAGCAGTGAAGAAGGAAAAGCGCGCATCGCGAAAGCAACACAAGGTGGTTTTGCTTTT
AATGAGCGCAAGATTTTGGATGCCTCTCACGTAGTGGTGTTTTGCGCCAAAACATCGATTGATGAAGCGT
ATTTACTCGACCTTTTGCAGAGCGAAGATAAAGATGGCCGCTTTGCCGATGTCGAAGCAAAAAATGGTAT
GCATGCTGGCCGCTCATTTTTCGTCAACATGCATCGCTTTGACTTGAAAGACGCGCATCACTGGATGGAA
AAGCAAGTTTACCTCAATGTCGGGACGCTGCTATTGGGGGCCTCTGCGATGGAGATCGACGCAGTGCCAA
TTGAAGGCTTCGATGCCAAGGTACTTGATGAAGAGTTTGGTCTGCGTGAGAAGGGCTTTACCAGCGTGGT
GATTGTGCCGCTGGGTTACCATAGCGAAGACGATTTTAATGCTAAGCTGCCAAAATCACGTTGGCCAGCA
GAGACTGTTTTTACCGAAATCTAA 
 
Amino acid sequence: 
MTIVQAAQSRYSTKAFDASRKLPEEKVAAVKELIRMSASSVNSQPWHFIVASSEEGKARIAKATQGGFAF
NERKILDASHVVVFCAKTSIDEAYLLDLLQSEDKDGRFADVEAKNGMHAGRSFFVNMHRFDLKDAHHWME
KQVYLNVGTLLLGASAMEIDAVPIEGFDAKVLDEEFGLREKGFTSVVIVPLGYHSEDDFNAKLPKSRWPA
ETVFTEI 
 
 
 
  
203 
 
YcnD (B.s) 
 
Nucleotide sequence: 
ATGAATGAAGTGATTAAATCATTAACAGACCACCGCTCGATTCGCAGCTATACAGATGAACCTGTAGCTA
AGGAACAATTGGACCAAATCATTCAAGCGGTACAATCTGCCCCAACTTCTATCAACGGGCAGCAAGTGAC
TGTGATCACAGTCCAGGATAAAGAGCGCAAAAAGAAAATCTCCGAGCTGTCAGGCGGACAGCCTTGGATT
GACCAGGCTCCTGTTTTCTTGCTGTTCTGCGCAGACTTCAACCGGGCCAAAATCGCGCTTGAGGATCTGA
ATGATATCAAAATGGAAATCACAAATGGCTTAGAGTCTGTTCTTGTCGGCGCAGTAGACGCTGGTATTGC
CCTCGGCACAGCGACAGCAGCAGCTGAATCACTCGGACTTGGCACGGTTCCGATCGGTGCGGTTCGCGGA
AACCCTCAAGAGCTGATCGAACTGCTTGAGCTTCCGAAATACGTGTTCCCTGTATCCGGCCTTGTCATCG
GCCATCCTGCTGACCGTTCAGCGAAAAAACCGCGCCTTCCGCAGGAAGCAGTCAATTATCAGGAAACATA
TTTGAATCAAGATGAGCTGACGTCTTACATTCAGGCATATGATGAGAAAATGTCTGAATACATGAATAAG
CGGACAAACGGAAAAGAAACAAGAAACTGGTCACAGGGCATCGCATCCTATTATGAGCGCCTGTACTATC
CACACATCCGTGAAATGCTTGAGAAACAAGGATTTAAAGTTGAAAAATAA 
 
Amino acid sequence: 
MNEVIKSLTDHRSIRSYTDEPVAKEQLDQIIQAVQSAPTSINGQQVTVITVQDKERKKKISELSGGQPWI
DQAPVFLLFCADFNRAKIALEDLNDIKMEITNGLESVLVGAVDAGIALGTATAAAESLGLGTVPIGAVRG
NPQELIELLELPKYVFPVSGLVIGHPADRSAKKPRLPQEAVNYQETYLNQDELTSYIQAYDEKMSEYMNK
RTNGKETRNWSQGIASYYERLYYPHIREMLEKQGFKVEK 
 
YdgI (B.s) 
 
Nucleotide sequence: 
ATGATCAAAACAAACGATTTTATGGAGATTATGAAAGGACGCCGTTCCATTCGCAACTATGATCCGACAG
TGAAAATCAGCAAAGAAGAAATGACAGAAATCTTAGAAGAAGCCACAACTGCTCCATCTTCTGTCAACGC
GCAGCCATGGCGTTTTCTCGTCATTGACAGCCCGGAAGGAAAAGAAAAGCTCGCACCGCTTGCAAGCTTT
AACCAAACTCAAGTCACAACATCATCTGCCGTCATCGCTGTATTTGCAGATATGAACAATGGAGACTACT
TAGAAGAAATCTATTCAAAAGCCGTGGAACTCGGTTACATGCCGCAGGAAGTCAAAGACAGACAAATCGC
CGCTCTGACCGCTCATTTTGAAAAGCTTCCGGCACAGGTGAACCGCGAAACGATCCTGATTGACGGAGGT
CTTGTTTCAATGCAGCTGATGCTTACTGCACGTGCGCACGGCTATGATACAAACCCGATCGGCGGATACG
ATAAAGAAAACATCGCGGAAACATTCGGTTTAGATAAAGAACGTTATGTACCGGTCATGCTTCTTTCTAT
CGGAAAAGCAGCAGACGAAGGCTATGCTTCCTACCGTCTGCCGATTGATAAAATTGCAGAATGGAAATAA 
 
Amino acid sequence: 
MIKTNDFMEIMKGRRSIRNYDPTVKISKEEMTEILEEATTAPSSVNAQPWRFLVIDSPEGKEKLAPLASF
NQTQVTTSSAVIAVFADMNNGDYLEEIYSKAVELGYMPQEVKDRQIAALTAHFEKLPAQVNRETILIDGG
LVSMQLMLTARAHGYDTNPIGGYDKENIAETFGLDKERYVPVMLLSIGKAADEGYASYRLPIDKIAEWK 
 
YwrO (B.s) 
 
Nucleotide sequence: 
ATGAAAATATTGGTTTTGGCAGTGCATCCTCATATGGAAACCTCAGTTGTGAATAAGGCATGGACAGAGG
AATTGAGTCAACATGACAATATCACAGTACGGGAGCTTTATAAAGAATACCCGAATGAAGCGATAGATGT
TGCGAAGGAGCAGCAGCTGTGCGAGCAATACGACCGGATTGTCTTCCAATTTCCGTTTTATTGGTACGGC
TCTCCGCCGCTCTTAAAAAAATGGCAGGATCTTGTGCTGACTTACGGCTGGGCCTTTGGTTCAGAAGGAA
ACGCCTTGCACGGCAAGGAGCTGATGCTGGCTGTATCAACAGGGAGCGAAGCGGAAAAATATCAGGCGGG
CGGAGCAAATCATTACTCGATCAGTGAGCTTTTGAAACCATTTCAGGCCACGAGTAATCTGATCGGCATG
AAATACCTGCCACCATATGTGTTCTATGGCGTGAATGATGCAACTGCAGAGGATATCTCTCTCAGTGCAA
AACGGTTAGCCGAATACATCCAGCAGCCTTTTGTTTAA 
 
 
Amino acid sequence: 
MKILVLAVHPHMETSVVNKAWTEELSQHDNITVRELYKEYPNEAIDVAKEQQLCEQYDRIVFQFPFYWYG
SPPLLKKWQDLVLTYGWAFGSEGNALHGKELMLAVSTGSEAEKYQAGGANHYSISELLKPFQATSNLIGM
KYLPPYVFYGVNDATAEDISLSAKRLAEYIQQPFV 
 
 
 
 
 
  
204
YwrO (L.i) 
 
Nucleotide sequence: 
ATGAAAACATTAGTTATTATCGCACATCCGAATATCGAAAATTCACGCGTAAATAGAGTTTGGAAAGAAG
CACTTTTAAAAAGTACAGAAGAGGTGGCAATTCATGAGTTATATGAAGTTTATCCTAACTGGGATATTGA
TGTAACCTTTGAACAACAACAATTGCAAAACTACGATAAAGTCATTATCCAATTTCCATTTTATTGGTAC
AGCTACCCGCCGTTATTAAAAAAATGGTTCGATGATGTCTTTTCGTATGGCTGGGCTTACGGCTCAAAAG
GGGACAAGATGGCTGGGAAAAAGCTTGCTCTTGCAGTTTCAATTGGCGATAAAAAATATAATTATAAAGA
AGATGCACCAATTGGCTATTCACTAGACACATTACTTACACCATTTCGAGCAACAATAAACCACATTCGA
GCTGACTATAGAGGGGCCCACACGATATATGGCAGCTCCTTTGAAGTCACAGATGAAGAAATAGTAGAAA
ATGCGTATGTGTATGCAAACAAGTTTATTAAAACGTTAAATTAG 
 
Amino acid sequence: 
MKTLVIIAHPNIENSRVNRVWKEALLKSTEEVAIHELYEVYPNWDIDVTFEQQQLQNYDKVIIQFPFYWY
SYPPLLKKWFDDVFSYGWAYGSKGDKMAGKKLALAVSIGDKKYNYKEDAPIGYSLDTLLTPFRATINHIR
ADYRGAHTIYGSSFEVTDEEIVENAYVYANKFIKTLN 
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Appendix 2: HPLC chromatograms of CB1954 and PR-104A 
reduction products 
 
 
Figure A2.1. HPLC analysis of products of 
NTR-catalysed reduction of CB1954. 
Buffered reactions consisting of CB1954 (200 
µM), co-substrate (NAD(P)H; 1 mM) and 
purified candidate NTR (0.5-2 µM) were 
incubated at room temperature for 10-30 minutes 
prior to chromatographic separation of reaction 
products (as outlined in section 2.16). Eluates 
were continuously monitored at 262 nm. 
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Figure A2.2. HPLC analysis of products of 
NTR-catalysed reduction of PR-104A. 
Buffered reactions consisting of PR-104A (200 
µM), co-substrate (NAD(P)H; 1 mM) and 
purified candidate NTR (0.5-2 µM) were 
incubated at room temperature for 10-30 minutes 
prior to chromatographic separation of reaction 
products (as outlined in section 2.16). Eluates 
were continuously monitored at 254 nm. 
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